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The delivery of chemotherapy at home: an evidence
synthesis
Mark Corbett,1 Morag Heirs,1 Micah Rose,1 Alison Smith,1
Lisa Stirk,1 Gerry Richardson,2 Daniel Stark,3 Daniel Swinson,4
Dawn Craig1 and Alison Eastwood1*
1Centre for Reviews and Dissemination, University of York, York, UK
2Centre for Health Economics, University of York, York, UK
3Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, UK
4St James’s Institute of Oncology, Leeds Teaching Hospitals Foundation NHS Trust, Leeds, UK
*Corresponding author alison.eastwood@york.ac.uk
Background: Recent policy and guidance has focused on chemotherapy services being offered closer to
home, but the clinical and economic implications of this are uncertain.
Objectives: To compare the impact of delivering intravenous chemotherapy in different settings on a
range of outcomes, including quality of life, safety and costs.
Design: Multimethods approach: systematic review of clinical effectiveness, qualitative and
cost-effectiveness studies; description of the patient pathway and brief survey of current provision;
and development of a decision model to explore aspects of cost-effectiveness.
Setting: Provision of intravenous chemotherapy.
Participants: Chemotherapy patients.
Interventions: Setting in which chemotherapy was administered (home, community or outpatient).
Outcome measures: Safety, quality of life, preference, satisfaction, opinions/experiences, social
functioning, clinical outcomes, costs and resource/organisational issues.
Data sources: Sixteen electronic databases (including MEDLINE, EMBASE and The Cochrane Library) were
searched from inception to October 2013 for published and unpublished studies.
Review methods: Two reviewers independently screened potentially relevant studies, extracted data and
quality assessed the included studies. Study validity was evaluated using appropriate quality assessment
tools. Clinical effectiveness and cost-effectiveness studies were summarised narratively, and qualitative
studies were synthesised using meta-ethnography.
Results: Of the 67 eligible studies, 25 were comparative, with nine including a concurrent economic
evaluation. Although some of the 10 randomised trials were designed to minimise avoidable biases, slow
recruitment rates and non-participation of eligible patients for setting-related reasons meant that trial
sample sizes were small and populations were inherently biased to favour the home or community
settings. There was little evidence to suggest differences between settings in terms of quality of life,
clinical outcomes, psychological outcomes or adverse events. All nine economic evaluations were judged as
having low or uncertain quality, providing limited evidence to draw overall conclusions. Most were
cost–consequence analyses, presenting cost outcomes alongside trial results but deriving no summary
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measure of benefit. Poor resource use reporting and use of different perspectives across settings made
results difficult to compare. Seventeen qualitative studies (450 participants) were judged as moderate to
good quality, although all compared new or proposed services with existing outpatient facilities and biased
samples were used. The three main lines of argument were barriers to service provision, satisfaction with
chemotherapy and making compromises to maintain normality. Most patients made explicit trade-offs
between the time and energy required for outpatient chemotherapy, which reduced quality of life, and an
increased sense of safety. A patient pathway was described, informed by expert advice and a brief survey
of NHS and private providers, which identified wide variation in the ways in which home and community
chemotherapy was delivered. Considering limitations of the available data and variation in provision,
cost-effectiveness modelling results were not robust and were viewed as exploratory only; the results were
highly unstable.
Conclusions: Primary studies comparing settings for administering intravenous chemotherapy appear
difficult to conduct. Consequently, few robust conclusions can be made about the clinical effectiveness
and cost-effectiveness. Qualitative studies indicate that the patient time and energy required for outpatient
chemotherapy reduces quality of life. A nested randomised controlled trial within a larger observational
cohort of patients is proposed to enhance recruitment and improve generalisability of results. Future
economic evaluations require detailed patient characteristic, resource use, cost and quality-of-life data,
although their results are likely to have limited generalisability.
Study registration: This study is registered as PROSPERO CRD42013004851.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
There is an increasing focus in the NHS on delivering care closer to home. Chemotherapy treatment isoffered in community, home and hospital settings. To explore the differences between these settings
for patients and service providers, a review of the existing evidence and a survey of current service
provision were undertaken. An economic model was developed also.
The systematic literature review identified little robust evidence. The studies had small sample sizes and
populations likely to prefer home or community settings. They demonstrated little difference in terms of
quality of life, physical or emotional symptoms, or adverse events. Previous economic evaluations provided
limited evidence on cost-effectiveness and for informing the economic model.
The studies about patient experiences indicated that decisions about treatment setting are strongly
influenced by a desire for normality. The time and energy required for outpatient chemotherapy reduces
overall quality of life and so patients prefer alternative settings. However, competing factors and patient
preference reflected individual situations.
The survey showed wide variation in the current provision of home and community chemotherapy in the
NHS. Eligibility varied by provider, with chemotherapy regimen and patient response to initial treatment in
hospital important determinants.
The economic modelling was limited by a lack of data and by the broad variation in NHS treatment
delivery pathways.
A better design for future research might be to nest a randomised trial within a larger observational study.
For a reliable economic evaluation, broad observational data will be needed to explore variations and
ensure generalisability.
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Scientific summary
Background
Throughout the NHS there is an increasing focus on developing service models of care which meet the
needs of patients, with care being delivered locally wherever possible to maximise convenience and
centralised where necessary to improve outcomes. For cancer treatment, recent policy and guidance has
focused on chemotherapy services being offered not only in cancer centres and cancer units but also in
community and home settings, while maintaining safety and quality and delivering an efficient service.
Many hospitals across England and Wales are delivering chemotherapy services at full capacity, with
increasing demand for services putting a strain on NHS capacity resources. This can have a detrimental
effect on patient experience as a result of longer waiting times. Delivering chemotherapy closer to home
may be an approach by which the NHS could relieve demand for outpatient services while maintaining
or even improving patient care. Nevertheless, the clinical and economic implications of delivering
chemotherapy closer to home are uncertain.
Objectives
This aim of this study was to compare the impact of delivering intravenous chemotherapy in different
settings (home, community and hospital outpatient) on a range of outcomes, including quality of life,
safety and costs.
Methods
A systematic review of clinical effectiveness, qualitative and cost-effectiveness studies was undertaken.
A decision model was developed to explore aspects of cost-effectiveness. Data from published and
unpublished studies were sought systematically from 16 electronic databases (including MEDLINE, EMBASE
and The Cochrane Library, searched from inception) in March 2013; updated searches of the most relevant
databases were undertaken in October 2013. Reference lists and Google (www.google.co.uk) searches
were used to identify any further studies.
Studies of cancer patients receiving intravenous chemotherapy in two or more of the following settings
were eligible: home, community based (e.g. general practitioner practice, mobile bus, or community
hospital) and hospital outpatient. Within-setting comparisons were also eligible. Studies had to report at
least one of the following outcomes: safety, quality of life, preference, satisfaction, social functioning,
clinical outcomes (such as self-rated health), costs or resource/organisational issues. Any type of
comparative design (including economic evaluation) was eligible. Single-setting studies were also identified
and included, but were used in the review only where they might usefully supplement the comparative
study evidence (this happened only for qualitative studies). Quality assessment tools, specific to particular
study designs, were used to evaluate the validity of the included studies.
Two reviewers independently screened all of the potentially relevant studies, and data extracted and
quality assessed those included. Discrepancies were resolved by discussion. Clinical effectiveness and
cost-effectiveness studies were summarised narratively; qualitative studies were synthesised using
meta-ethnography.
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To supplement the published evidence and to gain insight into the variation in current NHS practice, a
survey was undertaken, canvassing views from relevant professionals about their experience of providing
home and community chemotherapy. The results of the survey were intended to help to describe the
patient pathway and inform the development of a decision model. A lack of evidence led to a simple
model based on one UK trial (OUTREACH) being developed. The aim of the model was to assess the
cost-effectiveness of intravenous chemotherapy delivered in the home, community or outpatient setting in
a population considered eligible for home treatment. The model was conducted from a NHS perspective
using a 12-week time horizon. The summary measure of benefit was quality-adjusted life-years.
Results
The literature searches identified 4272 references and 245 potentially relevant full papers were screened.
A total of 67 studies were included: 25 comparative studies and 42 single-setting studies. Of the
25 comparative studies, 10 were randomised controlled trials (RCTs) and 15 were non-randomised studies;
nine of the comparative studies included a concurrent full economic evaluation. Most studies evaluated
adult populations and compared home and hospital outpatient settings.
The 10 randomised trials recruited 482 participants in total. Several trials were appropriately designed to
minimise avoidable biases. However, slow recruitment rates and the non-participation of eligible patients
for setting-related reasons meant that trial sample sizes were small and populations were inherently biased
to favour the home or community settings. This bias was evident in the results for the preference and
satisfaction outcomes, although these data were limited as only one trial studied strength of preference.
Perhaps surprisingly, there was little evidence to suggest differences between settings in terms of quality of
life, clinical outcomes or psychological outcomes. Adverse event data also did not suggest any important
differences between settings; these data were limited by the small study sizes. The 15 non-randomised
studies added little to the randomised trial evidence: the main limitations were the small populations and a
high risk that the study results were biased as a result of confounding.
All nine of the economic evaluations were judged as being of low or uncertain quality. Most were
cost–consequence analyses, which presented cost outcomes alongside clinical trial results but derived no
summary measure of benefit. Only one evaluation assessed patient health-related quality of life and
reported utility outputs (many studies used patient preference as an outcome measure). Poor reporting of
resource use and use of different perspectives across different settings made the results difficult to
compare. High levels of uncertainty made it difficult to ascertain whether or not costs or outcomes differed
between settings. In general, these studies provided limited evidence from which to draw an overall
conclusion regarding cost-effectiveness or to inform or populate a decision model.
The 17 qualitative studies evaluated the opinions and experiences of more than 450 participants in total,
including patients, family members and health-care professionals. Generally, study quality was moderate to
good but most studies did not appear to consider the impact of the researcher on data collection and
analysis. Overall, data were grouped under three main lines of argument: barriers to service provision,
satisfaction with chemotherapy and making compromises to maintain normality. The last of these was
seen as key to being able to survive a difficult time and look forward.
Most patients made explicit trade-offs to maximise their resources (such as time, money and energy).
Normality was maintained more easily when family life was minimally interrupted, the impact of cancer on
daily life and family members was controllable, and patients were able to participate in activities of value.
Time spent travelling and waiting for treatment meant less time and energy for normal life. Outpatient
settings were most often associated with increased confidence in staff ability to deal with adverse
reactions, but there was evidence that good, visible communication between an expert centre and a
community or home location could alleviate some safety concerns. Based on available data, the time and
energy consumed by outpatient treatment reduced overall quality of life such that patients preferred
SCIENTIFIC SUMMARY
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alternative treatment settings. These themes were particularly evident in accounts from patients receiving
palliative treatment and from parents of children with cancer.
We circulated the survey widely and it was passed on further by initial contacts. This made it impossible to
calculate a response rate. Twenty-two NHS organisations (all in England) and nine private providers
responded to the survey. The results suggested wide variation in the ways in which home and community
chemotherapy was delivered. It was evident that more patients were eligible for community treatment than
home treatment and that chemotherapy regimen and patient performance were important determinants
of eligibility. Private providers were frequently used to deliver treatment in the home setting and appeared
to use more selective eligibility criteria (e.g. treating patients only after two or more cycles had been
delivered in hospital). Several NHS organisations highlighted that value-added tax savings associated with
home chemotherapy were a significant motivator for providing such a service.
We anticipated that we would be able to develop and populate a robust decision model through
combination of the published evidence and the survey. However, limitations of the available data meant
that results from the cost-effectiveness model were highly unstable and should be viewed as exploratory
rather than robust.
In the base-case analysis, intravenous chemotherapy in the community setting was the most cost-effective
option, but none of the settings had a high probability of being the most cost-effective. Sensitivity analyses
highlighted the fragility of the results to parameter changes. Adjusting cost values within plausible ranges
also altered the preferred treatment setting. There was significant uncertainty over which treatment
settings were cost-effective. Robust data to inform cost-effectiveness modelling would be needed to
resolve this uncertainty, as well as further consideration of service configuration and appropriate
patient pathways.
Conclusions
The results of this study highlighted not only avoidable study design and reporting limitations but also
inherent and sometimes unavoidable difficulties that arise during primary studies of chemotherapy settings.
Several studies were designed appropriately to minimise avoidable biases but implementing randomised
trials in this area appears difficult in terms of patient accrual and recruiting unbiased populations. These
issues impacted on the concurrent economic evaluations and were further compounded by poor reporting
of cost and resource data. Consequently, few robust conclusions can be made about the clinical
effectiveness and cost-effectiveness of different settings. High uncertainty remains owing to trial sizes that
were potentially too small to detect effects reliably. It was unclear whether or not the quality-of-life
instruments used in the studies were sensitive enough to detect differences in quality of life between
chemotherapy settings. Accordingly, the results of the exploratory cost-effectiveness model based on the
OUTREACH trial were not robust and the cost-effectiveness results of the model should be interpreted
with caution.
Qualitative studies were more informative. They indicated that decisions and preferences about intravenous
chemotherapy treatment setting are strongly influenced by a desire to maintain normality. Patient time and
energy required for outpatient chemotherapy reduces overall quality of life enough for patients to prefer
alternative treatment settings. However, compromises were needed to balance competing factors and
patient preference for specific locations reflecting individual situations. Limitations of the qualitative studies
were that all evaluated a new or proposed service against an existing (perhaps struggling) hospital
outpatient setting, and participants were drawn from biased samples.
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Implications for research
Considering the likely challenges involved in performing further RCTs using conventional study designs, a
better design might be to nest a RCT within a larger observational cohort of patients: ambivalent patients
could be randomised and patients with preferences could receive their preferred setting. Such a study
might also incorporate (into questionnaires) the qualitative data themes identified in this review. Efficacy
estimates would result from the randomised component of the study. Any additional influence of
motivational factors could be studied by comparing randomised and non-randomised patients treated in
the same setting. The results from this nested design should also indicate whether or not there are any
clinical or demographic differences between the different populations at baseline, and produce estimates
of likely rates of uptake of the different settings, to help inform future service provision. Such a study
should more clearly identify and quantify issues such as setting-related adverse events, waiting times,
anxiety and transport problems, and indicate how their prevalence and impact might vary according to
patient characteristics.
For an economic evaluation to be reliable, detailed patient characteristics, resource use, cost and
quality-of-life data are needed. The ideal collection method for these parameters is a large multicentre RCT
that incorporates a wide variety of providers. However, a key theme that emerged from the review and
survey concerned a high level of variation in current practice in the NHS. This variation makes it unlikely
that a RCT will provide sufficient evidence for a broad economic evaluation. We surmise that, in order to
explore this variation and mitigate generalisability issues, broad observational data will be necessary.
Information from large observational data sets such as the Systemic Anti-Cancer Therapy and the General
Practice Research Database could be linked to provide a clearer portrait of current provision.
Study registration
This study is registered as PROSPERO CRD42013004851.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Background
H istorically, chemotherapy treatment for cancer patients was delivered in hospital. More than 10 yearsago, a BMJ editorial noted a shift in chemotherapy practice in the UK from inpatient to outpatient
ambulatory therapy.1 The editorial highlighted a small but growing body of evidence suggesting that
chemotherapy in the home was both safe and acceptable, but also identified a need for further
exploration of patient selection and cost-effectiveness.
Potential benefits of receiving chemotherapy treatment at home include less travelling to hospital facilities,
reduced risk of hospital-acquired infection, receiving treatment in the comfort and security of the home,
less disruption to family life and an increased feeling of control over treatment and illness.2 Potential
concerns for patients include increased feelings of isolation, decreased contact with hospital staff (such as
specialist nurses) and other patients, feelings of insecurity from a perception of reduced support outside
the hospital setting, and the possibility of less continuity of care.3
Safety is often perceived as being a key issue in the delivery of chemotherapy owing to the toxicity of the
drugs, the costs of management of preventable toxicities and the need for specialist skills to administer
and monitor treatment. The OUTREACH trial report indicated that clinicians were reluctant to refer patients
for home or general practice chemotherapy in part because of patient safety concerns.4
It is important to ensure that the risks of toxicity are managed by a cohesive multiprofessional team, that
problems with toxicity are identified promptly and correctly managed and that concordance with treatment
is optimised if outcomes are to be maintained. Severe side effects can be very disturbing and may
influence a patient’s decision to continue with treatment; this is true in any setting, but may possibly have
a longer term impact on patients when experienced at home. Whatever the treatment setting, severe
adverse events mostly occur between treatment-days and so even outpatients experience them outside
hospital. Appropriate pre-treatment assessment and patient education are key issues that apply to patients
in any setting. Health-care professionals involved with the administration and monitoring of treatment
need to have the relevant skills and expertise.
Throughout the NHS there has been an increasing focus on making care more centred on the needs and
preferences of patients.5 In the area of cancer services, the Cancer Reform Strategy has pledged that care
will be delivered in the most clinically appropriate and convenient setting for patients.6 The Department of
Health Cancer Policy Team has produced guidance to develop chemotherapy services in the community
[such as in general practitioner (GP) surgeries or patients’ homes],3 which builds on best practice guidance
provided in the National Chemotherapy Advisory Group report published in 2009.7 These documents
promote the consideration of opportunities to devolve chemotherapy from cancer centres and cancer units
to community settings while maintaining safety and quality, and delivering an efficient service. However, a
report on how effectively strategies laid out in the Cancer Reform Strategy have been utilised to improve
cancer services for patients found a lack of activity in the commissioning of services, with only 26% of
primary care trusts having undertaken a cost–benefit analysis looking at different ways of delivering
cancer services.8
These initiatives should be considered within the context of plans in England to reduce the number of
centres commissioned for specialised services and focus provision in a smaller number of centres.9 It is
currently unclear if chemotherapy will be included within the definition of a specialised service, or if this
will depend on the nature of the cancer being treated. Such a policy change may have implications for
where cancer chemotherapy is prescribed and administered, including options for delivery closer to home.
It is likely that many outpatient facilities across England and Wales are delivering chemotherapy services at
full capacity (assuming a 15% year-on-year growth in demand), and increasing strain to the service is
anticipated.7 Future demand for services is likely to increase further; increasingly early detection of cancer,
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improving cancer survival and an ageing population are key factors. For hospitals without the resources to
appropriately expand their capacity in terms of either staffing levels or physical space, it is likely that future
patients will face longer waiting lists or a reduced service. Delivering chemotherapy closer to the home
may enable hospitals to relieve the demand for hospital ward services while maintaining patients’ care.
The various chemotherapy delivery practices used in the UK reflect the different challenges of, for example,
large cancer centres and district general hospitals.10 Nurse-led chemotherapy is well established within
the outpatient setting but home and community delivery of chemotherapy is not currently widespread.
Different geographic challenges exist for provision in remote and rural communities compared with urban
centres. The Department of Health lists exemplars of NHS community chemotherapy services in
Sunderland, Dorset, West Anglia, East Anglia and East Kent, and there are health-care companies who
undertake chemotherapy in the community, offering services to both private and NHS providers, for
example Healthcare at Home (HaH), BUPA Home Healthcare, Baxter, Calea and Alcura.3
Successful services are likely to be closely tailored to the local requirements and available resources, and as
such are expected to vary considerably. For example, Leeds Teaching Hospitals NHS Trust does not provide
intravenous chemotherapy at home, at least in part because of the logistics of covering a large and diverse
catchment area; patients can receive intravenous chemotherapy in the community (at Otley community
hospital) and would attend pre-treatment assessment clinics at St James’s University Hospital in Leeds.
Conversely, the Sunderland model covers a relatively small urban area, which allows for a range of services
to be provided (Box 1).
BOX 1 Case study of a successful service
Case study of a successful service: Sunderland
In the Sunderland model, intravenous chemotherapy is available across three different settings according to
patient choice where eligibility criteria are met (drug is given in short infusions lasting < 5 hours, or as bolus
treatment that is not associated with a high risk of anaphylaxis). This model of care has been in operation since
2009 and is entirely provided by the local NHS hospital, covering a 15-mile radius from the main hospital. Initial
assessments are carried out by the chemotherapy nurse prior to treatment being scheduled.
From initiation of treatment, patients choose their preferred setting. Bookings are made through a single
appointment system, which allows flexibility so that patients can move between locations to suit
their schedules.
l Hospital outpatient (one venue, provided 6 days per week with a Saturday clinic 8.30 a.m. to 2.30 p.m.,
extended working until 7.00 p.m. midweek, approximately 40 patients per day).
l Outreach service (one venue, primary care centre provided 3 days per week, approximately 15 patients
per day).
l Patient home (try to group geographically, provided 4 days per week, six to eight patients per day).
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Chapter 2 Introduction
Aims
This aim of the project was to investigate the impact of the delivery of intravenous chemotherapy in
different settings on quality of life, safety, patient satisfaction and costs. Our focus was the provision of
intravenous chemotherapy led and managed from the oncology department and delivered in the patient’s
home, in the community or in the hospital outpatient department.
Objectives
The project comprised four elements:
l a systematic review of the clinical and economic literature to bring together and assess the
existing evidence
l a brief survey to gather information about the structure of services and variation in practice across
the NHS
l a description of the general pathway for patients who will be offered chemotherapy
l the development of a decision model to compare delivery of chemotherapy for an eligible population in
three settings.
In addition to the project team, an advisory group of specialist nurses, pharmacists, and patient
representation was formed to help to guide each of the elements from the proposal stage through to the
final report. This report details the methods and results for each element, draws together and discusses
the findings and identifies the implications for health care and future research.
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Chapter 3 Systematic review
Introduction
To provide a complete overview of the current published evidence base for the delivery of intravenous
chemotherapy closer to home, a series of three interlinked systematic reviews was undertaken. Each review
assessed a different type of evidence: comparative clinical effectiveness, cost-effectiveness and qualitative
studies. We used the same methodology across reviews except where different types of evidence
precluded this; any alternative methods are clearly described and signposted.
Together, the three reviews summarise the totality of the evidence base by addressing particular questions
and focusing on the most appropriate type of evidence. The reviews were conducted in parallel within
an explicit and pragmatic mixed-methods framework based on principles of complementarity. This
approach is based loosely on the approach pioneered by the Evidence for Policy and Practice Information
(EPPI) and Co-ordinating Centre (the EPPI approach).11
The same researchers worked on each of the three reviews to ensure a collaborative approach. Regular team
meetings and discussions during study selection, data extraction and analysis promoted cross-fertilisation of
ideas. Matrices were used to collate the summary findings from each of the three reviews. Commonalities
and divergences between the results were identified and integrated with the findings informing the decision
model. Chapter 6 presents the meta-synthesis of all elements from the project.
Methods
Searches
The aim of the literature searches was to systematically identify research on the impact of setting (closer to
home) on the delivery and outcomes of intravenous chemotherapy.
The base search strategy was constructed using MEDLINE and then adapted to the other resources
searched (Box 2).
BOX 2 MEDLINE search strategy
MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)
URL: http://ovidsp.ovid.com/
Date range: 1946 to week 2 March 2013.
Date of search: 25 March 2013.
1564 records identified.
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Search strategy
1. exp neoplasms/ (2,406,640)
2. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,ab. (2,073,583)
3. oncologic nursing/ (6088)
4. or/1-3 (2,889,785)
5. drug therapy/ (33,151)
6. Antineoplastic Combined Chemotherapy Protocols/ (97,247)
7. chemotherapy, adjuvant/ or consolidation chemotherapy/ or maintenance chemotherapy/ (27,648)
8. administration, intravenous/ or infusions, intravenous/ (46,068)
9. chemotherapy.ti,ab. (223,465)
10. systemic therapy.ti,ab. (5856)
11. intravenous drug therapy.ti,ab. (39)
12. adjuvant therapy.ti,ab. (14,653)
13. or/5-12 (357,679)
14. home care services/ or home care services, hospital-based/ (28,037)
15. *Outpatients/ (2136)
16. *Ambulatory Care/ (14,592)
17. *ambulatory care facilities/ or *outpatient clinics, hospital/ (13,416)
18. community health services/ or community health nursing/ or community health centers/ (47,800)
19. general practitioners/ or physicians, family/ or physicians, primary care/ (16,406)
20. general practice/ or family practice/ (61,185)
21. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory or
domicil$)).ti,ab. (42,475)
22. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to home).ti,
ab. (15,680)
23. or/14-22 (207,550)
24. 4 and 13 and 23 (1144)
25. home infusion therapy/ (579)
26. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,ab. (719)
27. (chemotherapy adj6 service$).ti,ab. (184)
28. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician$ or
primary care physician$)).ti,ab. (19)
29. (self-infusion adj6 home).ti,ab. (21)
30. home infusion.ti,ab. (254)
31. or/25-30 (1591)
32. 4 and 31 (751)
33. 24 or 32 (1595)
34. exp animals/ not humans/ (3,782,734)
35. 33 not 34 (1564)
BOX 2 MEDLINE search strategy (continued)
The search included the following components:
1. cancer terms AND
2. chemotherapy terms AND
3. generic home care/ambulatory care terms.
These terms were combined with (OR), the following terms:
1. cancer terms AND
2. home chemotherapy terms.
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No date, language or other limits were applied and, where possible, animal-only studies were excluded.
The strategy was constructed by an information specialist within the Centre for Reviews and Dissemination
(CRD) and subsequently peer reviewed by another information specialist prior to use.
Search terms were identified by scanning key papers known at the beginning of the project, through
discussion with the review team and the use of database thesauri.
The full strategies from all of the databases are given in Appendix 1.
Sources of both published and unpublished information were identified by an information specialist with
input from the project team. MEDLINE and MEDLINE In Process & Other Non-Indexed Citations; Allied and
Complementary Medicine Database; British Nursing Index; Cumulative Index to Nursing and Allied Health
Literature; The Cochrane Library; Conference Proceedings Citation Index – Science; Dissertation Abstracts;
EconLit; EMBASE; Google; Health Management Information Consortium; Inside; Office for Health
Economics Health Economic Evaluations Database; PsycINFO; PubMed; Social Policy and Practice;
ClinicalTrials.gov and Current Controlled Trials databases and the Google search engine were searched.
Databases were searched from date of inception to March 2013. Update searches were undertaken in
October 2013.
Reference searches of all included randomised controlled trials (RCTs) and relevant systematic reviews were
undertaken. Where necessary, authors of eligible studies were contacted for further information and
experts in the field were contacted to see whether or not they had access to further material.
We contacted private providers of home care through the National Clinical Homecare Association
(including HaH, Bupa, Baxter, Calea and Alcura) to identify unpublished reports, evaluations or
resource information.
We also contacted the Medicines and Healthcare products Regulatory Agency to request information on
suspected adverse drug reactions and adverse events for intravenous home chemotherapy drugs. Route of
administration was available, but the system does not store information on the setting where the drug was
given or the adverse event occurred. Therefore, no data relevant to this project could be collated.
Inclusion criteria
Population
Cancer patients receiving intravenous chemotherapy.
Interventions and comparators
Studies comparing intravenous chemotherapy in two (or more) of the following settings:
l home setting (includes nursing homes)
l community-based setting (e.g. GP practice, community clinic, community hospital or mobile units)
l hospital outpatient setting.
Within-setting comparisons were eligible if the study compared different organisational or
management approaches.
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Outcomes
Any of the following:
l safety
l patient quality of life
l preference
l satisfaction (including treatment compliance/adherence)
l social functioning
l clinical outcomes
l patient and carer opinions and experiences
l costs
l resource/organisational issues (including access).
The clinical outcomes of interest were self-rated health or measures of performance status.
Study designs
Any type of comparative design was eligible. To obtain information about patient quality of life,
satisfaction, preferences and opinions, studies that reported results for only one eligible setting and
qualitative research (any of the three settings) were considered, providing that they had a stated aim to
evaluate one or more of these outcomes. Given the review focus on home and community settings, and
the potential diversity and likely volume of these studies in an outpatient setting, we focused on studies
of the home and community settings.
Full economic evaluations that compared two or more eligible settings and considered both costs and
consequences (including cost-effectiveness, cost–utility or cost–benefit analyses) were eligible.
Screening and study selection
Two researchers independently screened all titles and abstracts obtained using the predefined eligibility
criteria. Discrepancies were resolved by consensus, with recourse to a third researcher where necessary.
Full manuscripts of potentially relevant studies were obtained where possible and were screened in
duplicate. Studies in any language were eligible for inclusion.
Data extraction and quality assessment
Studies were assessed for quality as part of the data extraction process using criteria relevant to the
topic and study designs included. Data were extracted into structured forms using a pre-piloted form in
EPPI-Reviewer (EPPI-Centre, Institute of Education, University of London, London, UK). Piloting was
undertaken by each researcher involved with the process and refined as necessary prior to full data
extraction to ensure consistency. Data extraction and quality assessment was conducted by one researcher
and checked by a second researcher for accuracy, with any discrepancies resolved by discussion or by
recourse to a third researcher where necessary.
Clinical studies
Data were extracted on details of study methods, country and geographical region in which the study was
conducted, whether it was single or multicentre, dates over which the study was conducted, patient
characteristics, interventions, comparators where appropriate, all relevant outcome measures and results.
The quality of included comparative studies was assessed using criteria appropriate to the study design,
adapted from published checklists.12
Randomised controlled trials
Randomised controlled trials were assessed using the Cochrane risk of bias tool, which focuses on the domains
shown to impact on the trial results in particular (selection, performance and detection biases and attrition).13
The tool was modified to incorporate assessment of baseline imbalances when we evaluated selection bias.14
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Non-randomised comparative studies
Study quality evaluations were based on recently published papers detailing methodological issues and
assessment of bias in non-randomised studies.15–18 Confounding variables (variables other than the
intervention being studied, which might affect study outcomes when groups are compared) are known to
be a very important source of bias in non-randomised studies.19 As there were many potentially important
confounders for our review question, we focused our assessment on evaluation of the risk of bias due to
confounding. This was done by answering the following questions:
1. How were the groups formed?
2. Were the effects of any confounders taken into consideration during the design and/or statistical
analysis stages?
3. What methods were used to control for confounders?
4. Were data on the measured confounders recorded precisely enough?
5. Were any key confounders not controlled for?
The important confounders we considered were type of cancer, stage of cancer, type of chemotherapy,
age, performance status [e.g. Karnofsky, Eastern Cooperative Oncology Group (ECOG) or Lansky scores],
quality of life, treatment intent (curative or palliative) and distance from hospital. These confounders were
chosen for their potential to affect outcomes such as quality of life and patient satisfaction. Some of these
confounders are correlated.
Where these confounders were not measured, and not taken into account in the design or analysis of the
study, the study results were deemed likely to be at a high risk of bias. Studies where such details were
not clear were judged to have an unclear risk of bias. Given the non-randomised nature of the studies
and the lack of assurance provided about the methods used, the implications of an unclear risk of bias
judgement are similar to those of a high risk of bias judgement and the study results should not be
interpreted as being reliable.
Where the answer to question 2 was ‘yes’, the details of which confounders were controlled for were
recorded and the remaining questions were answered; the overall risk of bias judgement (from
confounding) was then made based on the answers to questions 3, 4 and 5. Where the answer to
question 2 was ‘no’ or ‘not reported’, a high or unclear risk of bias judgement was made and the
remaining questions were not answered. An assessment of whether or not there was evidence that
potential confounders did not actually result in confounding was also made when considering question 2.
For non-randomised studies there is evidence that confounding may not, on average, cause bias in the
estimation of adverse effects.17 We considered this during our assessments according to how likely a given
adverse effect (as defined in individual studies) might be affected by confounding.
As cost and resource outcomes were extracted to inform the review’s economic modelling, formal
synthesis and quality assessments were not routinely performed for these outcomes.
Non-comparative studies were not extracted or quality assessed, but they are listed for reference in
Appendix 2.
Cost-effectiveness studies
Data extracted from economic evaluations included interventions compared study population; dates to
which the data related; measures of effect; direct costs (medical and non-medical); currency used;
utilities/measure of health benefit; and results and details of any decision modelling applied. The quality
assessment of the economic evaluations was informed by use of the Drummond 36-point checklist.20 The
purpose of the review was to provide an overview of the current cost-effectiveness evidence base and help
to inform the development of a de novo decision model. Any additional information that could aid
development of a de novo decision model was also extracted.
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Qualitative studies
Qualitative studies were assessed for methodological quality using criteria based on the work of Mays and
Pope, among others.21–23 As with the quantitative studies, the focus was on those domains which are
expected to influence the reliability of the findings. Domains included transparency and documentation of
the data collection and analysis processes, description and justification of sampling, validity appropriate
to the method being used, reflexivity and clear distinction between data and interpretation.
The results sections from each included study [apart from one Doctor of Philosophy (Ph.D.)] thesis were
extracted from portable document format files and entered into NVivo (QSR International, Warrington, UK)
as text documents.24 We used online translation for one paper in Danish. This unconventional approach
appeared to generate reasonable approximations of the original meaning and avoided the expense and
delay of professional translators; this was balanced against the possibility of losing some meaning
in translation.
The Ph.D. thesis24 was read through with the other papers, but not extracted and coded until nearer the
end of the process. The thesis was useful as a way of checking for gaps or absences in the data as a
whole, but it was too dense and, in places, of less immediate relevance to warrant full extraction.
Synthesis
Clinical effectiveness data
Our detailed narrative synthesis explored the methodology and reported outcomes of included studies.
Key study characteristics, patient outcomes and quality assessment were tabulated to provide clear
summaries of the included studies. The clinical and statistical heterogeneity of the accumulated evidence
was assessed. Differences between studies were discussed in the text and the potential impact of these
differences on outcomes was explored. The results were interpreted in the context of the quality of the
individual studies.
As anticipated, the available data were too heterogeneous for quantitative synthesis.
Cost-effectiveness data
The findings of the systematic review of full economic evaluations were summarised in a
narrative synthesis.
Qualitative data
The qualitative studies were synthesised using meta-ethnography, an approach which searches each
primary study and systematically extracts key findings and interpretations.25,26 These data are then
compared using a constant comparison method, which categorises key concepts to look for overlapping
themes in order to enable linking of material. Each finding is subsequently assessed for similarity or
difference to the other studies, and the goal is to develop, in an iterative manner, this reciprocal
translation. Ultimately, new lines of argument can be developed which go beyond the data contained
within the original studies.
The focus of the analysis was on themes and ideas relating directly to the provision of intravenous
chemotherapy with particular reference to treatment location, rather than the experience of having cancer
treatments per se.
Each results section was read closely on multiple occasions and coded line by line using participants’ words
where possible. Initially, codes were tagged according to the setting (e.g. code ‘prefer to go home after
treatment’ was linked to ‘outpatient setting’). Subsequent readings of the texts and resultant codes led to
the reworking of the coding framework into key elements rather than distinguishing by treatment location.
Codes were collapsed where possible and a process of diagramming used to explore links and interactions
between the key lines of argument and categories.
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Results
The electronic database searches identified 4260 references. A further 12 references were found by Google
searches or by checking reference lists of included randomised trials and relevant systematic reviews. After
screening titles and abstracts, full copies of 245 papers were assessed for inclusion in the review. Figure 1
illustrates the flow of studies through the review process. Fourteen references were of papers related to
another reference already included. Sixty-seven eligible studies were identified. Nine of the 25 comparative
studies (10 RCTs and 15 non-randomised studies) fully evaluated in the review undertook concurrent full
economic evaluations; these were evaluated separately in the review to enable a more detailed assessment.
The 42 studies of single-settings are listed in Appendix 2. We identified a larger than expected number of
comparative studies, and so we evaluated only those single-setting studies which might usefully add to the
synthesis of the comparative studies. Consequently, single-setting studies were used only to inform the
Unique references retrieved from database
searches up to November 2013
(n = 4260)
Potentially
relevant papers
(n = 233)
Articles assessed
(n = 245)
Eligible references
(n = 81)
Included studies
(n = 67, with 14 linked references)
RCTs
(n = 10)
10 with clinical data
6 economic evaluations
4 with qualitative data
15 with clinical data
3 economic evaluations
3 with qualitative data
Clinical data not used
0 economic evaluations (N/A)
10 with qualitative data
Non-randomised studies
(n = 15)
Single-setting studies
(n = 42)
Excluded, n = 164
References identified by
reference list and Google
searches, n = 12
Excluded on title or
abstract, n = 3870
Single-setting outpatient
studies, not obtained, n = 137
Unobtainable, n = 20
FIGURE 1 Flow chart of study selection. N/A, not applicable.
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evaluation of qualitative data on patient, relative or caregiver experience of intravenous chemotherapy
(see Chapter 3, Results, Qualitative studies). As we anticipated there to be a large number of single-setting
outpatient studies, we ordered full papers only for studies that appeared likely to report qualitative data.
The following sections present a detailed breakdown of the results of the RCTs, non-randomised studies
and economic evaluations. For each study design, study characteristics, risk of bias or quality assessment
and results are presented.
Clinical effectiveness studies
Randomised trials
Study characteristics
Ten randomised trials investigated the effect of setting for patients receiving intravenous chemotherapy
(Table 1). Six trials used a crossover design (where participants act as their own controls, and typically
receive all interventions in succession). Three trials used a parallel design (where participants typically receive
TABLE 1 Summary of randomised trials included in the review
Study Country
Sample
size
Recruitment
ratea
Setting
OutcomesHome Community Outpatient
Corrie et al.
2013
(OUTREACH)4
England 97P 1.7 ✓ ✓ ✓ Quality of life, anxiety,
depression, health status,
costs, satisfaction, serious
adverse events
bChen and
Hasuimi
199927
Japan 10P NP ✓ ✓ Quality of life, anxiety,
nursing time
bChristiansen
et al. 201128
Denmark 51C 1.4 ✓ ✓ Quality of life, adverse effects,
time spent receiving
chemotherapy, preference,
costs
Pace et al.
200929
England 42C 3.2 ✓ ✓ Preference, anxiety, depression,
safety, resources
Hall and
Lloyd 200830
England 15P 2.5 ✓ ✓ Experience and satisfaction,
costs
King et al.
200031
Australia 74C 1.5 ✓ ✓ Preferences and strength of
preference, satisfaction,
unmet need, quality of life,
costs
Rischin et al.
200032
Australia 25C 1.8 ✓ ✓ Preference, satisfaction,
complications, costs
Stevens et al.
200633
Canada 29C NP ✓ ✓ Quality of life, social/
psychological interactions,
adverse events, costs
Remonnay
et al. 200234
France 52C 1.6 ✓ ✓ Satisfaction, costs, quality of
life, anxiety
Borras et al.
200135
Spain 87P 6.7 ✓ ✓ Toxicity, withdrawals,
health-care resources, quality
of life, satisfaction, Karnofsky
Index
C, crossover design; NP, not possible; P, parallel-group design.
a Number recruited per centre, per month (estimated using the total number of patients randomised, the number of
centres and the recruitment periods, except when NP).
b Studies reported only as a conference abstract.
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only one intervention). One study reported only as an abstract appeared to use parallel groups and
incorporated elements of a crossover design.27 Most studies were reported as full published papers;
two were reported only as conference abstracts.27,28 Studies were published between 1999 and 2013.
Three studies were conducted in the UK (England),4,29,30 two were conducted in Australia,31,32 and
one study was conducted in each of Canada,33 Denmark,28 France,34 Japan27 and Spain.35
Eight studies27,28,30–35 compared chemotherapy in the home setting with chemotherapy in a hospital
outpatient setting. One study29 compared a community setting with a hospital outpatient setting. One
study4 was a three-armed trial that compared home, community and outpatient settings. Setting details
were generally not well reported; for example, aspects such as the number of nurses per patient, the
degree of access to parking, and facility details were only occasionally provided. The two community
settings studies assessed treatment delivered in GP surgeries and community outreach centres.4,29
Treatment durations were often not stated explicitly or were expressed in terms of cycles; however, most
studies reported chemotherapy durations ranging between approximately 2 and 8 months.
All of the trials except Stevens et al.33 studied adults, with reported mean (or median) ages ranging from
57 years to 64 years. Around half of the studies were of mixed populations; patients with colon, breast,
and pancreatic cancer were the most frequently studied. Studies were also conducted solely in populations
with ovarian,27 colon28 or breast cancer.30 The study in children was of a population with acute
lymphoblastic leukaemia.33
The treatment intention was not always reported. Where reported it varied both within and across studies,
with chemotherapy administered with either palliative or curative intent (sometimes as an adjuvant
treatment). Few studies reported details on where chemotherapy drugs were prepared: in two trials drugs
were prepared in the hospital pharmacy4,29 and in one trial a community pharmacy was used.33 Full study
characteristics are reported in Appendix 3.
Recruitment and participation
In total, 482 participants were randomised across 10 trials. Sample sizes ranged from 10 to 97. Six studies
reported a target sample size; three of these achieved or exceeded their small recruitment targets of 30 or
fewer patients. Three studies did not achieve their targets: in one study a target of 20 patients was not
reached (reasons unclear); one study was terminated early when 52 of a targeted 160 participants had
been randomised,34 because a large majority preferred the home setting; and the largest included study
(OUTREACH) was stopped owing to the poor recruitment rate when 97 of a targeted 390 participants had
been randomised (the decision was made on the advice of the independent data monitoring committee).4
Despite this early termination, the OUTREACH trial rate of recruitment (estimated at around 1.7 patients
per month per centre) was similar to the estimates for many other trials (rates ranging from 1.4 to
2.5 patients per month per centre), except for the Borras et al.35 trial (around 6.7 patients per month/
per centre) and the Pace et al.29 trial (around 3.2 patients per month per centre) (see Table 1 for details).
Five of the nine trials where the outpatient setting was the standard care setting (the only routinely
available setting) reported details of eligible patients who were not randomised. Between them, these five
trials randomised 294 participants, but 100 eligible patients chose not to participate for setting-related
reasons. Generally, these participants withdrew from the trial to revert to standard practice (which was
their preferred setting). In one trial home chemotherapy was already an option before the trial
began – and eligible patients had to be registered on the ‘chemotherapy in the home program’.32 In this
study several patients chose not to participate because they wanted only home treatment. These data
highlight the inherent bias (in terms of the types of population recruited) often encountered in trials that
evaluate settings (see Chapter 6, Limitations of the evidence and of the review for more discussion of
this point).
No consistent trends were found in the setting-related reasons for participants who withdrew or dropped
out of trials (some studies reported limited details or none at all).
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Risk of bias
Results of the risk of bias assessments are presented in Appendix 4. Even though only the OUTREACH trial
clearly reported on both the sequence generation and allocation concealment methods,4 most studies can
be judged as being at a low risk of selection bias overall. This is largely because treatment groups had
similar characteristics at baseline, a factor which was mainly a result of the use of a crossover design.
All studies were judged to be at high risk of performance bias; study participants and personnel will have
been aware of which setting had been allocated, and avoidance of such bias is impossible. Similarly, results
for the subjective patient-reported outcomes, such as quality of life and satisfaction, were judged to be at
high or unclear risk of bias in all studies. Conversely, the risk of detection bias was judged low for studies
reporting adverse events because they are mostly not subjective outcomes.
In four of the 10 trials the risk of attrition bias was judged to be low. There were insufficient details for the
remaining six trials; accordingly, these trials were judged to be at an unclear risk. Four trials were found to
be at a low risk of reporting bias, two were at a high risk of bias owing to missing results (or result detail),
and in the remaining trials the risk was unclear.
Of the six crossover trials, only three clearly reported using appropriate statistical analyses. In three
crossover trials the use of a crossover design appeared questionable, because of the number of patients
withdrawing or dropping out because of disease progression.
Results and synthesis of randomised clinical effectiveness trials
Quality of life
Seven of the 10 randomised trials reported that they evaluated some measure of quality of life; actual
result data were available for only four trials (see Table 1). There were no statistically significant differences
in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (30 items)
(EORTC QLQ-C30) self-rated quality of life between any settings (home vs. outpatient;4,28,35 home vs. GP,
outpatient vs. GP4). Both home and outpatient settings were associated with statistically significant
better results for the EORTC QLQ-30 Emotional Function outcome than in the GP surgery setting in the
OUTREACH trial; there were no statistically significant differences between home and hospital settings.4,35
One trial used Functional Living Index Cancer (FLIC) scores as a measure of quality of life and found that
setting (home vs. outpatient) had no effect on either total FLIC scores or any of the seven dimension
scores.31 The remaining trial studied 23 children using the Paediatric Oncology Quality of Life Survey
(POQOLS).33 It found statistically significant improvement associated with the home setting, compared with
the outpatient setting, in terms of sensitivity to restrictions in physical functioning and the ability to
maintain a normal physical routine. There were no statistically significant differences between the settings
in terms of emotional distress and reaction to current medical treatment.
Clinical and psychological outcomes
Two trials reported results for EORTC QLQ-C30 self-rated health (see Table 1).4,35 Both suggested that
there was no difference between the home and outpatient settings. One trial compared GP and outpatient
settings and GP and home settings and reported no statistically significant differences. The other study
evaluated Karnofsky Index scores and reported identical scores for the home and outpatient settings.
Two trials evaluated participants using the Hospital Anxiety and Depression Scale (HADS).4,29 Results from
one trial suggested that higher levels of both anxiety and depression were associated with the GP setting,
compared with the home or outpatient settings, but the results were statistically significant only for the GP
versus outpatient comparison (for depression). There was little indication of any meaningful differences
between the home and hospital settings. The other trial did not report any data, but stated that there
were no significant differences between the community hospital and outpatient settings for both anxiety
and depression.
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Satisfaction and preferences
Five trials reported quantitative results for satisfaction (and related outcomes). Specific outcomes varied
between studies (see Table 1). Two trials reported statistically significant results suggesting satisfaction
benefits in terms of nursing care for the home and community settings, compared with the outpatient
setting.29,35 The largest study (OUTREACH) that compared home, GP surgery and outpatient settings in the
UK reported that 78% of participants were satisfied with their treatment setting, regardless of location.4
An Australian trial reported that significantly more patients found the outpatient setting more depressing
than the home setting, although no significant differences were found for patient needs.31 Other studies
suggested no differences between groups in terms of global satisfaction,29 or doctor-care outcomes.35
Five trials reported quantitative results for preferences, but only one of these trials evaluated strength of
preference.31 In the four trials where patients experienced two settings (because a crossover design was
used) between 70% and 95% of patients preferred the home setting,31,32,34 and 97% preferred a
community outreach setting,29 when compared with the outpatient setting. One trial stopped recruiting
participants early owing to the strong preferences expressed for home treatment.34
Results from the study that considered strength of preference suggested that preferences were not very
strong. It found that 34% of the participants who preferred home treatment changed their preference
to outpatient treatment if home treatment was to involve waiting an extra hour, and that 27% of
participants who preferred outpatient treatment changed their preference to home treatment if faced with
an extra hour of waiting.31 These results suggest that for some patients time is more important than
setting. This trial was the only study to consider the issue of recruitment bias. The authors performed an
additional analysis of patient preference by also including the 13 patients who chose not to participate in
the trial for setting-related reasons, which they interpreted as a preference for the outpatient setting;
similarly, this analysis also included the eight patients who chose not to receive home treatment after
experiencing outpatient treatment (see Appendix 3). The results indicated that the proportion of patients
who preferred home care to outpatient care was 48%.
Safety
Six trials reported on adverse events (see Table 1). Four trials provided some assessment of whether
adverse events were related to setting (e.g. in one trial a nurse was unable to cannulate an outreach
patient, who was consequently treated at the cancer centre).4,29,32,33 They found no evidence to suggest
significant differences existed between settings for any type of adverse event. Two studies evaluated only
toxicity and also found no differences between settings.28,35
Full result details for all outcomes are presented in Appendix 5.
Non-randomised studies
Study characteristics
Fifteen non-randomised, comparative studies investigated the effect of setting for patients receiving
intravenous chemotherapy; they were reported between 1989 and 2013 (Table 2).24,36–49 Several studies
were not easy to identify or access: four were reported only as conference abstracts,42,44,47,48 one was only
available as a Ph.D. thesis,24 one was an unpublished internal report36 and one was only available as an
online report.37 Five studies took place in England,24,36,39,44,46 four in the USA,42,43,47,48 two in Denmark38,41
and one each in Wales,40 Australia,45 Canada37 and France.49
In three studies,24,39,41 the only review-relevant outcomes were qualitative (see Results, Qualitative studies). In the
remaining 12 studies, eight compared the home and outpatient settings,38,42–46,48,49 two compared community
settings with outpatient settings,37,47 one compared home with community settings40 and one compared all
three types of settings.36 Population sizes were not always clearly reported, but ranged from 14 to around 2800
patients (more than half of the studies were of fewer than 100 patients). Most studies were of mixed
populations; most patients had colorectal cancer, breast cancer or lung cancer. Mean ages ranged from
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50 years to 75 years, where reported. One study was in children with leukaemia or lymphoma and was the only
study which indicated where the chemotherapy drugs were prepared; this study also clearly reported setting
details (e.g. home care was provided by one or two nurses, depending on the tasks involved).38 In other studies
the setting details were not generally well reported; exceptions were descriptions of a community mobile
chemotherapy unit,39 and community oncology clinics.37 Full study characteristics are reported in Appendix 7.
Risk of bias
Table 3 details the results of the risk of bias assessment of the non-randomised studies. Most studies were
judged to be at a high or unclear risk of bias due to confounding. Although four studies did consider the
effect of confounders in their study design and/or analysis plan, they did not investigate all the likely
TABLE 2 Summary of the non-randomised studies included in the review
Study Country
Sample
size
Setting
OutcomesHome Community Outpatient
Taylor 200824 England ≈ 140 ✓ ✓ Qualitative data on provision of care at
home from health professionals and
patients
NHS Bristol
201036
England 848 ✓ ✓ ✓ Patient experience
Pong et al.
200037
Canada 435 ✓ ✓ Self-reported health status, costs,
satisfaction; reasons for choosing
setting
Hansson et al.
201338
Denmark 75 ✓ ✓ Patient- and parent-reported health-related
quality of life, psychological impact on
family, costs
Mitchell 201139 England 20 ✓ ✓ Patient experience (qualitative),
satisfaction, costs
Barker 200640 Wales 14 ✓ ✓ Toxicity, satisfaction
Frølund 201141 Denmark 6 ✓ ✓ Qualitative data on experiences of
chemotherapy
aGrusenmeyer
et al. 199642
USA NR ✓ ✓ Costs, satisfaction
Herth 198943 USA 80 ✓ ✓ Hope, coping
a
Ingleby et al.
199944
England 25 ✓ ✓ Costs
Lowenthal
et al. 199645
Australia 179 ✓ ✓ Safety, costs, resource use
Payne 199246 England 53 ✓ ✓ Quality of life, Karnofsky performance
aSatram-Hoang
and Reyes
201147
USA ≈ 2800b ✓ ✓ Time to treatment initiation, duration
of treatment, number of cycles
delivered, compliance
aSouadjian
et al. 199248
USA Unclear ✓ ✓ Costs, complications, quality of life,
preference
Vergnenègre
et al. 200649
France 20 ✓ ✓ Adverse events, costs
NR, not reported.
a Studies reported only as a conference abstract. For one comparative study the design was unclear and only a conference
abstract was available.42
b This is an estimate, as the total population of 3690 patients included 25% who received only rituximab.
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confounders. The two studies which were given a low-risk judgement both reported adverse events as
their only review-relevant clinical outcome; the types of adverse event assessed were unlikely to have been
affected by any confounding factors in the populations studied.
Non-randomised study results
Three studies evaluated quality of life but their results did little to augment the RCT evidence: two studies
were small, with a high risk that confounding would affect the reliability of their results; and one study
was reported only as an abstract (making it difficult to interpret the results).38,46,48 There were similar
issues for the four studies of patient satisfaction.37,39,40,42 One study included 435 patients but they were
selected retrospectively, with no consideration made for confounding factors; and the study was in
Canada, where the travel time and distances are different from those likely to be encountered in the UK.37
Only one of the four studies which had a safety outcome yielded informative results;45 this Australian study
reported that complications in the home setting were rare, although no comparative data were reported
for the outpatient setting for this particular outcome. Two of the three other studies that looked at safety
had very small sample sizes,40,49 and the other was only reported as an abstract.48 Three studies that looked
at qualitative patient experience are discussed in Results, Qualitative studies.
Only one comparative study looked at the issue of treatment compliance in any detail.47 It was conducted
in the USA and studied approximately 2800 follicular lymphoma patients receiving chemotherapy [with
or without rituximab (Mabthera, Roche)]. The study concluded that patients treated in the outpatient
setting tended to have longer times to treatment initiation and fewer cycles across all regimens, and were
less likely to receive a compliant dosing schedule than patients treated in a community clinic setting.
However, the reliability of these conclusions was unclear as the study was only reported as an abstract
(the risk of bias due to confounding was unclear). The results for all the non-randomised studies are
presented in Appendix 5.
Cost data
Fourteen comparative studies reported costs as an outcome (see Tables 1 and 2). Cost data were recorded
only to help inform the decision modelling part of the report and are presented in Appendix 6.
Clinical results evidence summary
The included studies revealed inherent difficulties in conducting randomised trials of chemotherapy
settings. Even trials that were designed appropriately to minimise avoidable biases faced problems not only
of patient accrual but also of recruiting a population to enable an unbiased evaluation of the settings.
These seemingly unavoidable selection biases might be expected to produce results that favour home
(or community) settings. Even so, there was little evidence of clinically relevant differences between
settings in terms of quality of life and clinical and psychological outcomes. The only potentially meaningful
differences were seen for some patient satisfaction and preference outcomes. However, strength of
preference was studied in only one trial, with preferences appearing not to be strong in around one-third
of patients. The limited safety evidence available suggested there were no differences between settings.
The non-randomised studies added little to the randomised trial evidence (although community settings
were more frequently studied). The main limitations were the small populations and the high risk that
study results were biased due to confounding.
Cost-effectiveness studies
Study characteristics
Nine economic evaluations published between 1996 and 2013 met the criteria for inclusion. The key
characteristics, methods and results for the nine studies are summarised in Table 4. Details of patient
characteristics and treatment regimens can also be found in Table 4. All nine evaluations also met
the inclusion criteria and have been assessed independently as comparative studies.
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Three of the evaluations were conducted in Australia,31,32,45 two in the UK (England),4,29 two in France34,49
and one in each of Canada33 and Denmark.38 Most studies assessed adult populations; two studies
assessed paediatric populations.33,38 Six evaluations were conducted alongside RCTs, two alongside
non-randomised controlled studies,38,49 and one was conducted as part of a retrospective audit.45 Most
studies did not conduct a full incremental analysis i.e. to produce [incremental cost-effectiveness ratios
(ICERs)], but instead reported cost and health outcomes separately. Costs and outcomes were generally
assessed over a short time horizon (1 year or under).
All of the non-UK studies compared treatment delivered in the home with treatment delivered in a hospital
outpatient setting.31–34,38,45,49 The two UK studies included community settings: Pace et al.29 compared
treatment delivered in a community hospital setting with treatment delivered in a hospital outpatient
setting; and OUTREACH4 compared home, GP surgery and hospital outpatient settings. None of the
economic evaluations assessed the delivery of chemotherapy by mobile bus units. One study assessed the
delivery of home chemotherapy by a third-party charity organisation.34 In all other studies it was implied
that home/community care was delivered by the health service.
As highlighted in the clinical study sections, most studies assessed mixed populations with various cancer
types, including breast cancer, colon cancer, lung cancer, gastrointestinal cancer, lymphoma, pancreatic
cancer and leukaemia. One study assessed only patients with acute lymphoblastic leukaemia.33 An array of
treatment regimens was used for a mixture of curative, supportive and palliative intent. The populations
appeared to be heterogeneous in terms of disease severity.
The nine evaluations conducted alongside clinical studies recruited a total of 593 patients and
487 participants were evaluated in the concurrent economic evaluations. Most of these participants were
evaluated in the two non-randomised studies; 179 patients were evaluated in the retrospective audit45 and
75 were evaluated in the controlled study.38 The six evaluations made concurrently with RCTs were based
on small data sets:4,29,31–34 the largest study (OUTREACH)4 had complete primary outcome data (EORTC
QLQ-C30 Emotional Function subdomain) on only 57 participants across three treatment arms/settings.
Chapter 6 contains an overview of recruitment and participation within the RCTs (see Limitations of the
evidence and of the review). The number of participants informing the concurrent cost-effectiveness
analysis is presented in Table 4, alongside other study characteristics and findings.
Economic quality assessment
The Drummond checklist was used to assess methods and reporting in the nine included economic
evaluations.20 Clinical studies undertaken alongside the economic evaluations were assessed for risk of bias
as part of the quality evaluation of comparative studies (see Table 3 and Appendix 4). All of the
evaluations suffered from limitations, as highlighted by the checklist. Many did not undertake appropriate
data collection and/or sensitivity analyses. Seven of the nine studies reported no data on resource use
outcomes, which significantly reduces the transparency and transferability of the results. Five studies
reported disaggregated costs (costs for each of the included cost categories rather than a total cost only),
but the usefulness of such costs in terms of informing potential UK NHS cost estimates is limited without
resource use data. Reporting of methods used to derive cost and resource use outcomes was limited and
this made the validity of the cost estimates unclear. Most studies failed to report the price year or any cost
adjustments applied. None of the studies conducted an adequate analysis of the potential impact of
uncertainty on the results; all three studies that included sensitivity analyses were limited in scope. Most
studies failed to consider the generalisability of their results. Full results for the quality assessment can be
found in Table 5.
Overall, the studies were deemed to be of low or uncertain quality due to small sample sizes; limited
reporting on resource use, costs and methodology; and lack of robust sensitivity analyses. There is likely to
be significant uncertainty around the cost-effectiveness results.
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Economic study results
Health outcomes
Several health outcomes were assessed in the nine economic evaluations: EORTC QLQ-C30, FLIC scores,
safety and adverse events, patient satisfaction and patient preferences. It was unclear why only one
economic evaluation reported quality-adjusted life-year (QALY) outcomes when these would better
facilitate modelling.
There was no robust evidence of any meaningful between-setting differences for most health outcomes
(EORTC QLQ-C30, FLIC scores, safety and global satisfaction). There was less than robust evidence that
emotional functioning, anxiety and depression were improved in the home and outpatient settings
compared with a GP surgery (OUTREACH)4 and that satisfaction was higher in the home than in the
outpatient setting in terms of nursing care and the depressive nature of the setting.29,31 Evidence in the
child population was limited. Children’s quality of life was improved in the home setting, compared with
an outpatient setting.33 A full description of these health outcome results, as measured in the trials, is
presented in Results, Clinical effectiveness studies.
OUTREACH measured patient utility across outpatient, home and community (GP practice) settings in a UK
population using the European Quality of Life-5 Dimensions (EQ-5D) questionnaire.4 The study recruited
97 participants: 57 patients provided data for analysis of the primary end point EORTC QLQ-C30 and
48 provided EQ-5D utility scores; there were no details of why nine patients provided data on the primary
outcome but not for EQ-5D.
The OUTREACH publication4 reported total QALYs gained but not baseline values. Mean differences
from baseline over a 12-week period showed that the community setting produced the largest change
[0.191 QALYs; standard deviation (SD) 0.04 QALYs], followed by hospital outpatient (0.174 QALYs;
SD 0.034 QALYs), and home (0.165 QALYs; SD 0.053 QALYs).
The OUTREACH authors provided us with an analysis of the difference in mean differences adjusted for
baseline EQ-5D utility values. With adjustment for differences in baseline QALYs, hospital outpatient
chemotherapy was found to produce the most QALYs and was used as the reference for other treatment
settings. Compared with the outpatient setting, the community setting (GP practice) had a mean
difference of –0.009 (p= 0.0471) and the home setting had a mean difference of –0.010 (p= 0.374)
(P McCrone, Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, King’s College
London, personal communication). These data implied that patients treated in a GP/community and
hospital settings had a lower health-related quality of life at baseline, suggesting that they might have
been in a poorer health state than participants who were treated at home.
There were significant limitations with these data. In particular, they were based on a small number of
patients (19 or fewer in each treatment arm) and both the adjusted and unadjusted QALY results were
subject to significant uncertainty. None of the results achieved statistical significance and it would be
inappropriate to draw definitive conclusions on the basis of these data.
Resource use and costs
Reporting for resource use and costs across the nine economic evaluations was variable. Cost categories
and perspectives were similarly inconsistent. These inconsistencies in resource use and perspectives across
the economic evaluations make it difficult to ascertain any objective trend in favour of one treatment
setting over another.
Only two studies reported resource use, an Australian study45 and a UK study,29 but details were limited to
travel and labour. Both studies reported resource use for nurse travel to community or home settings.29,45
Pace et al.29 reported resource use for patient travel, in addition to nurse travel, to a community outreach
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site, and the number of nurses needed to deliver the service in the community setting. Lowenthal et al.45
reported hours spent on delivering treatment as well as time spent travelling and preparing treatments.
Costs across the included evaluations varied widely. Most studies were from non-UK settings, which can
limit the generalisability of resource use and cost data to the NHS and reduced their usefulness in
informing a de novo model for this review. Costs and resource use across the countries vary greatly owing
to differences in health-care delivery systems and differences in the prices paid for services.
One of the non-UK studies, Remonnay et al.,34 compared chemotherapy administered in an outpatient
setting with chemotherapy administered at home by a charitable organisation. The care concept has
relevance to the UK as several examples of chemotherapy delivered in the community as part of a
partnership between a charitable organisation and hospital have emerged in recent years.50–53 In the
Remonnay et al. study,34 the charitable organisation paid higher costs for chemotherapy drugs than the
outpatient facility (25% to 121% higher) because of differences in purchasing methods. In sensitivity
analysis, drug costs were made equivalent for home administration, which led to home chemotherapy
being less costly than outpatient administration. This was primarily due to large overhead costs in the
outpatient setting. The study was generally well reported, but did not report resource use, which limits
transferability to a UK setting. The authors were contacted for further information, but no response
was received.
The review identified two UK economic evaluations, both of which, owing to scope and reporting, were of
limited usefulness in informing a de novo model. The study by Pace et al.29 was concerned only with travel
time and did not consider other health-care resources and costs that might differ between settings. The
OUTREACH trial4 presented only total costs for each treatment arm in their published paper, with no
breakdown of the costs within each intervention arm. Correspondence with the authors led to additional
cost data being provided. These data were broad cost categories including inpatient and outpatient
costs, day hospital costs, accident and emergency (A&E) visits, non-cancer medications and nurse diary
contacts. The review team identified some discrepancies in these data. Queries were raised with the
authors, but were not resolved. In brief, for some cost categories the data appeared to be resource use
with no total cost provided, for other categories the data were total costs with no resource use data, and
for some categories it was not clear which were being presented.
Overall, the evidence on resource utilisation and costs was extremely limited. Data sets were small, results
were inconsistent and there was a great deal of between-study heterogeneity for patient characteristics
and methodology; these limit the generalisability of the results.
Economic evidence summary
Quality across the economic evaluations was variable, and overall should be considered poor. Biases in
the clinical study, the level of reporting on resource use and associated unit costs, and the lack of
health-related quality-of-life outcomes were major limitations. Poor reporting of resource use and the use
of different perspectives across the different settings made the results difficult to compare. Several
economic evaluations used patient preference as an outcome measure, rather than health-related
quality-of-life outcomes, which are more widely used to inform decision-making.29,32,34,45,54 High levels of
uncertainty make it difficult to ascertain whether or not costs or outcomes differ between settings.
Qualitative studies
Overview of study characteristics and quality
Seventeen qualitative or mixed-methods studies were included in this review (published between 1984 and
2012).4,24,29,30,32,39,41,51,55–64 The studies were conducted in Canada (four55–57,60), the USA (one59), the
UK (nine4,24,29,30,39,51,62,63), Denmark (two41,61), Iceland (one64) and Australia (one32). UK studies were in
England (six4,24,29,30,39,62) and one in each of Wales,51 Northern Ireland63 and Scotland.58 Table 6 displays a
summary of the included study characteristics. Appendix 8 gives full details of the extracted data. Table 7
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provides summary quality assessment results. Stevens et al. 200655 and Stevens et al. 200456 are separate
publications from the same study, where one paper reported on health-care professional views and the
other focused on the experiences of the children and their parents; these two publications have been kept
separate for clarity and, therefore, there were 18 sources of data contributing to the synthesis.
Participant views represented include chemotherapy patients (16 studies;4,24,29,30,32,39,41,51,55,57,59–64 two
included children55,61); carers/partners or children’s parents (four studies24,39,55,61); and health-care
professionals (five studies4,24,56,58,62). The study contexts varied, with half the studies taking place within a
clinical study. Participants often spoke comparatively about their experiences based on current and prior
treatment received or given.
Six papers contributed data on community provision of intravenous chemotherapy.4,29,39,51,57,58 Eleven papers
contributed data on the home setting4,24,30,32,41,55,56,59–61 and one paper was a theoretical discussion of a
proposed service.62 All 18 papers included discussion of outpatient settings and two studies focused
exclusively on this.63,64 The OUTREACH study contributed data on all three settings.4
As discussed in the summary of the quantitative studies (see Chapter 6, Strengths of the review, Clinical
effectiveness studies) study populations are likely to reflect a limited and biased perspective given the
nature of the research. All papers dealing with community or home chemotherapy were based around
new services, pilots or trials, which implies that the provision may be particularly high quality. It was rare to
see any indications of problems with the new services. There was one comment about the chance of the
community chemotherapy bus being cancelled but the patient noted that this never occurred. One
Canadian study mentioned problems with drug deliveries.55 There were no studies discussing new
community cancer suites or outpatient chemotherapy suites; these facilities tend to offer integrated care in
light and airy spaces designed for comfort.65,66
Almost all patients expressed a preference for treatment location, with varying degrees of strength. The
few patients who did not seem to mind about location were clear that the treatment was a necessary
inconvenience regardless of the place it occurred.
It is worth noting that although Smith and Campbell58 was a discussion around a proposed community
service, the views and comments from participants were essentially the same as those given by patients
who had received community chemotherapy in other studies. This suggests that focus group work may be
a useful preamble to setting up new services, as both patients and health professionals are likely to identify
any potential barriers and benefits, enabling pre-emptive action.
Fifteen studies4,24,30,39,41,51,55–58,60–64 used interviews to gather data (one study used telephone interviews58),
and two used open-ended questions on a questionnaire.29,32 One study collected data through focus
groups, open-ended questionnaires and telephone interviews.24
Most papers did not clearly identify the author’s position, or appear to engage substantially with reflexivity.
That is, they did not appear to consider the impact of the researcher on the data collection and analysis.
Four papers at least partly addressed these issues including considering the potential impact of the author
on the data collection and analyses process.39,41,60,61 Other papers either did not clearly identify the
researcher who collected and analysed the data or did not discuss the implications where the researcher
was a cancer nurse.30
The most common form of sampling was based on convenience; fewer studies used purposive sampling
and three studies included all patients who participated in the trial or pilot.29,30,32 Information on
participation rates was scantly reported across the studies making it difficult to draw any general
conclusions. In some studies, staff delivering care to study participants were responsible for recruitment or
suggesting participation; this may have contributed some bias.
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Study methodology was reported infrequently. Analyses were most commonly labelled as content analysis
(five studies55,56,58,61,64) or thematic (four studies24,30,51,62). Two studies used framework,4,57 two used
phenomenology,39,41 one used the constant comparative method60 and one used narrative analysis.63
Three studies did not report their methods of analysis.29,32,59
Validation and the consideration of validity can be a problematic topic within qualitative research. Ten out
of 18 studies39,41,55–58,60,61,63,64 in this group reported using some form of validation. This included peer
discussion, independent coding by more than one researcher and discussion of preliminary findings. Most
studies provided clear quotations from the participants and emphasised the primacy of the interviewee’s
voices. Thirteen out of 18 studies24,30,39,41,55–58,60–64 drew clear distinctions between collected data and
researcher interpretation. Transferability and generalisability were discussed in some detail by nine studies.
Synthesis
Overall, the data were grouped under three main lines of argument (Table 8). Two were relatively
self-contained: one addressed issues around perceived cost and barriers to service use, while the second
addressed satisfaction with treatment experience and provision.
The third line of argument was more substantial than the other two, and more clearly relates to specific
issues of the setting for intravenous chemotherapy. The decisions made by patients, carers and family
members were focused on maintaining normality in everyday life. Compromises were required to balance
competing factors and patients’ location preferences reflected their individual situations.
The three main lines of argument are not entirely independent; where links were obvious these have been
noted in the descriptive text that follows.
TABLE 8 Overview of main lines of argument
Key lines of argument
Barriers to service provision
Satisfaction with intravenous
chemotherapy
Making compromises to
maintain normality
Example
codes
Staff personal safety concerns Communication Medical expertise
Reluctant to treat Information provision Safety
Patient safety Understanding information Additional procedures and tests
Lack of professional support Privacy Keeping cancer out of the
home
Capacity concerns ‘KFC’-style treatment Shared experiences with other
patients
Cost of the service (patient and staff
views)
Rapport and relationship with
health professionals
Time: travel time and costs
Lack of communication between
health professionals
Security Time: waiting for treatment
Time: to spend on other
activities
Anxiety
Fatigue and energy
Identity
Control
KFC, Kentucky Fried Chicken.
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Line of argument: perceived barriers
Most data within this concept were contributed by health professionals (oncologists and nurses of varying
grades) rather than by the patients (Figure 2).
Several patients cast doubt on the cost-effectiveness of home chemotherapy, even where they had
reported positive experiences:
It’s just not cost-effective we’re going into a period of austerity, you know cut backs and all the rest
of it [patient]
It’s crazy [wife]
It doesn’t make any sense to me [patient]
Patient and wife39
Comments such as this suggest that patients may not take advantage of an offered service where they feel
it is a waste of resources, even if they would find it personally useful.
The health professionals from Kelly et al.’s study62 raised issues of the costs in setting up the service and
numbers of patients who could be treated, commenting that it was very difficult to accurately estimate
costs for a new service. The consultant questioned whether or not offering home chemotherapy would
simply mean that the spare capacity in the outpatient ward would be swallowed up by new demands.
Similar views were expressed by health-care professionals in the study by Taylor.24
You can’t take one bit out and leave a gap and not expect it to fill in very quickly. We’re more like a
beach than a building.
Consultant62
Health professionals from the Stevens et al. study55 commented that additional administrative tasks
required for home visits were time-consuming. While actual visit time was relatively brief, preparation calls,
such as checking drug deliveries or telephoning for blood test results, were described as ‘frustrating’.55
Potential barriers
Safety (staff/
patient)
Reluctance to
treat
Communication
Lack of
professional
support
Capacity
Cost
FIGURE 2 Line of argument: barriers.
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Both consultants and nurses raised concerns around the personal safety of health professionals travelling
alone to patients’ homes.4,24
If something went wrong you are on your own, you’ve got no back-up whatsoever if
anything happened.
Chemotherapy nurse4
One consultant highlighted that working in settings other than outpatient wards meant a potential lack of
peer support and guidance for staff.
The nurses will be doing it in isolation, they can’t ask anyone to come and have a look and it’s quite
nice often to run things past someone else.
Oncologist4
The potential for lack of communication or inconsistent treatment between settings was also flagged up
by health-care professionals in Stevens et al.56 This was seen as a factor that could damage trust between
outpatient and community staff teams, but clarifying responsibilities and increasing communication would
reduce this.
Many hospital HPs [health professionals] indicated that inconsistent interaction with the child and
family was somewhat distressing and that they would prefer regular updates on the child’s progress
. . . The HPs also emphasised the need for treatment procedures to be consistent in the home
and hospital.56
Line of argument: satisfaction
There was a cluster of codes around satisfaction with the treatment overall including facilities and staff
(Figure 3). This seemed to sit outside the trade-off being made by patients to maintain normality and is
likely to reflect concerns and experiences about NHS treatment in general. Data here include elements
specific to home and community treatment.
Satisfaction
Information
provision/
absorption
Privacy
KFC-style
treatment
Rapport
Security
Communication
FIGURE 3 Line of argument: satisfaction. KFC, Kentucky Fried Chicken.
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As mentioned earlier, all of these data relate to new community or home services, and to pre-existing
outpatient settings. None of these studies looked at the newer, purpose-built chemotherapy suites, and so
it is unsurprising that many of the comments about physical facilities reflected unfavourably on the
outpatient environment. Mobile buses in particular were described as being relaxed, warm, calm and very
unlike a busy hospital.51 This has clear links into the largest line of argument around maintaining normality:
such facilities offer a middle ground between the comfort of home and the barren hospital.
Communication Good communication (e.g. between community chemotherapy settings and the main
cancer hospitals) was cited as a factor in increased confidence for patients receiving treatment in other
locations. The faxes, e-mails or telephone calls indicated that local staff were in contact with, and
supported by, the larger cancer care team. This category links into medical expertise versus normality as
discussed in the third line of argument.
The staff at the [regional] cancer center phoned the nurse here and told her what she was to give me
and she had everything ready for me the next day. I feel confident that if I called her, she would
have the answer . . .
Patient57
This communication also balanced out some of the potential disadvantages in a less technologically
developed community setting.
Maybe you don’t have the technology that you would have at the big cancer centers . . . but I believe
that in the smaller clinics the comfort you find with the communication compensates for some of the
loss in technology.
Patient57
In contrast, poor communication around waiting times and making appointments was felt to be a
particular problem in outpatient settings. This is explored in more detail in the following section. Patients
were clear about not holding the nurses responsible but complained about the organisational aspects
and systems.
You couldn’t fault the staff it’s just that it doesn’t seem to be very logistically organised at all . . . All I
can say about it is it just needs leadership. . . . since the new clinic [has been built] the appointments
are worse, far worse.
Patient39
Aspects such as the physical layout of the outpatient units, the use of temporary facilities that are still
required after 10 years, and logistical difficulties in scheduling appointments all tended to lead to
frustration on the part of both health-care professionals and patients. As Kelly et al.62 reported, staff
working in the chemotherapy unit experienced regular difficulties when trying to communicate between
these different sites.
There’s just so many links in the chain that almost inevitably one breaks down. So it’s set up to be very
difficult to manage.
Nurse62
Information There was often a large amount of information to take in before and after chemotherapy
treatment. One study indicated that patients struggled to access the desired information from their doctors
in the outpatient setting which reduced control and increased anxiety.63 Data from Crisp,60 and Hall and
Lloyd30 suggested that patients found it easier to understand the information in the home setting rather
than in an outpatient clinic. Patients commented that they felt more able to ask questions of the nurses
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when at home and that the extra time made it easier to ask about the niggling concerns that might be
missed in an appointment with the doctor. In one example, the nurse telephoned the patient later on
to answer a specific query, indicating a high level of ongoing communication.
I was able to really talk to the nurses and the nurses had a lot more time with me. It was one on one
time. So I got way more information from my treatment at home meetings than with my doctor.
Patient60
Privacy The mobile bus services were mentioned in relation to privacy, both positively and negatively.
Iredale et al.51 reported that patients felt it was like having a private room, whereas Mitchell’s39 participants
reported that the close proximity of the treatment chairs meant very little privacy in relation to physical
aspects of treatment. However, this was not perceived to be an unresolvable problem once, for example,
patients ‘get used to knowing what to wear’.
Home settings were associated with increased privacy, which patients valued in relation to the side effects
of the chemotherapy. Crisp reported patients preferring to use ‘their own bathrooms for vomiting or
diarrhoea or taking steps to make intravenous insertion easier’.60 Home chemotherapy was described as
more private also because no-one was listening in on patients’ conversations.30
Rapport with health professionals and individuality A mixture of experiences was reported across
settings in relation to forming good relationships with the health professionals. There was no clear
indication that one setting resulted in better rapport than any of the others and some patients were
particularly keen to highlight the excellent care they received from both outpatient and community or
home chemotherapy staff.
Hospital staff appeared to be under more pressure than their home or community counterparts; however,
they were still delivering excellent care in most of the accounts included in this synthesis. Patients valued
the human contact as highly as the actual treatment itself.
This also included the importance of receiving treatment, which was given in a warm and sensitive
way, and caring encounters were seen as closely intertwined with the treatment itself.
Author interpretation64
In one of the studies which included interviews with children, they commented that they liked the hospital
sessions particularly because of getting to see their favourite regular nurses.55
Community chemotherapy settings were most often described as personal, friendly and more relaxed than
outpatient clinics, which allowed more time to ask questions. This included the input of the mobile bus
driver, who made patients a cup of tea and showed them where to wait for treatment.39,51
The patient who said that they preferred outpatient over community treatment cited ‘the gloomy décor
and lack of atmosphere at the outreach location’,29 which may suggest that physical environments are
influential in decision-making. Alternatively, this may highlight the particularly subjective nature of such
experiences and judgements. It was not clear from the data how such preferences interacted with travel
time and waiting times.
Consistency of nursing staff was mentioned most often in relation to chemotherapy delivered at home.
Having the same nursing team for each visit combined with the feeling of having their ‘undivided
attention’ to increase satisfaction levels.30,41,60,61 Patients did not have to repeat themselves to multiple new
nurses and there was an improved understanding of their circumstances, which led to an easier exchange
of information. Seeing the same well-qualified and punctual nurses was particularly important for parents
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in the Hansson et al. study, who felt this increased security. The children enjoyed showing their home-care
nurses around the home.61
I like to have the same nurse who is my main nurse, it is the relationship with my nurse, she knows
everything about me and I know a lot about her, this is like a friendship.
Paediatric patient64
In contrast, Frølund reported that patients felt that it was more important to be treated by an experienced
nurse than to see the same nurse on every visit. This was not reflected in other data but remains a valid
comment on treatment preferences.41
Despite these generally positive comments, one couple reported that they felt that the home-care nurse
had less time for questions and discussion than the hospital nurses.67 The only negative comments from
health-care professionals reflected the reduced contact with parents and children who were having
treatment at home. While the hospital nurses valued having the extra time to spend with other patients,
they worried about how the home treatment children were coping with their treatments.56
Line of argument: compromise to maintain normality
The degree to which patients expressed a preference about where they received chemotherapy appears to
depend on which location offered the best possible compromise between a range of factors which are
discussed in the following pages. The balancing act can be seen as between factors that favoured
outpatient treatment and those that favoured an alternative to outpatient. That is, there was no clear
distinction between home and community settings (mobile or other location), but a collection of factors
which might sway a patient towards preferring non-outpatient treatment.
Themes pushing towards outpatient treatment Themes which seemed to push patients and carers/
parents towards outpatient treatment included medical expertise, safety, scheduling non-chemotherapy
treatments, keeping cancer out of the home and shared experiences with other patients (Figure 4).
Side effects 
Shared
experiences
Other
procedures
Medical
expertise
Keeping cancer
out of the home
FIGURE 4 Factors pushing patients towards outpatient treatment.
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Medical expertise and safety concerns Medical expertise and safety was mentioned in all of the
included study results and was clearly an important factor when patients and health-care professionals
were thinking about preferred treatment locations. Community clinics were generally characterised as
being less technologically advanced, although this was described as a ‘small disadvantage’ rather than a
major concern in one study.57
There was a mixture of experiences across those studies where patients experienced more than one
setting. As described earlier, for some patients the evidence of clear communication and support between
community and outpatient settings was sufficient reassurance,57 while for others they preferred to be
treated in hospital with immediate access to the expertise.4,39,64 These patients tended to have already
experienced outpatient care and were unwilling to try a service such as the mobile chemotherapy unit even
when assured it would be delivered by the same nurse team.
. . . it was exactly the same treatment as Cheltenham, . . . the reason I didn’t opt for it, and it isn’t
really logical, . . . was simply because I was confident with the treatment I had at Cheltenham and it
was the feeling of not wanting to put that at risk.
Patient39
Concerns about safety and being unwilling to take chances were most strongly expressed in one study of
paediatric cancer patients, although this was not consistently demonstrated in all child-related data. In
Stevens et al. 2006,55 some patients felt more secure in the hospital setting, particularly where there was a
concern about negative reactions to the chemotherapy.
Some studies highlighted specific concerns relating to the medical equipment such as catheters, pumps
and intravenous devices. Again, there was a mix of views between patients who were worried about what
might happen in the home setting,59 and those who found that it was easier to prepare for intravenous
insertions in the warmth of their own home60 and so worried less about the associated procedures.
Additional procedures and tests In all of this data set, patients still had to attend the outpatient clinics
for review meetings or monitoring via blood tests or other procedures. The logistical arrangements
prevented some patients from being able to have community chemotherapy owing to the need for
co-ordinating tests and treatments, which resulted in disappointment.39 In Stevens et al.’s Canadian
study,55 the children receiving home chemotherapy visited a local laboratory to have bloods taken while
the children having outpatient treatment had bloods taken in the hospital. This caused some problems as
the laboratory used venous sampling which could be more painful than the finger-stick sampling children
were accustomed to from the hospital. Although this was not seen as a major disadvantage, it was an
unpleasant experience which reduced the appeal of home chemotherapy treatments.55 There was no
evidence in the data that patients would prefer outpatient treatment in order to enable all of the tests and
procedures to be carried out in one location or visit.
Keeping cancer out of the home For some patients and parents of children, one of the key benefits to
having their chemotherapy in the outpatient unit (as opposed to at home) was the ability to keep the
cancer segregated from everyday life. In these situations, being able to go home after treatment was seen
as a relief and allowed the cancer to be left in the hospital.4,56,61,63
I know I sound a bit weird, but there is also the thing that if you are treating the cancer at home, then
the cancer is at home.
Patient4
The fact that the chemotherapy treatment was carried out as an outpatient was also seen as helpful; being
able to walk in and walk out reduced the feeling of being ill.63 Where there were other children in the
family, treatment in the hospital allowed the home to remain as a safe refuge, although treatment at
home was felt in some cases to reduce sibling anxiety about the whole process.61
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Shared experiences with other patients Opinions among the patients and families were mixed when it
came to the benefits of being treated among those experiencing similar illnesses.4,32,41,60,61,63 Health
professionals were also divided in their opinions.58,60 Positive aspects included being able to talk to other
patients, which was described as cathartic.
You’re talking to patients out in the waiting area, the person sitting beside you. Not talking in any
morbid way, but you’re exchanging experiences. It’s a great therapy.
Patient63
It also allowed the conversation to stay within the hospital setting.
It’s like a support group in its own. Once you do that, you don’t need to talk about it outside
anymore; you feel part of some kind of exclusive club.
Patient63
For some parents of children being treated with chemotherapy, being able to form relationships with other
families was seen as a useful source of support.61 One study reported that an adult patient felt that it was
beneficial to see others who were worse off.32
These benefits were also reported in relation to community chemotherapy settings, where smaller groups
of patients were often being treated simultaneously. The chance to share experiences was seen as part of
the treatment.
When I first went in I thought well this isn’t very private at all . . . actually as I sat and watched, I
thought no, these people are sharing conversation with each other . . . there was a kind of bonding
that went on between the patients.
Patient4
Some of the patients who had mainly received chemotherapy at home suggested that they might have
preferred the chance to meet other people in the same situation, although this was not particularly
strongly expressed.30,60
Themes pulling away from outpatient treatment Themes which pulled patients and carers away from
outpatient treatment and towards the alternative (regardless of what form that might take) included
specialist expertise, normal life, energy, travel, waiting time, identity, control, support network and anxiety
about treatment. These were more broadly grouped under the idea of patients desiring control over a
range of factors (Figure 5).
Pre-treatment anxiety Chemotherapy in the outpatient setting was frequently associated with
pre-treatment anxiety, nausea and other unpleasant side effects. Four studies also reported that following
a return to hospital treatment (either for routine reasons or due to the end of pilot service provision),
patients experienced anxiety-related problems.55,57,60,61
In contrast, community chemotherapy was seen as less stressful owing to reduced travel and easier
parking, while home chemotherapy was mentioned in relation to reduced treatment-related
anxiety.32,51,57,60 For one patient this was particularly pertinent as she also suffered from irritable
bowel syndrome:
Helen suffered from Irritable Bowel Syndrome (IBS), and described her difficulties travelling back and
forth to the hospital. At home, she had the luxury of using her own washroom and reported having
less frequent attacks as a result of reduced anxiety.60
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Identity and control The shared experiences and contact with other patients or families in the same
situation, mentioned earlier as a beneficial aspect of outpatient chemotherapy, were sometimes seen as a
disadvantage.4,41,60,61,63 Interestingly, none of the respondents mentioned these comments in relation to
community settings, although they would seem to be equally applicable.
Attending the hospital and seeing others who were more or less sick than them was quite difficult for
some patients. Seeing others who were more ill added to the anxiety and fear of future deterioration, and
in some cases emphasised their identity as a sick person.41,60
I know that death is coming, but I don’t need to be reminded of it several times a week.
Patient41
The whole experience of visiting hospital for chemotherapy was identified as potentially pulling patients
back into the sick role that many were trying hard to escape from.
Although health care professionals strive to promote patient independence and self-care, there are still
aspects of treatment that seem to pull the patient back into the traditional sick role.
Author summary60
The formation of friendships during treatment in outpatient hospital settings was discussed earlier as a
positive aspect, but loss of these friends when they died was difficult. For some participants this led to a
deliberate withdrawal from social contact.
I saw a lot of people dying, I found that very off-putting. I say to myself now, I’m not going to get
friendly with anybody else, because when something happens, and then, you know, it sort of
unnerves you.
Patient63
Treatment
Identity
Exposure to
friends/family
Anxiety
Timing
Resources
Waiting
In treatment
Time for other
activities 
Travel and
related costs
Time spent . . .
Energy levels
and fatigue
Travelling
FIGURE 5 Factors pulling patients away from outpatient treatment.
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While for some patients being treated as an outpatient made it easier to keep cancer away from the
home, for others being treated at home minimised the impact of the disease. This was particularly obvious
in data gathered from mothers with cancer who had young children. For example, the patient below
describes how the disruption to daily routines caused by outpatient treatment was more difficult than the
shorter home chemotherapy appointments.
My husband’s mom lives on Vancouver Island and she came over to help look after us and she was
really worried that the kids were going to associate her with Mom being sick. Because she would only
come when I was having treatments or when I needed help.
Patient60
In some situations home chemotherapy offered the chance for the children to see the benefits in reduced
stress and anxiety, which improved the family experience in general, while for other parents the home
treatments were more easily scheduled when children were at school, which made it easier to hide them.
I mean, we have such a close family. And we’re so involved with each other and I think for my
children to see me happy and settled is a gift for them.
Patient60
Overall, treatment at home was associated with having greater control over how much or how little other
family members living either at home or elsewhere were exposed to the chemotherapy processes.
Time also influenced this theme; as one participant eloquently stated, reducing the time spent on
treatment made the illness less invasive for the whole family.
Home care diminishes the invasion in one’s life that the illness represents. It simply makes that invasion
smaller: you don’t feel that affected by the illness as a family, when it means 20 minutes in your own
home compared to when it means 6 hours at the hospital.
Patient61
Being able to perform normal daily tasks as a result of receiving chemotherapy at home in turn reduced
the impact of the disease on their identity.
I have a deadly cancer, I know. It is there, and it will always be there . . . Home treatment makes me
feel normal . . . It helps that I can live as before I got the disease.
Patient41
Individuality In contrast to some of the positive views expressed within the qualitative synthesis (see Line
of argument: satisfaction), seeing different doctors in the outpatient setting who were not necessarily up
to speed on the case notes was described as disjointed and frustrating.39
This lack of individualised and tailored understanding was reflected in the comments from participants in
McIlfatrick et al.’s study.63 The outpatient setting was described as factory-like and dehumanising, with
little chance to discuss more general concerns or the person outside their cancer treatment.
It’s quick. It’s like a KFC [Kentucky Fried Chicken] cancer ward . . . you can see they have to, with, I
mean, with the amount of people that comes through. But they still try to keep a personal touch to it,
but it is hard for them.
Patient 763
Time: travel time (and costs) The time taken to travel to and from outpatient centres for chemotherapy
was frequently mentioned across the included studies, in terms of duration of travel, costs for patients and
carers and the energy expended.4,29,32,39,51,55–57,60–62,64
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For most patients the journey to the hospital took considerable time, with associated parking difficulties
and costs. This in itself might not have been such a problem, but when combined with the often long
waits for treatment, patients were spending almost a full day on the chemotherapy treatment.51
These long days were particularly difficult as patients were already feeling ill, and children might be
nauseous and anxious.
Traveling is difficult, especially when you know you’re going to be sick and it’s very tiring.
Parent of paediatric patient57
It was exhausting for the parents and the child to get up in the morning and go to the hospital and
they experienced it as stressful to leave the home with a child who was plagued by nausea
and vomiting.
Author summary61
Travel and parking costs were often mentioned as adding to the anxiety about chemotherapy treatment,
particularly for families with children and single parents who struggled to both find the funds and take the
time off work.55,61,62 Arranging childcare when the parent was required to attend hospital for treatment
incurred additional financial burdens, and in some cases significantly impacted on family life.60
The importance of reducing travel time lies in the ability of the patient (and their carer) to make ‘better
use’ of this time, and money, such that they might be able to continue to work, go to school and
participate in normal activities.55,60,61
Time: waiting for treatment Community and home chemotherapy settings benefited from reduced
travel times, but participants also commented frequently and favourably on the absence of waiting to be
treated. Community chemotherapy was highlighted for the short waiting time prior to treatment; patients
reported that they were able to arrive just before their appointment and be seen almost immediately. This
appeared to reflect a more organised system which was much appreciated by patients as it meant the
total time spent travelling and being treated was perhaps 2 hours rather than the full day required for
outpatient chemotherapy.
A typical day at the clinic is as long as a normal working day, whereas treatment at home is just over
an hour.
Patient41
In Mitchell’s study,39 waiting time and travelling time were some of the most important factors in every
patient’s choice to have treatment on the community chemotherapy bus.
Outpatient chemotherapy accounts frequently mentioned the unpredictable nature of waiting
times.39,56,60–62,64 Health professionals also mentioned the difficulty in managing waiting times, referring to
organisational factors such as drug ordering systems.
The way that the present service was configured contributed to this problem. For instance, delays
occurred between the ordering of chemotherapy drugs and their arrival in the clinic.62
Some participants commented that waiting itself was a tiring activity made more difficult by the lack of
facilities or the lack of heating, which made subsequent intravenous insertion more problematic.39,60,64
The waiting room was described as uncomfortable, and having to wait there was tiring for people
with little strength and sometimes in pain.
Author summary64
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Despite this issue, this same patient understood and was sympathetic to the possible reasons for the
unexpected delays.
Home settings generally involved no waiting time and the nurses were praised for their punctuality. The
decreased waiting time in home and community settings meant that the portion of the day spent on
treatment was significantly smaller, thus impacting on attempts to maintain normality. Some of the health
professionals from the Stevens et al. study56 commented that the increased flexibility within home
chemotherapy benefited their teenage patients, but could be more stressful for the staff, who were trying
to accommodate patient requests.
I found that we were juggling a lot. Trying to work around the teenagers’ schedules because you
would end up calling them to say that you were going to come to do the chemo and they would say
‘Oh no I’m off to something or other tonight’.
Nurse56
Waiting and travel time somewhat naturally clustered together within the data set. McIlfatrick et al.’s
paper63 adds a useful aspect by highlighting that, for patients, this meant more than just travelling to and
waiting for treatment.
Whenever you have the treatment, your life does revolve around it . . . you are marking time.
Patient63
Time: time to spend on other activities/relationships In many of the studies where home or
community chemotherapy was available, patients commented favourably on being able to do things
(such as bathe and eat) when they wanted rather than have those activities ‘dictated by the convenience
of hospital routine’.59 The time which was freed up by not having to travel such long distances or wait as
long for treatment could then be used for jobs around the house or going back to work (adult patients) or,
for children, being able to continue attending school.30,41,55,57,60
This additional time allowed patients to stay in touch with their own personal support networks, whether
these were family or friend oriented. Outpatient care was associated with the loss of these networks,59,60
although for some patients the relationships formed with other patients might have been
some compensation.
When patients are diagnosed with cancer, they are displaced from their homes to a contrived, heavily
scheduled setting such as a hospital. Routines are lost, and the patient becomes bound by ‘the system’.
Author summary60
Patients were keenly aware of having a limited amount of time to spend with friends and family,
particularly in cases where the treatment was not likely to be curative. Parents valued the opportunity to
spend more time with partners and children.
Savouring positive experiences as a family frequently becomes paramount to cancer patients and
their families.
Author summary59
Home chemotherapy was most often mentioned in relation to being able to spend more of the available
time with key people.
Time is a great opponent . . . An invincible opponent. I know that I have an incurable disease, and
therefore it is very important that I can be with family and friends. For me, home treatment has given
me this opportunity to a greater extent.
Patient41
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Fatigue and energy Chemotherapy was universally described as a difficult process resulting in fatigue
caused by both the treatment side effects and the travelling and waiting time.
I found even driving (to the hospital) and getting my chemo, by the time I got home, I’d have to have
a nap. I found myself getting tired from it really quick.
Patient60
This was important both to patients and to their carers, who were also affected. For example, parents of
children receiving chemotherapy commented on the beneficial effects of home care for their children, and
also for themselves.
[W]ith home care the children could sleep as much as they needed . . . a great burden had been
lifted from their shoulders in a period when they didn’t have much energy due to their child’s
life-threatening disease and their lack of a normal everyday life.
Parent of paediatric patient61
Patients talked about having a finite budget of energy, with home and community chemotherapy leaving
more resources for them to spend as they chose after treatment.
In the past I put a cross in calendar. The whole day was devoted to the treatment . . . when I receive
treatment at home; I have the energy to do other activities.
Patient41
Qualitative summary
The synthesis incorporated data from 18 papers and over 450 participants including health professionals,
patients (adults and children), parents, carers, siblings and partners. Most of the available data focused on
experiences of outpatient and home settings for intravenous chemotherapy, with some data on community
settings including mobile bus units. Overall, the quality of the included studies was moderate to good.
Maintaining normality was the important overarching theme which tied much of the data together. Across
the data set, the importance of maintaining normality throughout a difficult illness/treatment was seen as
key to being able to survive and look forward. Exactly what normal life constituted varied from patient to
patient. Most patients were clearly making explicit trade-offs to maximise their resources (e.g. time, money
or energy). Looking at the data set, it was rarely as simple as saying that one setting maintained normality
and alleviated any safety-related concerns. Health professionals recognised and referred to this when
talking about their patients, indicating a shared understanding.
Normality was more easily maintained when family life was minimally interrupted, the impact of cancer on
daily life and family members was controllable, and patients were able to participate in activities of value.
The time and energy consumed by chemotherapy underpinned much of this category: time spent travelling
and waiting for treatment meant less time for normal life. The energy expended on treatment (including
travel and waiting time) could leave patients unable to participate in important activities. Although
treatment- and setting-related anxiety or side effects were mentioned, these seemed to be important
because dealing with the anxiety, stress and nausea took up valuable time and energy.
While the outpatient settings were most often associated with increased confidence in the staff’s ability to
deal with adverse reactions, there was some evidence that good, visible communication between an expert
centre and an outreach location could ameliorate some of the safety concerns. Based on the available
data, the time and energy consumed by outpatient treatment reduces overall quality of life and this is a
sufficient driver for patients to prefer alternative treatment locations. These themes were particularly
evident in the accounts from patients receiving palliative treatment and from parents of children
with cancer.
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Chapter 4 Identifying current provision
Introduction
Based on the scoping work undertaken to facilitate this research and discussions with our advisory group,
we were aware that there appeared to be variation in chemotherapy delivery practices throughout the UK.
This variation was expected to include the likely existence of a variety of systems, reflecting the different
challenges of large cancer centres and district hospitals, for example. Nurse-led chemotherapy is
established in some centres but home delivery of chemotherapy is not widespread. Different geographic
challenges exist for provision in remote and rural communities compared with more urban-based
centres.3,10 Some hospitals elect to utilise private providers to deliver services, while some elect to deliver
these ‘closer to home’ services using their own NHS resources. To gain insight into the variation in current
practice in the NHS, we undertook a survey canvassing views from relevant professionals about their
experience of the delivery of home and community chemotherapy. The survey was not intended to be
comprehensive; rather, it was intended to provide a general overview that would help to describe the
patient pathway and inform the development of the decision model.
Methods
Owing to the likely variation in private provision and NHS provision of services, we designed two
questionnaires on current provision of intravenous chemotherapy administered at home and in the
community. Both were administered using an internet-based survey programme (Survey Monkey:
www.surveymonkey.com) between June 2013 and September 2013. One was circulated to NHS trust
organisations providing chemotherapy services and the other was sent to commercial organisations
identified as providing home care or community services on behalf of the NHS.
Invitations to participate in the NHS provision questionnaire were sent via e-mail to stakeholders across
England and Wales. Individuals were identified via the Cancer Network websites (where still available) and
their replacement clinical groups, and through contacts provided by members of the advisory group. The
survey was administered between June 2013 and September 2013. Invited participants were encouraged
to disseminate the questionnaire to colleagues. Briefly, the questionnaire asked participants whether or not
their hospital offered chemotherapy at home and/or in the community, how long their service had run for,
who delivered it, what type of pharmacy was use and staffing details, as well as setting characteristics for
the community setting. The full survey is available in Appendix 9.
The private provider questionnaire was sent to HaH, Calea UK Ltd, Bupa Home Healthcare, Baxter, Polar
Speed Distribution Ltd, Alcura UK, Evolution Homecare Services Ltd, B. Braun Medical Ltd and MedCo.
These providers were identified via the advisory group who provided contact details for the National
Clinical Homecare Association, an industry body representing companies providing clinical home care
services to NHS patients along with charitable and independent sectors within the UK. In brief, the survey
asked whether the organisation delivered intravenous chemotherapy in the home or community setting on
behalf of the NHS, what aspects of home or community chemotherapy were provided, who was involved
in administering and overseeing the service, and whether or not any unpublished information was
available. For organisations that provided the service, follow-up questions were sent to gather further
details about provision of home- and community-based intravenous chemotherapy. The full survey is
available in Appendix 10.
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Responses
The aim of the surveys was to provide a general overview of current provision to inform this project. In the
following sections we describe and summarise the main responses to the surveys. Full details of all
responses to both surveys are available on request.
NHS provision survey
Respondents and services provided
We sent 65 e-mails inviting stakeholders to participate and sent a reminder e-mail to non-respondents
after 2 months. Respondents were encouraged to forward the survey to other contacts; this increased the
number of responses at the expense of making the percentage response unclear.
In total, 26 people from 22 organisations provided usable survey responses to the NHS survey. Sixteen of
the 22 organisations were in the north of England and six were in the south. Organisations included trusts,
specific hospitals and one commissioning body. Respondents were in various roles including commissioners,
pharmacists, cancer nurses, oncologists, regional managers, haematologists, directors and administrators.
All survey respondents were in England.
Ten organisations provided chemotherapy at home or in the community: three delivered intravenous
chemotherapy only in the home, three delivered only in a community setting and four delivered treatment
in both settings.
Figure 6 provides a flow chart demonstrating the services provided by respondents.
Aspects of the service and pharmacy use
Two of the seven organisations that provide chemotherapy at home indicated that the NHS delivered all
aspects of the service, one failed to respond and four indicated that they used a private provider to deliver
some or all of the service. Two of those using a private provider indicated that they used a hospital
pharmacy for home chemotherapy; both of these deliver treatment in the home and community setting.
The other two organisations which deliver in both settings were both NHS-provided services,
including pharmacy.
Two of the three organisations providing treatment only in a community setting indicated that the NHS
provided all aspects of the service, including hospital pharmacy, and one did not respond. Table 9 provides
service provision details for settings offered, pharmacy use and training/recruitment requirements for
services in the home or community.
Staff and training necessary for administration of chemotherapy at home or
in the community
Staff involved in administration of chemotherapy in the home or the community included oncologists,
nurses, haematologists and pharmacists. Five organisations responded that additional training and/or
additional recruitment was required for their service, two indicated that no additional training was required
and three did not respond. Nurses were the focus of additional training, which included training nurses to
higher certification levels, training them on how to use mobile chemotherapy units (chemotherapy bus),
and lone-worker training. Three of the five organisations that indicated additional training was required
delivered in both settings (two NHS and one private provider). Two organisations delivered only in a
community setting using a NHS service.
Three organisations indicated that hiring additional staff was required, while two indicated that it was not
and five failed to respond. All of those that indicated that they would need to hire additional staff also
indicated that additional training would be required; two of these were community NHS-delivered services
and the other a NHS-delivered service across both settings. The two organisations that indicated no
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65 contact e-mails
26 responses
11 indicated
providing no
home or
community
chemotherapy
22 organisations
4 duplicate organisations
1 oral chemotherapy
1 trastuzumab (monoclonal antibody)a
10 home and/or
community
chemotherapy
1 community
chemotherapy
3 deliver
exclusively
home
chemotherapy
11 indicated
providing home
or community
chemotherapy
12 provide no
home or
community
chemotherapy
3 deliver
exclusively
community
chemotherapy
4 deliver
community
and home
chemotherapy
FIGURE 6 Flow chart of current NHS provision of home and community intravenous chemotherapy.
a, Herceptin®, Roche.
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additional hiring also indicated no additional training requirements; both services had home services that
were delivered by private providers.
The number of nurses involved in delivering intravenous chemotherapy in a home or community setting
varied between organisations. Two organisations used one nurse at their community locations and
three organisations used two nurses. Two organisations did not report how many nurses they used for
community chemotherapy locations. The number of nurses who administered each individual treatment at
home and community locations was fairly consistent. All five organisations that provided a response
reported that one nurse was involved in each intravenous treatment.
The details of services provided, by whom and where, plus additional staff hiring and training requirements
for each of the organisations, are presented in Table 9.
Eligibility for participation in home chemotherapy
Various eligibility policies were described for home chemotherapy. One of four organisations that provided
home chemotherapy via a private provider reported an eligibility requirement of ‘a few’ cycles delivered in
hospital; another reported that eligibility decisions were based on regimens; and two did not report
eligibility requirements. There were few responses regarding eligibility requirements for chemotherapy;
three organisations provided no response to eligibility requirements for chemotherapy at home and one
reported that drug regimen suitability determined patient eligibility for chemotherapy at home.
Three of the seven organisations that provided chemotherapy at home reported that patients were
referred to the service by consultants, and two indicated that consultants and specialist nurses could refer
patients to the service. No other organisations provided referral details.
Three organisations provided estimates for the proportion of patients eligible for the home service and the
proportion of patients accepting the service. There was a mix of proportions eligible and accepting, with
some eligibility levels of < 5%. Both organisations that indicated < 5% eligibility also indicated that they
used a home-care provider, with HaH named by one. Both organisations that had home services
completely delivered by the hospital reported eligibility levels higher than those using a service delivered
through a home-care provider (Table 10).
Eligibility for participation in community chemotherapy
In the community setting, patient eligibility criteria focused primarily on suitability of regimens and patient
distance from their hospital. Only one organisation expressed eligibility limitations based on which cycle of
chemotherapy was being administered; they reported that patients must be fit and have had two cycles
in hospital. Two indicated that distance of patient travel was a factor in eligibility, but did not quantify
what distances were acceptable. Three quantified the percentage of patients eligible for chemotherapy in
the community: one reported that 60% of patients were eligible and 80% of eligible patients accepted;
another reported that 10–15% were eligible and 10–15% accepted; and a third reported that 50% of
patients were eligible, with 30% accepted (see Table 10).
Provision of chemotherapy services at home and in the community
Three organisations delivered chemotherapy in the community using mobile chemotherapy units. The other
four organisations that delivered intravenous chemotherapy in a community setting used different
locations: two in community hospitals, one in a satellite unit in a primary care centre and another used a
room in a local hospice.
There were several similarities between home and community chemotherapy administration. Patients in
both settings were cared for between chemotherapy treatments at their regular institutions and given
access to standard 24-hour advice telephone lines, and patients were referred to both services by
consultants and specialist nurses.
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Organisations that indicated they did not provide chemotherapy at home or
in the community
There were 12 organisations that did not provide intravenous chemotherapy at home or in the community;
six indicated that they were interested in providing a service and three indicated that they may be
interested in providing a service in the future. One organisation had indicated that they provide home
chemotherapy, but only provided home trastuzumab. No organisations said that they would not consider
providing a community or home service. Of the six organisations that said they would consider providing a
service, one organisation was working on a proposal for a service, and another indicated that a service was
not offered yet but was at an advanced stage of planning.
Barriers to service delivery
One of the aims of the survey was to identify barriers to service provision in the community and at home
from those who provided services, and those who did not provide services. Common concerns existed in
both groups. The full set of responses to these questions is available on request. Some commonly
perceived barriers highlighted by responders were:
l costs of running a service
l value-added tax (VAT) savings, which were driving which drugs were offered at home rather than the
suitability of the drugs for administration at home
l the fact that there might have been less expensive ways to deliver chemotherapy in the community
than delivering at home, but current regulations did not allow or incentivise more efficient
community delivery
l issues with consultant support for home services
l poor strategic planning
l broad geographical area that would be difficult to serve
l interest in delivering a service but lack of a commissioned service
l limited numbers of eligible chemotherapy regimens
l lack of nursing resources
l lack of suitably trained staff
l a need to convince patients to use the service.
There were several limitations to the survey: the sample was small; the information provided by
respondents was generally not very detailed; the survey requested recollections and descriptions from
providers rather than service data; and questions were not always interpreted as intended. However, the
aim was to provide a picture of current provision and add clarity to the patient pathway, where possible.
The survey highlights the wide variation in current provision.
Private provider survey
All nine groups that we contacted responded to the survey but only HaH, Bupa Home Healthcare and
Calea Ltd currently provided chemotherapy closer to home. None of the respondents described providing
intravenous chemotherapy services in a community setting. However, the survey did not have
differentiated questions regarding home and community services, and so a description for a home service
did not necessarily preclude the provision of intravenous chemotherapy in a community setting. Both HaH
and Bupa ran comprehensive home chemotherapy services that included patient registration; prescription,
preparation and delivery of cytotoxic drugs; supply of nurses; patient counselling, and telephone support
for adverse reactions; and logistics and waste removal for a variety of chemotherapy regimens (specific
regimens were considered commercially sensitive and not disclosed). Calea provided off-the-shelf and
compounded methotrexate to NHS trusts in the Yorkshire region inclusive of nurses where necessary.
HaH indicated that they provided chemotherapy in the home or community setting to more than 40 NHS
trusts. Bupa did not provide information on how many NHS organisations they provided with home or
community chemotherapy services.
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Further follow-up with the organisations yielded limited results. Questions about customer satisfaction,
quality-of-life data, cost data and resource use were generally unanswered. Some providers said that
information on these outcomes was commercially sensitive; other organisations might have been
non-responsive for similar reasons. HaH responded to some queries, and instructed our team to seek
answers related to quality of life, patient satisfaction, adverse events and resource use from their health
informatics service, Sciensus Ltd. On investigation it was apparent that information was not freely available
from Sciensus. We did not pursue paying for information.
Healthcare at Home provided some useful descriptions of their service via personal communication
(S McAndrew HaH, 12 September 2013, personal communication). They indicated that their home
chemotherapy service uses a regional hub for northern Europe, with support services for adverse reactions
and general patient counselling provided from this facility. They also indicated that next-day service was
available to the UK mainland, major islands and northern Europe using their own vehicle fleet from their
regional hub. According to HaH, nurse travel to patients and between patients averaged 1 hour. HaH used
their own private pharmacy, which might have made them eligible for a zero VAT rating on drugs they
delivered in the home, under current UK legislation.68
Bupa did not respond to additional requests for information but their website was very informative and
included thorough service descriptions and a full list of chemotherapy regimens eligible for home
delivery.69,70 Bupa provided a business example on their website where the cost of a drug administered at
home is reduced by 20% compared with NHS administration. This appeared to indicate that private
providers were providing drugs with zero VAT liability.69
From the private provider survey, it is clear that the consolidated nature of the private providers enabled
them to serve larger regions. All private organisations that provided home chemotherapy to the NHS did so
across multiple trusts.
Summary of current provision
There was great variety in service provision, with differences in the total number of staff involved, who
provided services and how they were provided. The total number of nurses involved in delivering home
and community services varied across providers, but the numbers administering each individual treatment
were consistent: one at home, and one or two in the community setting.
Private providers were often used for administering home chemotherapy; this usually entailed using a private
pharmacy. These private providers appear to have very selective eligibility criteria to their programmes and
only accept patients after two or more cycles have been delivered in hospital. The percentage of patients
eligible in privately provided programmes was lower than that provided in services that were administered
completely by the NHS. Outside private provider requirements for a certain number of cycles in hospital,
regimen appeared to be the most important determinant of eligibility, followed by patient performance.
Community settings included three mobile units (chemotherapy bus), two community hospitals, a satellite
unit in a primary care centre and a room in a local hospice. Most community providers indicated that the
NHS provided all aspects of the service. Regimen and patient fitness for treatment appeared to be the
most important determinants of eligibility for home chemotherapy. More patients were eligible for
chemotherapy in the community than at home.
Private providers were found to offer a potentially wide variety of regimens70 and provide comprehensive
chemotherapy services to a large number of trusts (HaH), but it was unclear what effect their services had
on patient quality of life or patient satisfaction. Private providers were able to take advantage of VAT
exemptions for drugs, and provide services across multiple providers, both of which could lead to less
expensive and more efficient service capabilities.
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Chapter 5 Patient pathway
Overall pathway
Using the evidence identified through the systematic review and survey, and with advice from our advisory
group, we have outlined the general pathway that an intravenous chemotherapy patient may follow
through the NHS. The pathway involves many steps, some of which are outside the scope of the decision
problem this research is addressing. They are outlined, however, to give context to the question that will
be addressed.
l Step 1: access and referral to an oncologist.
l Step 2: assessment and decision to treat, patient consent.
l Step 2a: assessment of decision to treat with chemotherapy.
It is anticipated that these three steps (1 to 2a) will be the same regardless of the setting in which the
treatment will be delivered. On completion of these three steps a group of patients eligible and willing to
receive intravenous chemotherapy have been identified. Figure 7 depicts the pathway for this population.
In addition to the figure, the following is a summary of some of the considerations made at each step in
the pathway. The evidence collated from the questionnaires, outlined earlier in Chapter 4, suggests
that the eligibility criteria for treatment at home may be stricter than the criteria for treatment in the
community. Therefore, a proportion of the total population eligible for intravenous chemotherapy will be
eligible to receive that treatment in a community setting and a subgroup of those will be eligible to receive
their treatment at home.
l Step 2b: assessment of eligibility for treatment at community and/or home.
Step 2a Step 2b (i) Step 2b (ii) Step 2c
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for home
chemotherapy
Not eligible for
community
chemotherapy
Eligible for
community
chemotherapy
All i.v.
chemotherapy
Choose
outpatient
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for home
chemotherapy
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chemotherapy
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for home
chemotherapy
Choose home
chemotherapy
FIGURE 7 Patient pathway. i.v., intravenous.
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In any organisation delivering treatments within these settings, individual patient eligibility criteria will be
defined [step 2b (i)]. Eligibility criteria are expected to consist of the following elements:
l patient fitness status (ECOG performance status, comorbidities)
l drug regimen suitability (drug stability, length of infusions, low-risk adverse event profiles)
l clinical perception of individual patient probability of being hypersensitive to drugs (this can be
mitigated through having one or two cycles in hospital)
l clinical perception of individual patient susceptibility to severe adverse events
l cancer type (breast, lung, colon, etc.)
l cancer stage/grade
l line of treatment (first, second, third)
l neoadjuvant/adjuvant versus primary treatment
l patient age (children, young adults, adults, elderly).
Once patient eligibility is determined, it is expected that an assessment [step 2b (ii)] of the patient’s home
environment and location would be necessary unless the patient expresses a preference for treatment not
to take place at home. The elements considered in any such assessment are likely to include:
l distance from home to hospital or drug preparation unit
l whether the patient lives alone or has support
l whether or not the patient has pets and if they can be removed for the treatment duration
l whether or not the patient has children and if they will be present at treatment delivery
l whether or not the home is of an acceptable cleanliness
l whether or not there is a place for the nurse to wash their hands
l whether or not there is a workspace available.
These assessments may be undertaken by a multidisciplinary team (led by the oncologist and specialist cancer
nurse) or by the specialist chemotherapy nurse. These assessments ensure that patients and their homes are
suitable. There is also the issue of patient choice. Assuming that the health service organisation is in a position
to offer all three treatment settings, there are still a number of considerations for the patients and uptake of
treatment in alternative settings is likely to be variable. Across regions, choice and preference may depend on
socioeconomic variation, geographical differences and the overall demographics of the regional population.
Other determinants of uptake may be significantly different. It is expected that an individual’s choice may
be influenced by the following aspects:
l time constraints
l labour force participation
l distance to the hospital
l availability of transport
l cost of transport and parking
l ease of hospital access
l appreciation by some people of a change of location and social interaction
l availability of childcare
l symptom severity
l clinical advice and enthusiasm of health-care workers
l society’s acceptance of home chemotherapy
l wish to keep treatment out of the home
l personal aversion/fear of hospitals
l personal relationship with hospital staff
l quality of past hospital care
l provision of safety information
l family agreement and support.
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The main focus of this report is on the later part of the pathway, wherein patients eligible for home
chemotherapy receive treatment in their chosen location. The decision problem addressed in the economic
modelling will not take account of eligibility criteria and how clinical staff might identify people to be
offered home intravenous chemotherapy as a treatment option. Instead, it commences with an eligible
population and addresses the question of which setting is most cost-effective for this population.
Decision model
One of the aims of the systematic review was to identify relevant data for a decision model. The systematic
review produced little relevant evidence to facilitate answering the decision problem robustly. In an
attempt to illuminate the issues surrounding the cost-effectiveness of delivering community-based
chemotherapy, we have taken the best available evidence identified during the review and used this to
undertake exploratory decision modelling.
The systematic review identified nine economic evaluations that compared chemotherapy in an outpatient
hospital setting with chemotherapy administered in a home and/or community setting. The limitations of
these economic evaluations are described in Chapter 3 (see Cost-effectiveness studies). This report is
targeted for a UK audience and so the most relevant economic evaluations for model inputs were the
OUTREACH trial4 and Pace et al.29 Both of these studies were set in the UK and provided some, albeit
limited, information on costs and outcomes for a relevant UK population.
The systematic review identified eight studies which were not full economic evaluations but reported costs
and/or resource use. Six studies were not from the UK; two only provided cost information42,48 and the
remaining four were not included for reasons of generalisability.27,28,35,37 The two UK studies were not
sufficiently detailed to provide any additional information above that presented in the OUTREACH trial.30,71
In the UK, cost–utility analyses (CUAs) are generally considered the most relevant type of economic
evaluation to help to inform decision-making.72 Cost–utility studies represent intervention costs and
intervention benefits measured in QALYs. QALYs measure a person’s remaining quantity and also quality
of life. These analyses usually produce ICERs, calculated as the costs of intervention A minus the costs of
intervention B, divided by the benefits of intervention A minus the benefits of intervention B. These
analyses can contain multiple interventions, in which case each intervention is compared with the next
least costly intervention. Because the OUTREACH trial produced a CUA in line with UK methodological
guidelines, the base-case model replicates data from the OUTREACH trial with some augmentations made
where necessary. The following sections outline the model structure, parameters and results.
Model structure
A simple decision model was developed in Excel (Microsoft Excel 2010, Microsoft Corporation, Redmond,
WA, USA) to assess the cost-effectiveness of intravenous chemotherapy delivered in the home, community
or outpatient setting in a population considered eligible for home treatment. Figure 8 shows this patient
pathway and how it relates to the broader issues around the implementation of chemotherapy at home or
in the community. Many aspects of the implementation of community and home chemotherapy are not
part of the decision problem addressed by the model and these are shaded green.
All of the patients in the model are assumed to be eligible for home chemotherapy. They then choose
where they receive their treatment, and incur costs and accumulate QALYs over the time horizon of the
decision-tree model.
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The patient population of the model is assumed to replicate patient characteristics from the OUTREACH
trial: patients were above the age of 18 years with an ECOG performance status of 0–2, lived within a
30-minute drive of the recruiting hospital, and either were about to commence or had commenced a
course of cancer treatment with standard infusions lasting < 4 hours for a minimum of 12 weeks with
intent to treat, cure or provide palliative care. Patients were required to have a life expectancy > 6 months
and be capable of independent transportation to the hospital. Patients were not taking any unlicensed
drug as part of their treatment. Patients randomised between the three settings were broadly similar in
ECOG performance, treatment intent and gender. There were small differences in cancer types in
each arm.
We ran the model for a cohort of cancer patients receiving intravenous chemotherapy. The distribution of
patients across the model arms was derived from anticipated patient choices based on data from the
OUTREACH trial. Cost and utility weights are applied dependent on the treatment setting. Owing to
limitations with the trial data, we elected not to extend the time horizon of the model beyond that of the
trial (12 weeks) to avoid introducing more uncertainty through the use of extrapolation. The time horizon
was 12 weeks and, as a consequence, the cost and utilities were not discounted in the base case. Costs
are reported in 2012 pounds sterling.
Model parameters
Patient choice
The initial distribution of patients to different settings within the model was determined by patient choice
assumptions derived from OUTREACH.4 As highlighted in the systematic review of clinical effectiveness,
patients may participate in a trial because they want the new treatment; others may elect not to
participate to ensure that they are not exposed to unwanted treatment. In OUTREACH, patients who
wanted outpatient hospital chemotherapy or did not want to receive treatment in a particular setting could
simply opt not to participate in the trial. The proportion of patients in the model choosing each setting
was, therefore, adjusted for recruitment bias, based on methodology from King et al.31
Step 2a Step 2b (i) Step 2b (ii) Step 2c
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FIGURE 8 Modelling patient pathway. i.v., intravenous.
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Although OUTREACH reported preference data, it did not utilise a crossover design and patients were
asked whether or not they would prefer to continue treatment in their allocated setting. These patients
experienced only one setting during the trial and so it is unclear if their decision was informed by past
experience of chemotherapy in the hospital outpatient setting or if patients were naive to chemotherapy.
Owing to this, it was unclear in which setting any given patient would choose to have treatment had they
experienced multiple settings.
To adjust for this limitation of the OUTREACH data we assumed that the patient population had had weak
preferences as in King et al.31 Assuming indifference to treatment settings may be considered conservative
as we cannot know the motivation of patients who chose to participate in the trial; they might have
participated because of preference for treatment settings other than the outpatient default. Patients who
chose not to participate in the trial owing to a stated preference were by definition not indifferent to the
setting and so we needed to adjust for this potential bias. Our adjustments took into account patients’
expressed reasons for preferring one setting over another as described in Chapter 3 (see Qualitative
studies) and the analysis in King et al.,31 where patients who had declined to participate in the trial due to
strong preferences were reintegrated into the data to adjust preferences; this resulted in 48% of patients
preferring chemotherapy at home, as outlined earlier (see Chapter 3, Clinical effectiveness studies and
Satisfaction and preferences).31,54
In OUTREACH, 33 patients were randomised to home, 32 were randomised to community (GP practice)
and 32 were randomised to outpatient. Fifty-three patients declined to take part in the trial: 35 wanted an
outpatient setting; 16 did not want chemotherapy in a GP practice; and two preferred chemotherapy at
home. Following the King et al.31 methodology, these 53 patients excluded owing to preference were
added to those who chose to participate in the OUTREACH trial with the assumption that patients with a
stated preference for outpatient would receive outpatient and those with a preference against the GP or
home setting would be split evenly between the alternative settings. As the results from the King et al.31
study suggested that overall patient preference may not be particularly strong, we assumed patients who
stated no preference to be indifferent to treatment setting allocation.
After adjustments, the resultant probabilities suggested that 27.3% of patients would choose to have their
chemotherapy at home, 22.0% would choose to have it in the community and 50.7% would choose the
hospital outpatient setting. In a probabilistic sensitivity analysis, a Dirichlet distribution was used to reflect
the uncertainty surrounding choice. Table 11 shows the transition probabilities between states used within
the model and the mortality rate applied to all states.
At this point, including patient choice does not affect OUTREACH results because any benefits and costs in
a setting are divided by the number of people in that setting and so they are cancelled out. However, if
throughput is introduced to the model, and this throughput determines fixed costs and potential savings
due to economic efficiency, then patient choice will impact the results of the model.
TABLE 11 Transition probabilities for the decision model
Intervention Mean n SE Distribution Source
Patients choose home 0.273 43 Dirichlet OUTREACH,4 King et al.31
Patients choose community 0.22 33 Dirichlet OUTREACH,4 King et al.31
Patients choose outpatient 0.507 76 Dirichlet OUTREACH,4 King et al.31
Probability of death 0.06 1,278,602 0.0018 Beta ONS Cancer Survival in England 201273
ONS, Office for National Statistics; SE, standard error.
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The model allows for the possibility that patients may die based on Office for National Statistics mortality
statistics for 20 common cancers.73 Although there were no mortalities recorded in the OUTREACH trial,
it is possible that, in practice, some patients receiving chemotherapy will die over a 12-week or longer
period. The mortality rate was assumed to be the same for each setting and so had no effect on the model
outcomes. The mortality parameter was included to allow for longer model lengths and to improve the
face validity of the model.
Patient quality of life
The OUTREACH trial reported the number of QALYs gained over the 12-week length of the trial. Utility values
were derived using the EQ-5D questionnaire as completed by the patients in the trial. Questionnaires were
completed at baseline and 4, 8 and 12 weeks; only outcomes at 12 weeks were analysed. The model uses the
12-week QALYs derived from OUTREACH. These data are treated as utility scores, assuming constant utility
over the time period, implying that any QALY gains are equivalent to multiplying the utility score at 12 weeks
by 12/52. The QALYs in OUTREACH were reported without baseline values and so the base-case model has
no adjustment for baseline values. Table 12 presents the utility values in the model derived from OUTREACH.
The uncertainty in the underlying utility data was represented using beta distributions in probabilistic sensitivity
analysis. The utility value for the death state was assumed to be the customary value of zero.
Costs
The original OUTREACH publication reported total costs with no details of what these comprised.
We obtained additional cost category data from the authors.
Total costs were divided into the following categories: inpatient, outpatient, day hospital, A&E visits,
community care, medication (excluding cancer drugs) and nurse contact. Follow-up data provided by the
authors were reported as average costs per patient for each category in each setting, with no reported
resource use. However, included data suggested that A&E visits, as a cost category, cost on average £3–4
per patient. Clarification was sought from the authors whether the value they reported was the average
number of visits, as their table appeared to indicate, or the total number of visits to A&E for each
treatment arm, but no additional information was provided. Therefore, we have assumed that this is an
error and that the number represented total visits to A&E per arm, rather than the average costs of those
visits. In order to produce the average cost of each emergency room visit, we multiplied the NHS reference
cost for A&E visits by the number supplied from the OUTREACH trial and divided this by the number of
participants in each arm. The cost of one A&E visit without any follow-up visits according to NHS reference
costs was £122 in 2011–12.74
Cost data provided on request from the OUTREACH trial did not contain SDs or standard errors;
aggregate costs reported in the published study provided SDs for total costs in each study arm. We
assumed that the proportion of the SD to the mean for cost categories would be similar to the proportion
of the SD to the mean for total costs. The proportions of the SD of costs to mean costs are shown in
Table 13. We assumed that the proportion of the SD to costs for all arms would be the average of the
three, that is 75%.
In a probabilistic sensitivity analysis, gamma distributions were used to represent costs, as the skew of the
gamma distribution and bounding between zero and positive infinity make it a good choice for
representing costs. Table 14 incorporates all updated costs from the OUTREACH trial inclusive of our
TABLE 12 Utility values used in the decision model
Intervention Mean EQ-5D n SD
Outpatient 0.754 14 0.147
Home 0.715 15 0.230
Community (GP practice) 0.828 19 0.173
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TABLE 13 Proportion of SD to mean cost from OUTREACH trial
Setting SD (£) Mean cost (£)
Proportion of SD to
mean cost
Hospital outpatient 1831 2221 0.82
Community (GP practice) 1759 2497 0.70
Home 1590 2139 0.74
TABLE 14 All costs used in the decision model
Intervention Mean (£) n SD (£)
A&E visit costs 122.00 150,041 41.30
Outpatient
Inpatient 321.12 13 240.84
Outpatient 880.74 13 660.56
Day hospital 716.57 13 537.43
A&E visits 37.54 13 28.15
Community care 210.64 13 157.98
Medication (non-cancer) 8.26 13 6.20
Nurse diaries 151.78 13 113.84
Total costs: outpatient 2326.65 13 1744.99
Home
Inpatient 215.80 20 161.85
Outpatient 588.54 20 441.40
Day hospital 292.20 20 219.15
A&E visits 18.30 20 13.73
Community care 242.64 20 181.98
Medication (non-cancer) 11.36 20 8.52
Nurse diaries 857.00 20 642.75
Total costs: home 2225.84 20 1669.38
Community (GP)
Inpatient 367.58 17 275.68
Outpatient 617.45 17 463.09
Day hospital 214.77 17 161.07
A&E visits 21.53 17 16.15
Community care 284.98 17 213.73
Medication (non-cancer) 16.52 17 12.39
Nurse diaries 1073.83 17 805.37
Total cost: community 2596.65 17 1947.49
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assumptions modifying A&E costs and inflating prices using 2011–12 Personal and Social Services Research
Unit price indices for medical services.75 The cost of an A&E visit was derived from 2011–12 NHS reference
costs;74 all other costs were derived from the OUTREACH trial.4
Cost-effectiveness results
The base-case deterministic model results are presented in Table 15. These results do not account for
uncertainty; in order to do this, a probabilistic sensitivity analysis was undertaken varying all model
parameters within their assigned distribution for 10,000 simulations. The results of the probabilistic analysis
are presented in Table 16 and in graphical form in Figures 9 and 10.
In the base case, home chemotherapy is both the least costly and the least effective treatment setting,
followed by outpatient chemotherapy, which has an ICER of £11,201 per QALY compared with the home
setting. Assuming the standard National Institute for Health and Care Excellence (NICE) cost-effectiveness
threshold willingness-to-pay range of £20,000–30,000 per QALY gained, the ICER of £15,882 per QALY
for community chemotherapy compared with outpatient chemotherapy indicates that delivering
chemotherapy in a community setting is cost-effective.72
Table 16 shows the probability of cost-effectiveness of the different settings at several values. NICE
guidance also advises that ICERs greater than £30,000 per QALY may be considered for treatments that
meet criteria for end-of-life care,72,76 which may be important for specific chemotherapy regimens that
meet end-of-life care criteria.
Table 16 and Figures 9 and 10 clearly demonstrate the high level of uncertainty surrounding any decision
based on the OUTREACH trial data. There are no treatments that have a high probability (> 60%) of
being the most cost-effective treatment setting between a £0 and £30,000 per QALY willingness-to-pay
threshold. Only at a threshold of £50,000 per QALY does the likelihood of community chemotherapy
being the most cost-effective option rise above 60%. Home and outpatient chemotherapy never have a
probability of being the most cost-effective treatment of much more than 45%, and this only occurs at a
willingness to pay of £0 per QALY with the treatment setting being home chemotherapy. Figure 10 shows
that up to a threshold ICER of £7200 per QALY chemotherapy delivered in the home setting is the
preferred option, up to an ICER of £16,400 per QALY outpatient chemotherapy is the preferred setting,
and above this value community chemotherapy is preferred.
TABLE 15 Base-case cost-effectiveness results
Intervention Costs (£) QALY Incremental costs (£) Incremental QALY ICER (£)
Home 2225.84 0.165 – – –
Outpatient 2326.65 0.174 100.81 0.009 11,200.89
Community 2596.65 0.191 270.00 0.017 15,882.39
TABLE 16 Probability of cost-effectiveness at various thresholds
Setting
Threshold values (£/QALY)
£0 £10,000 £20,000 £30,000 £50,000
Home 0.462 0.351 0.260 0.196 0.128
Outpatient 0.383 0.376 0.340 0.300 0.218
Community 0.155 0.273 0.400 0.504 0.655
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While this model based on the OUTREACH trial found that the most cost-effective option across accepted
willingness-to-pay thresholds in the UK was chemotherapy delivered in the community, as previously stated
its purpose is exploratory and the results should not be considered robust or used to inform decisions.
Model limitations include:
l The OUTREACH trial had very small numbers of patients returning health economic outcomes for the
CUA (no more than 20 for cost outcomes, and no more than 19 for QALYs).
l No differences in health-related quality of life were statistically significant.
l The precise details of each of the settings used in OUTREACH may be different from those used in the
same setting in a different location.
l The model is simplistic and may not represent important nuances in delivering chemotherapy.
l The generalisability of the patient population is unclear.
Sensitivity analyses
We used sensitivity analyses to further explore impacts of assumptions and small adjustments on data.
The limitations of the model meant that an exhaustive suite of sensitivity analyses might not be helpful and
could possibly mislead readers. For this reason we performed only three formal sensitivity analyses:
l Scenario 1: utilities adjusted for baseline.
l Scenario 2: the mean cost of community care in the home setting was made equal to the mean cost of
community care in the community (GP) setting (£285) and the mean nurse diary costs for the
community (GP) setting were made equal to those in the home setting (£857).
l Scenario 3: mean inpatient stay costs in the home setting were made equal to community (GP) setting
costs (£368).
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FIGURE 10 Cost-effectiveness acceptability frontier.
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These analyses highlight the uncertainty in the outcomes and the impact on the cost-effectiveness of each
setting as a result of making small plausible changes to the data. The results of all sensitivity analyses are
reported in Table 17. In addition to these analyses, the potential implications of using different analytical
perspectives are discussed, as well as potential effects of VAT exemptions on provision of chemotherapy
services in the home.
Adjusting for baseline imbalances in utility scores
Information provided from the OUTREACH trial indicated that the authors had adjusted QALY gains for
baseline imbalances. Because no baseline values were reported and only a difference in difference analysis
was provided, this sensitivity analysis assumes that the difference in baseline values is maintained in the
difference in final QALYs gained. To maintain consistency, these values were converted to utility scores for
use in the model. Table 18 shows the utility adjustments made in the OUTREACH data.
Using these adjusted values in the model changes the ICER of the chemotherapy settings. In the base case,
chemotherapy administered in a community setting was the most effective option at a threshold of
£20,000. In this sensitivity analysis, chemotherapy in the community is both more costly and less effective
than administration in the outpatient setting. The ICER for outpatient chemotherapy compared with
chemotherapy in the home setting also improves.
TABLE 17 Results of scenario analyses
Intervention setting Costs (£) QALYs Incremental costs (£) Incremental QALYs ICER (£)
Scenario 1
Home 2225.84 0.164 – – –
Outpatient 2326.65 0.174 100.81 0.010 10,080.80
Community 2596.65 0.165 270.00 –0.009 Dominated
Scenario 2
Home 2268.17 0.165 – – –
Outpatient 2326.65 0.174 58.47 0.009 Dominated
Community 2379.82 0.191 111.64 0.026 4294.03
Scenario 3
Outpatient 2326.65 0.174 – – –
Home 2377.62 0.165 50.97 –0.009 Dominated
Community 2596.65 0.191 270 0.017 15,882.39
TABLE 18 Utility adjustments for scenario 1
Intervention Base-case QALYs Base-case utility score Adjusted QALYs Adjusted utility score
Home 0.165 0.754 0.164 0.711
Outpatient 0.174 0.715 0.174 0.754
Community 0.191 0.828 0.165 0.715
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This analysis emphasises the uncertainty surrounding the utility values used in the model. Given the small
sample size in the OUTREACH trial and the suggestion of baseline differences, the utility data cannot be
considered reliable. It is likely that the quality of life of patients depends on their disease, treatment
status (palliative, supportive or curative), age, and other factors that the OUTREACH data may not have
captured. Clarification was sought from the authors on whether or not the data were adjusted for patient
characteristics other than baseline EQ-5D scores, but none was received. Given the small patient numbers,
it is unlikely that any such adjustment would have been plausible or would reduce the uncertainty. Further
research is necessary to confirm or refute differences in patient quality of life between settings.
In scenario 2, making the mean cost of community care in the home setting equal to the mean cost
of community care in the community (GP) setting, and the mean nurse diary costs for the community (GP)
setting equal to those in the home setting, resulted in outpatient care being extendedly dominated;
this means that a hypothetical combination of home and community chemotherapy services would be
more cost-effective than outpatient chemotherapy on its own. In scenario 2, chemotherapy in the
community setting is the most cost-effective option with an ICER that is lower than the base-case analysis.
Similarly, scenario 3 makes home more costly than outpatient and it remains less effective. In scenario 3,
home is dominated and community is the most cost-effective option.
Other areas of interest for exploration
The perspective of all our modelling analyses is the NHS and Personal and Social Services perspective
(only costs to the NHS and Personal and Social Services are included). Other perspectives could be analysed
and may produce different results.
Some economic evaluations included in our systematic review included patient or carer costs: patient
travel costs;29 parent travel costs, payments for physician/care provider visits, medication, babysitting, lost
productivity and government transfer payments;33 and patient travel costs.34 These are valid perspectives,
but their relevance to NHS decision-makers may be limited even though they are interesting.
The Centre for Health Economics, University of York, published a contingent valuation study of patient
time.77 This study asked patients to value different usages of their time such as time to start of treatment
(between scheduling an appointment and receiving treatment), travel time, time waiting at a health facility
for treatment and time receiving treatment.
In our model, time to start of treatment and time receiving treatment are expected to be independent of
the setting and so only values related to travel time and waiting time are reported. The Centre for Health
Economics study measured Dutch patients’ valuations of travel and waiting time for patients in three
treatment areas (radiotherapy, orthopaedics and rehabilitation) and found that they valued each hour of
travel time at £11.54 and each hour of waiting time at £34.76.77 Chemotherapy patients were keenly
aware of how time spent travelling to hospital and waiting for treatment had negative impacts on
their time and energy. Including valuations of patient time could have significant impacts on the
cost-effectiveness of treatment settings for chemotherapy. However, our systematic review identified
only limited information on time spent travelling to and waiting in hospitals in the UK.
Several respondents in our survey of provision mentioned that drugs delivered at home were exempt from
VAT (current rate 20%) and that these savings were used to finance home chemotherapy services. This
view was reflected by the advisory group. Private providers have used VAT savings in trying to market their
home services to NHS providers.69 HM Revenue & Customs has indicated that medicines delivered
in the home may be eligible for a zero rating for VAT where requirements are met regarding drug use
and provision.68
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Considering that cost differences between the settings were small, reducing drug costs by 20% could alter
cost-effectiveness decisions on home provision of specific chemotherapeutic drugs. Drug costs were not
included in our model as they were not included in the OUTREACH data. However, it is likely that drug
costs make up a significant proportion of the total cost of treatment. This will be particularly true in the
case of newer chemotherapy drugs where the cost of the drug may represent most of the total treatment
cost. In these instances the impact of VAT exemptions may have an impact on where these drugs are
prepared and delivered.
Some of the issues outlined will not be relevant across the whole NHS, but local service configurations may
make them worthy of further investigation should data become available.
PATIENT PATHWAY
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Chapter 6 Discussion
The aim of this project was to investigate the impact of the delivery of intravenous chemotherapy indifferent settings on quality of life, safety, patient satisfaction and costs.
We performed three systematic reviews to provide a complete overview of the available published evidence
base. We supplemented the published evidence with a survey of current practice to better understand the
variation in chemotherapy deliver practices in the UK and facilitate the structuring of an economic decision
model. In this section we present a summary of those findings and their strengths and limitations and
bring together the elements of this mixed-methods project to draw summary conclusions and highlight the
implications for practice and further research.
Key findings
The results of this study highlight avoidable study design and reporting limitations, and inherent and
sometimes unavoidable difficulties, which arise when conducting primary studies to compare
chemotherapy settings. Although several studies were appropriately designed to minimise avoidable biases,
conducting randomised trials of chemotherapy settings nevertheless appears difficult in terms of both
patient accrual and recruiting a population to enable an unbiased evaluation of the settings. Consequently,
few robust conclusions can be made about the clinical effectiveness and cost-effectiveness of the different
settings. However, a prevalence of qualitative data enabled a broad evaluation of patient, relative and
caregiver experiences, with additional input from health-care professionals.
We identified eligible randomised trials and economic evaluations but there was a lack of useful data to
inform and populate a decision model, and little evidence of clinically relevant differences between settings
in terms of quality of life, and clinical and psychological outcomes (even though the biases when recruiting
patients would have been expected to favour the home or community settings). The synthesis of
qualitative studies indicated that decisions and preferences about intravenous chemotherapy treatment
setting are strongly influenced by a desire to maintain normality. The modelling developed in our study
was necessarily exploratory in nature owing to the limitations of the existing evidence base.
There was little evidence to indicate any effects of setting on quality of life. Trial samples sizes were likely
too small to detect any such effects. It was unclear whether or not the quality-of-life assessment tools used
were sensitive enough to detect differences between settings. The only potentially meaningful differences
evident from the clinical effectiveness review were for some patient satisfaction and preference outcomes.
However, strength of preference was studied in only one trial and preferences appeared not to be strong
in around one-third of the patients who said that they preferred home chemotherapy. These results
indicated that time was more important than setting for those patients.31 There were no comparative
studies of how preferences might change with other factors (such as distance from hospital, financial
costs, outpatient environment and nurse–patient relationship). The limited adverse event evidence available
gave no indication that there need be any safety concerns when delivering intravenous chemotherapy in
either the home or the community setting.
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The qualitative studies provided evidence from health professionals, patients (adults and children), parents,
carers, siblings and partners. The data focused on experiences of outpatient and home settings for
intravenous chemotherapy and included some data on community settings including mobile bus units.
The range of participants and experiences suggests that these data provide relatively comprehensive coverage.
We have presented a line of argument around barriers and perceived costs associated with non-outpatient
settings. Barriers to service provision centred on costs/resources, lack of support from key referring staff
and the need for more training or additional nurses. Staff expressed concerns about their personal safety
in relation to home chemotherapy services.
These issues were mirrored in the survey data presented in Chapter 4 and summarised in Table 19. The
second line of argument focused on factors influencing patient satisfaction with intravenous chemotherapy
across locations. Elements such as communication, information, privacy, rapport and individuality of
treatment are unlikely to be unique to chemotherapy treatments, but they indicate key areas where small
changes could result in substantially improved satisfaction.
The key line of argument derived from the qualitative data states that decisions and preferences about
intravenous chemotherapy setting are rooted in attempts to maintain normality. Various factors push
patients towards preferring hospital outpatient settings (mostly safety and expertise) while others pull
patients towards other settings (in order to have some control over resources, such as time or energy).
Medical expertise was the largest component which favoured outpatient treatment; however, this was
seen as a trade-off against other settings which facilitated more normality in everyday life. Time was one
of the largest factors that drew patient preference away from outpatient settings; it is important to
understand that this is about more than waiting times, travel time and length of appointment. Cancer
patients and their families were very conscious of the limited resources at their disposal in terms of time
and energy. When chemotherapy treatment absorbed too much of these resources, the resulting fatigue
impacted heavily on every other aspect of their life. This suggests that complaints about waiting time
should be seen in a broader context.
TABLE 19 Barriers to provision
Qualitative synthesis Survey data
Staff personal safety concerns
Reluctance to treat in other locations Lack of consultant support for the service
Difficulty convincing patients
Adverse event concerns Limited eligible treatment regimes
Lack of professional support Regulations interfere with cost-effective provision
Capacity concerns Practical difficulties
Lack of nursing staff
Cost of the service (patient and staff views) Concerns about costs
Lack of communication between health professionals
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Limitations of the evidence and of the review
Clinical studies: recruiting a representative and unbiased population
A key issue to consider when interpreting the results of the randomised trials included in this review is
their generalisability. Although many studies (but not all) invited all eligible patients to participate, the
nature of the interventions in question (the settings) meant that potential participants were likely to have
pre-trial perceptions (opinions and likely preferences) about the interventions they might receive.
This is an uncommon problem during randomised trial recruitment because patients typically have limited
information on which to base prior perceptions (for at least one of the interventions being studied).
In most intervention trials it would be difficult for invited patients to attempt to compare the likely benefits
and harms of the interventions for them as individuals. Exceptions would include trials evaluating
chemotherapy settings, some behavioural intervention trials,78 and trials of participative interventions
(such as self-monitoring, rehabilitation and counselling interventions).79
It is unsurprising that many of the patients who declined to participate in the trials in this review did so
because they wanted to receive their chemotherapy in a hospital outpatient setting (or did not want the
home setting). By declining to participate, patients would guarantee that they receive chemotherapy in
their preferred setting. Conversely, patients who wanted to receive chemotherapy in the home (or
community) setting may be likely to accept their invitation to participate in a trial if it were the only route
by which they may receive chemotherapy at home or the only way of avoiding the hospital outpatient
setting. Consequently, the trial populations in this review are likely to over-represent hospital-averse (or
home-inclined) patients, and under-represent patients who are keen to receive chemotherapy in a hospital
environment. It is important that the results of these trials are interpreted with this in mind; the trial
populations are likely to prefer, to be more satisfied with, and to have a better quality of life, with home or
community chemotherapy than with hospital outpatient chemotherapy. Only one trial considered the
implications of this issue by performing additional analyses.31
Problems are also often encountered in recruiting sufficient numbers of patients into oncology trials,
although the reasons for limited accrual are not always easy to identify. A study of 82 oncology trials
found that therapeutic trials achieved sufficient accrual more often than non-therapeutic trials, but that
shorter consent forms, fewer exclusion criteria and simplicity of trial design were not associated with
achieving sufficient accrual.80 Many of the 82 trials were stopped early because of insufficient accrual.
The authors noted a need for research to better inform patient accrual prediction practices (a trend
towards accrual sufficiency was observed for trial protocols containing documentation supporting
predicted accrual goals). All the trials in our review randomised fewer than 100 participants and almost all
had slow rates of recruitment.
A systematic review which assessed studies of patients’ attitudes and barriers to participation in cancer
trials found that barriers to participation were protocol-related, patient-related or physician-related. The
most common reasons given as barriers included concerns with the trial setting; a dislike of randomisation;
general discomfort with the research process; complexity and stringency of the protocol; presence of a
placebo or no-treatment group; potential side effects; being unaware of trial opportunities; the idea that
clinical trials are not appropriate for serious diseases; fear that trial involvement would have a negative
effect on the relationship with their physician; and their physician’s attitudes towards the trial.81
Cost-effectiveness studies, exploratory economic modelling and brief survey
Studies in the cost-effectiveness review were generally poor quality; most were from outside the UK and
most did not report resource use or unit costs, and so their generalisability to the UK was limited. Given
these limitations, the evidence identified was of limited usefulness for informing a de novo economic
model. Sample sizes were generally small and studies were subject to broad uncertainty.
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Data from the OUTREACH trial were used to structure and populate a model to enable exploration of
cost-effectiveness. However, these data were derived from a small number of trial participants; no more
than 20 and as few as 13 patients contributed cost or QALY data for any trial arm. We addressed some of
the data limitations using assumptions; where possible these were validated with the authors, but this was
not possible in all instances.
The three settings used in OUTREACH may not be representative of all available settings. There appears to
be large variation in how UK services are delivered and it remains unclear that the three options modelled
would be viable for all organisations. Many will not be in a position to offer more than one alternative to
outpatient setting. Owing to capacity constraints, geographical location or other organisational structures,
the alternative(s) offered may not constitute a choice. It is possible that some patients may not have
multiple options for how they receive their treatment and may not be given a choice that includes settings.
Further, it was clear from the survey that third-party providers and chemotherapy buses are already
providing treatment closer to home and in the home, but owing to data limitations we were not in a
position to include these options as comparators in the model.
The brief survey of NHS and private providers was not intended to be comprehensive and so provided only
limited information. The number of responses was relatively low and might not have been representative
of the entire NHS, but nevertheless provided a rapid overview of the variation evident in current practice.
Qualitative studies
All of the studies evaluated a new or proposed service against an existing, perhaps struggling, hospital
outpatient setting. As discussed previously, participants were drawn from a biased sample. Methodologically,
the most common weakness was lack of reflexivity and consideration of the authors’ impact on the data,
which reduces the reliability of the findings.
In the review it would have been ideal for us to involve another member of the review team in the
synthesis process (rather than an external colleague) but this was not possible owing to limited experience
of qualitative data. Our use of online web-based translation services for one paper rather than an
experienced translator might have resulted in some loss of meaning or mistranslation.
Strengths of the review
This is the first systematic review to compare the effects of home, community and hospital outpatient
settings. The only other systematic review in this area compared only the home and hospital outpatient
settings and was broader in terms of the eligible populations (studies of patients taking oral chemotherapy
or other intravenous cancer therapies were included).82 This 2010 review concluded that there was no
current evidence that home therapy has any beneficial effect on quality of life or response to chemotherapy,
although the trials were not powered to detect these outcomes.
Our review was performed according to CRD guidance and reported according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses statement. Our comprehensive searches to identify
studies located several unpublished studies. A further strength is that we included non-randomised and
single-setting studies.
The qualitative review followed an established method (meta-ethnography), using qualitative data analysis
software (NVivo) to clearly track which studies contributed to each code; there was oversight from a
second reviewer with qualitative expertise and there was discussion of code and line of argument
development. Quality assessment was carried out based on clearly defined criteria that are linked to the
reliability of the findings rather than fidelity to a particular method.
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Our cost-effectiveness review represented a wide variety of potentially relevant outcomes including NICE’s
preferred measurement of health-related quality of life (EQ-5D) and cost and resource use data from the
UK. The model has limitations, but was based on UK data from a trial that compared three different
settings. The trial used QALYs and UK costs from the NHS perspective, both of which are in line with NICE
methodological guidance. By presenting the modelling we aimed to highlight the uncertainty in the data
and the impact of different assumptions when undertaking decision modelling in areas of such variability
in service delivery and data uncertainty.
Patient and public involvement
To ensure patient and public involvement (PPI) we recruited two representatives to the advisory group for
this project. One representative had received chemotherapy treatment for cancer and the other has a
wealth of experience in PPI. They were involved from the proposal stage helping to shape discussions
around choice of outcome measures and inform the researchers on issues of importance to patients.
As active members of the advisory group, both representatives were invited to review drafts and to
comment on the full report before submission. Comments from the PPI representatives indicated that they
found the process interesting but felt unable to contribute in detail as the focus was on discussing existing
research rather than directly shaping the treatment itself.
Patient and public involvement within the framework of a systematic review is often less about directly
influencing the methodology itself, but rather can help to sensitise the researchers to the outcomes of
importance to patients. Within this project, PPI helped to emphasise the importance of patient choice and
preference rather than just concentrating on clinical outcomes. Such outcomes are more likely to be
reported in mixed-methods or qualitative studies, and so it was important to ensure that our searches and
inclusion criteria were able to capture such studies.
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Chapter 7 Conclusions
Few robust conclusions can be made about the clinical effectiveness and cost-effectiveness of thedifferent settings in which intravenous chemotherapy is administered. This is largely a consequence of
the difficulties encountered during the clinical trials. There was a lack of useful data to inform and
populate an economic decision model, and little evidence of clinically relevant differences between settings
in terms of quality of life, and clinical and psychological outcomes. The results from qualitative studies
indicated that decisions and preferences about treatment setting are strongly influenced by a desire to
maintain normality.
Implications for research
Study design
Recruitment bias and patient accrual problems are likely to be difficult to overcome in randomised trials
that use conventional study designs. A more useful and representative study design might be to nest a
RCT within a larger observational cohort of patients; ambivalent patients could be randomised and patients
with preferences could receive their preferred setting. Such a study might also make use of the qualitative
data themes identified in our review, and incorporate them into questionnaires for use before any
chemotherapy is initiated and after chemotherapy in a particular setting is completed. Efficacy estimates
would result from the randomised component of the study and any additional influence of motivational
factors could be studied by comparing patients randomised to the home setting with those who chose the
home setting.
The results from this design should also indicate any clinical or demographical differences between the
different populations at baseline and produce estimates of likely rates of uptake of the different settings to
help inform future service provision. This study design would more clearly identify setting-related safety
issues (which appear to be one of the key concerns about the implementation of a home or community
chemotherapy service). Larger and more generalisable data sets would enable analyses to be made of
whether or not setting-related issues that are important to patients, such as waiting times, anxiety or
transport, vary according to patient characteristics.
This approach to study design is very similar to one advocated for trials of counselling following
mastectomy described in a paper about patient preference and randomisation; this discussion paper also
suggested a change-from-baseline approach when analysing some outcomes of non-randomised groups.79
Other similar designs include the randomised consent (Zelen) design83 and the cohort multiple RCT.84
However, in addition to the lack of patient consent issues to be considered when using these designs,
neither design uses a crossover component which, in this area of research, would appear to be the most
appropriate option for two reasons.
First, when compared with other designs, fewer patients would need to be randomised to obtain the same
number of observations and fewer observations are needed to obtain the same precision in estimation.
This is a consequence of patients acting as their own controls and between-patient variation being
eliminated.85 This should help to minimise patient accrual problems.
Second, each patient should experience both settings for an adequate period to enable a more accurate
estimate of preference.
Crossover trials have some disadvantages in this area of research: patients must have relatively stable
disease states; and dealing with dropouts can be more problematic than with parallel designs. Lack of
disease stability was an issue for some of the crossover trials in this review.29,31,34
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The many methodological issues identified in this review suggest that, whichever design is chosen for
future studies, a feasibility study should first be performed (with feasibility outcomes); any resulting larger
study should begin with a pilot phase.
The issues identified in this review which led to these recommendations for future research highlight the
importance of using systematic reviews to inform the design of new studies.86
Another recommendation for further research would be studies of within-setting comparisons; these are
absent from the evidence base and it is unclear how a new outpatient facility affects quality of life unless
it can be compared with an old facility. Similarly, no studies exist which compare different types of
community setting (e.g. community bus vs. GP facility).
Outcome measures
Many studies in this review used validated tools; such tools are often preferred because non-validated
scales may produce larger and less reliable effects. Existing validated tools tend to comprise a core set of
questions (20 to 30 items) and a number of cancer-specific add-on modules such as the EORTC QLQ-C30,
FLIC and Functional Assessment of Cancer Therapy.87–89 These measures tend to focus heavily on physical
functioning, particularly in the case of the EORTC QLQ-C30 and the FLIC, and so may not be responsive to
the kind of issues highlighted in the qualitative synthesis (e.g. available time and energy, control over
impact of the disease on daily life). Quality-of-life measures sensitive to these issues are needed to ensure
that future trials are equipped to detect significant differences where these exist. It may be important to
differentiate between patients receiving palliative versus curative treatment; some existing tools offer
separate modules to accommodate this. Part of the challenge is that many of these outcome measures
were developed to capture the burden of disease and not the burden of treatment.
As an alternative to developing new outcome measures, researchers may find it helpful to consider
patient-generated outcome measures. Specifically, Measure Your own Concerns And Wellbeing was
developed from the Measure Your Medical Outcome Profile tool for use in cancer treatment centres that
provided integrative treatment.90,91 Validation is ongoing. The innovative use of a patient-generated
format, Likert scales and questions about concerns or problems rather than symptoms may make this tool
a useful addition to future trials. MYMOP itself has previously been compared with the Short Form
questionnaire-36 items, Medical Outcomes Study – 6-item sale, Dartmouth COOP Functional Health
Assessment charts and the EQ-5D, and was shown to be both reliable and more sensitive to small changes
than the other outcome measures.91–93
Similar problems face the assessment of quality of life in paediatric populations; however, a well-validated
and relatively sensitive tool is available for use by researchers and was used by one study in this review.
The Paediatric Quality of Life (PedsQL) scale is a rigorously developed package of quality-of-life outcome
measures that includes the generic core scales (parent and child forms),94 a family impact module,95 and
several condition-specific add-on modules (including cancer).96 There has been some work to develop a
paediatric-oriented version of the EQ-5D, although this is expected to be less sensitive.97
Implications for practice
Considering the difficulties we have identified and reported in assessing the evidence base and developing
a decision model, commissioners should consider the issues we have described, alongside more bespoke
guidance and support. For example, the C-PORT Chemotherapy Capacity Planning Tool is a web-based
tool (owned and operated by the NHS: www.cport.co.uk/Home.aspx?ReturnUrl=%2fdefault.aspx) that
simulates the activity of an adult chemotherapy day case service. Within its many functions it provides
users with a visual picture of how their particular service operates in terms of capacity and demand,
resource utilisation and patient delays, and enables users to model the effects of potential change
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(to help to avoid bottlenecks) and plan for the introduction of new services. Our survey suggests that some
organisations use settings other than outpatient for the delivery of treatment and that the mechanisms for
delivering treatment in those different settings are variable.
It is not clear what the drivers are that determine the settings that organisations elect to offer. However,
these drivers are likely to be a key influence in the way in which services are delivered. Capacity is clearly
an issue across the NHS. Dealing with capacity through service reconfiguration is a local issue, dependent
on local needs and current service configuration. Patient choice may be a driver in some areas, but it is
unclear from the evidence we identified where choice fits into service configuration. In some situations,
patients will have choices regarding setting; in others, choice will be dictated by which service is available.
It is likely that service configuration is driven by capacity in areas such as outpatient clinics and pharmacy.
Patient choice may then be made available, if feasible, within the service configuration. Other factors, such
as VAT exemption on drugs prepared and delivered outside the hospital setting, loss of outpatient tariffs
should a service be moved to the home/community and the increasing number of oral treatments, will all
impact on local service configuration but are difficult to unpick at a national level.
Research and practice summary points
l Recruitment biases, and problems of recruiting enough willing participants, are unlikely to be overcome
in future randomised studies which use conventional study designs. However, randomised crossover
trials which are nested within much larger groups of patients (who can choose their preferred setting)
are likely to provide results which are relevant to patients seen in clinical practice. Such studies would
also help to inform decisions on future service provision.
l Any future studies should begin with feasibility and pilot phases, and aim to use patient questionnaires
to record qualitative data. Care should be taken to ensure that the tools used to record other study
data are sensitive enough to detect changes in outcome measures which are important to patients.
l Capacity and patient waiting times are among the key issues to consider when evaluating
service configuration.
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Appendix 1 Search strategies
MEDLINE and MEDLINE In-Process & Other
Non-Indexed Citations
URL: http://ovidsp.ovid.com
Date range: 1946 to week 2 March 2013.
Date searched: 25 March 2013.
Records found: 1564.
Update
Date range: 1946 to week 3 October 2013.
Date searched: 29 October 2013.
Records found: 1748.
Search strategy
Cancer terms 1. exp neoplasms/ (2,406,640)
2. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or
carcinoma$).ti,ab. (2,073,583)
3. oncologic nursing/ (6088)
4. or/1-3 (2,889,785)
Chemotherapy terms 1. drug therapy/ (33,151)
2. Antineoplastic Combined Chemotherapy Protocols/ (97,247)
3. chemotherapy, adjuvant/ or consolidation chemotherapy/ or maintenance
chemotherapy/ (27,648)
4. administration, intravenous/ or infusions, intravenous/ (46,068)
5. chemotherapy.ti,ab. (223,465)
6. systemic therapy.ti,ab. (5856)
7. intravenous drug therapy.ti,ab. (39)
8. adjuvant therapy.ti,ab. (14,653)
9. or/5-12 (357,679)
Home care terms 1. home care services/ or home care services, hospital-based/ (28,037)
2. *Outpatients/ (2136)
3. *Ambulatory Care/ (14,592)
4. *ambulatory care facilities/ or *outpatient clinics, hospital/ (13,416)
5. community health services/ or community health nursing/ or community health
centers/ (47,800)
6. general practitioners/ or physicians, family/ or physicians, primary care/ (16,406)
7. general practice/ or family practice/ (61,185)
8. ((service$ or therapy or treatment$) adj6 (home or community or outreach or
out-reach or ambulatory or domicil$)).ti,ab. (42,475)
9. (hospital at home or hospital in the home or own home$ or home care or homecare
or closer to home).ti,ab. (15,680)
10. or/14-22 (207,550)
Cancer+ chemo+ home care 1. 4 and 13 and 23 (1144)
DOI: 10.3310/hsdr03140 HEALTH SERVICES AND DELIVERY RESEARCH 2015 VOL. 3 NO. 14
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Corbett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
Home chemo terms 1. home infusion therapy/ (579)
2. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or
domicil$)).ti,ab. (719)
3. (chemotherapy adj6 service$).ti,ab. (184)
4. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or
family physician$ or primary care physician$)).ti,ab. (19)
5. (self-infusion adj6 home).ti,ab. (21)
6. home infusion.ti,ab. (254)
7. or/25-30 (1591)
Cancer+ home chemo 1. 4 and 31 (751)
Set 24 OR Set 31 1. 24 or 32 (1595)
Exclude animal-only studies
Final results set
1. exp animals/ not humans/ (3,782,734)
2. 33 not 34 (1564)
Key:
/= indexing term (MeSH heading)
exp= exploded MeSH heading
*=major MeSH heading
$= truncation
.ti,ab.= terms in either title or abstract fields
Adj6= terms within six words of each other (any order).
Other strategies
Allied and Complementary Medicine Database
URL: http://ovidsp.ovid.com
Date range: 1985 to March 2013.
Date searched: 25 March 2013.
Records found: 44.
Search strategy
1. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,ab. (13,694)
2. chemotherapy.ti,ab. (1083)
3. systemic therapy.ti,ab. (30)
4. intravenous drug therapy.ti,ab. (0)
5. adjuvant therapy.ti,ab. (76)
6. or/2-5 (1167)
7. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory
or domicil$)).ti,ab. (2940)
8. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to
home).ti,ab. (1167)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
9. 7 or 8 (3782)
10. 1 and 6 and 9 (26)
11. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,
ab. (21)
12. (chemotherapy adj6 service$).ti,ab. (8)
13. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician$
or primary care physician$)).ti,ab. (1)
14. (self-infusion adj6 home).ti,ab. (0)
15. home infusion.ti,ab. (8)
16. or/11-15 (34)
17. 1 and 16 (31)
18. 10 or 17 (44)
Key:
$= truncation
.ti,ab.= terms in either title or abstract fields
adj6= terms within six words of each other (any order).
British Nursing Index
URL: http://proquest.com
Date range: 1994 to March 2013.
Date searched: 25 March 2013.
Records found: 65.
Search strategy
S1 TI,AB(cancer* or neoplas* or tumor* or tumour* or malignan* or oncolog* or carcinoma*) 12003
S2 TI,AB(chemotherapy) (1121)
S3 TI,AB(“systemic therapy”) (15)
S4 TI,AB(“intravenous drug therapy”) (6)
S5 TI,AB(“adjuvant therapy”) (39)
S6 S2 or s3 or s4 or s5 (1167)
S7 TI,AB((service* or therapy or treatment*) NEAR/6 (home or community or outreach or “out-reach” or
ambulatory or domicil*)) (2719)
S8 TI,AB(“hospital at home” or “hospital in the home” or “own home*” or “home care” or homecare or
“closer to home”) (1084)
S9 S7 or s8 (3566)
S10 s1 and s6 and s9 (22)
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S11 TI,AB(chemotherapy NEAR/6 (home or community or outreach or “out-reach” or ambulatory or
domicil*)) (56)
S12 TI,AB(chemotherapy NEAR/6 service*) (37)
S13 TI,AB(chemotherapy NEAR/6 (“general practitioner*” or “family practitioner*” or “family doctor*” or
“primary care physician*”)) (0)
S14 TI,AB(“self-infusion” NEAR/6 home) (0)
S15 TI,AB(“home infusion”) (2)
S16 s11 or s12 or s13 or s14 or s15 (82)
S17 s1 and s16 (61)
S18 s10 or s17 (65)
Key:
TI,AB= terms in either title or abstract fields
*= truncation
NEAR/6= terms within six words of each other (any order)
“ ”= phrase search.
Cumulative Index to Nursing and Allied Health Literature
URL: http://health.ebsco.com
Date range: 1982 to March 2013.
Date searched: 25 March 2013.
Records found: 884.
Update
Date range searched: 1982 to March 2013.
Date searched: 29 October 2013.
Records found: 1069.
Search strategy
S1 (MH “Neoplasms+”) (162,398)
S2 cancer* or neoplas* or tumor* or tumour* or malignan* or oncolog* or carcinoma* (201,467)
S3 (MH “Oncologic Nursing”) OR (MH “Pediatric Oncology Nursing”) (10,675)
S4 S1 OR S2 OR S3 (216,493)
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S5 (MH “Chemotherapy, Adjuvant”) OR (MH “Chemotherapy, Cancer”) (11,453)
S6 (MH “Administration, Intravenous”) OR (MH “Infusions, Intravenous”) (6862)
S7 chemotherapy (21,389)
S8 “systemic therapy” (967)
S9 “intravenous drug therapy” (45)
S10 “adjuvant therapy” (1311)
S11 S5 OR S6 OR S7 OR S8 OR S9 OR S10 (29,231)
S12 (MH “Home Health Care”) (13,640)
S13 (MH “Home Nursing, Professional”) (6375)
S14 (MH “Community Health Nursing”) OR (MH “Community Health Services”) OR (MH “Community
Health Centers”) (29,922)
S15 (MH “Outpatients”) (28,597)
S16 (MH “Ambulatory Care”) (5611)
S17 (MH “Ambulatory Care Facilities”) OR (MH “Ambulatory Care Nursing”) (3924)
S18 (MH “Family Practice”) (9893)
S19 (MH “Physicians, Family”) (7696)
S20 (service* or therapy or treatment*) N6 (home or community or outreach or “out-reach” or
ambulatory or domicil*) (32,720)
S21 “hospital at home” or “hospital in the home” or “own home*” or “home care” or homecare or
“closer to home” (14,801)
S22 S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 (120,856)
S23 S4 AND S11 AND S22 (745)
S24 (MH “Home Intravenous Therapy”) (1197)
S25 chemotherapy N6 (home or community or outreach or “out-reach” or ambulatory
or domicil*) (214)
S26 chemotherapy N6 service* (77)
S27 chemotherapy N6 (“general practitioner*” or “family practitioner*” or “family doctor*” or “primary
care physician*”) (4)
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S28 “self-infusion” N6 home (3)
S29 “home infusion” (263)
S30 S24 OR S25 OR S26 OR S27 OR S28 OR S29 (1476)
S31 S4 and S30 (320)
S32 S23 OR S31 (884)
Key:
MH= indexing term (MeSH heading)
*= truncation
“ ”= phrase search
N6= terms within six words of each other (any order)
ClinicalTrials.gov
URL: www.clinicaltrials.gov
Date searched: 27 March 2013.
Relevant records found: 0.
Search strategy
chemotherapy AND home 154 - none relevant
“ambulatory chemotherapy” (0)
“chemotherapy in the community” (0)
“domiciliary chemotherapy” (0)
“home intravenous therapy” (0)
“self-infusion at home” (0)
“home infusion” 5 - none relevant (0)
“outreach chemotherapy” (0)
“out-reach chemotherapy” (0)
chemotherapy AND “general practice” (9) - none relevant
chemotherapy AND “primary care” (76) - none relevant
Key:
“ ”= phrase search.
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The Cochrane Library
URL: http://onlinelibrary.wiley.com
Date searched: 25 March 2013.
Cochrane Database of Systematic Reviews, Issue 2 of 12, February 2013.
Records found: 2.
Update
Date searched: 29 October 2013.
Cochrane Database of Systematic Reviews, Issue 10 of 12, October 2013.
Records found: 3.
Search strategy
#1 MeSH descriptor: [Neoplasms] explode all trees
#2 cancer* or neoplas* or tumor* or tumour* or malignan* or oncolog* or carcinoma*:ti,ab,kw
(Word variations have been searched)
#3 MeSH descriptor: [Oncologic Nursing] this term only
#4 #1 or #2 or #3
#5 MeSH descriptor: [Drug Therapy] this term only
#6 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] this term only
#7 MeSH descriptor: [Chemotherapy, Adjuvant] this term only
#8 MeSH descriptor: [Consolidation Chemotherapy] this term only
#9 MeSH descriptor: [Maintenance Chemotherapy] this term only
#10 MeSH descriptor: [Administration, Intravenous] this term only
#11 MeSH descriptor: [Infusions, Intravenous] this term only
#12 chemotherapy or “systemic therapy” or “intravenous drug therapy” or “adjuvant therapy”:ti,ab,kw
(Word variations have been searched)
#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Home Care Services] this term only
#15 MeSH descriptor: [Home Care Services, Hospital-Based] this term only
#16 MeSH descriptor: [Outpatients] this term only
#17 MeSH descriptor: [Ambulatory Care] this term only
#18 MeSH descriptor: [Ambulatory Care Facilities] this term only
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#19 MeSH descriptor: [Outpatient Clinics, Hospital] this term only
#20 MeSH descriptor: [Community Health Services] this term only
#21 MeSH descriptor: [Community Health Nursing] this term only
#22 MeSH descriptor: [Community Health Centers] this term only
#23 MeSH descriptor: [General Practitioners] this term only
#24 MeSH descriptor: [Physicians, Family] this term only
#25 MeSH descriptor: [Physicians, Primary Care] this term only
#26 MeSH descriptor: [General Practice] this term only
#27 MeSH descriptor: [Family Practice] this term only
#28 service* near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*):ti,ab,kw
(Word variations have been searched)
#29 therapy near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*):ti,ab,kw
(Word variations have been searched)
#30 treatment* near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*):ti,ab,
kw (Word variations have been searched)
#31 “hospital at home” or “hospital in the home” or “own home*” or “home care” or homecare or
“closer to home”:ti,ab,kw (Word variations have been searched)
#32 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28 or #29 or #30 or #31
#33 #4 and #13 and #32
#34 MeSH descriptor: [Home Infusion Therapy] this term only
#35 chemotherapy near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*):ti,
ab,kw (Word variations have been searched)
#36 chemotherapy near/6 service*:ti,ab,kw (Word variations have been searched)
#37 chemotherapy near/6 (“general practitioner*” or “family practitioner*” or “family doctor*” or
“family physician*” or “primary care physician*”):ti,ab,kw (Word variations have been searched)
#38 “self-infusion” near/6 home:ti,ab,kw (Word variations have been searched)
#39 “home infusion”:ti,ab,kw (Word variations have been searched)
#40 #34 or #35 or #36 or #37 or #38 or #39
#41 #4 and #40
#42 #33 or #41
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Key:
MeSH descriptor= indexing term (MeSH heading)
*= truncation
“ “= phrase search
:ti,ab,kw= terms in title, abstract or keyword fields
near/6= terms within six words of each other (any order).
The Cochrane Library
Date searched: 25 March 2013.
l Database of Abstracts of Reviews of Effects: Issue 1 of 4, January 2013.
¢ Records found: 9.
l Health Technology Assessment Database: Issue 1 of 4, January 2013.
¢ Records found: 2.
l NHS Economic Evaluation Database: Issue 1 of 4, January 2013.
¢ Records found: 67.
l Cochrane Central Register of Controlled Trials: Issue 2 of 12, February 2013.
¢ Records found: 161.
l Cochrane Methodology Register: Issue 3 of 4, July 2012.
¢ Records found: 9.
Update
Date searched: 29 October 2013.
l Database of Abstracts of Reviews of Effects: Issue 3 of 4, July 2013.
¢ Records found: 9.
l Health Technology Assessment Database: Issue 3 of 4, July 2013.
¢ Records found: 2.
l NHS Economic Evaluation Database: Issue 3 of 4, July 2013.
¢ Records found: 67.
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l Cochrane Central Register of Controlled Trials: Issue 9 of 12, September 2013.
¢ Records found: 161.
l Cochrane Methodology Register: Issue 3 of 4, July 2012.
¢ Records found: 9.
Search strategy
#1 MeSH descriptor: [Neoplasms] explode all trees
#2 cancer* or neoplas* or tumor* or tumour* or malignan* or oncolog* or carcinoma* (Word variations
have been searched)
#3 MeSH descriptor: [Oncologic Nursing] this term only
#4 #1 or #2 or #3
#5 MeSH descriptor: [Drug Therapy] this term only
#6 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] this term only
#7 MeSH descriptor: [Chemotherapy, Adjuvant] this term only
#8 MeSH descriptor: [Consolidation Chemotherapy] this term only
#9 MeSH descriptor: [Maintenance Chemotherapy] this term only
#10 MeSH descriptor: [Administration, Intravenous] this term only
#11 MeSH descriptor: [Infusions, Intravenous] this term only
#12 chemotherapy or “systemic therapy” or “intravenous drug therapy” or “adjuvant therapy”
(Word variations have been searched)
#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Home Care Services] this term only
#15 MeSH descriptor: [Home Care Services, Hospital-Based] this term only
#16 MeSH descriptor: [Outpatients] this term only
#17 MeSH descriptor: [Ambulatory Care] this term only
#18 MeSH descriptor: [Ambulatory Care Facilities] this term only
#19 MeSH descriptor: [Outpatient Clinics, Hospital] this term only
#20 MeSH descriptor: [Community Health Services] this term only
#21 MeSH descriptor: [Community Health Nursing] this term only
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
#22 MeSH descriptor: [Community Health Centers] this term only
#23 MeSH descriptor: [General Practitioners] this term only
#24 MeSH descriptor: [Physicians, Family] this term only
#25 MeSH descriptor: [Physicians, Primary Care] this term only
#26 MeSH descriptor: [General Practice] this term only
#27 MeSH descriptor: [Family Practice] this term only
#28 service* near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*)
(Word variations have been searched)
#29 therapy near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*)
(Word variations have been searched)
#30 treatment* near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*)
(Word variations have been searched)
#31 “hospital at home” or “hospital in the home” or “own home*” or “home care” or homecare or
“closer to home” (Word variations have been searched)
#32 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28 or #29 or #30 or #31
#33 #4 and #13 and #32
#34 MeSH descriptor: [Home Infusion Therapy] this term only
#35 chemotherapy near/6 (home or community or outreach or “out-reach” or ambulatory or domicil*)
(Word variations have been searched)
#36 chemotherapy near/6 service* (Word variations have been searched)
#37 chemotherapy near/6 (“general practitioner*” or “family practitioner*” or “family doctor*” or
“family physician*” or “primary care physician*”) (Word variations have been searched)
#38 “self-infusion” near/6 home (Word variations have been searched)
#39 “home infusion” (Word variations have been searched)
#40 #34 or #35 or #36 or #37 or #38 or #39
#41 #4 and #40
#42 #33 or #41
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Key:
MeSH descriptor= indexing term (MeSH heading)
*= truncation
“ ”= phrase search
near/6= terms within six words of each other (any order).
Conference Proceedings Citation Index – Science (Web of Knowledge)
URL: http://wokinfo.com
Date range: 1990 to March 2013.
Date searched: 25 March 2013.
Records found: 135.
Update
Date range: 1990 to October 2013.
Date searched: 29 October 2013.
Records found: 141.
Search strategy
# 1 266,359 Topic=(cancer* or neoplas* or tumor* or tumour* or malignan* or oncolog* or carcinoma*)
# 2 27,630 Topic=(chemotherapy)
# 3 625 Topic=(“systemic therapy”)
# 4 3 Topic=(“intravenous drug therapy”)
# 5 1960 Topic=(“adjuvant therapy”)
# 6 29,227 #5 OR #4 OR #3 OR #2
# 7 5659 Topic=((service* or therapy or treatment*) NEAR/6 (home or community or outreach or out-
reach or ambulatory or domicil*))
# 8 1213 Topic=(“hospital at home” or “hospital in the home” or “own home*” or “home care” or
homecare or “closer to home”)
# 9 6636 #8 OR #7
# 10 61 #9 AND #6 AND #1
# 11 119 Topic=(chemotherapy NEAR/6 (home or community or outreach or “out-reach” or ambulatory
or domicil*))
# 12 13 Topic=(chemotherapy NEAR/6 service*)
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# 13 2 Topic=(chemotherapy NEAR/6 (“general practitioner” or “family practitioner*” or “family doctor*”
or “family physician*” or “primary care physician*”))
# 14 2 Topic=(“self-infusion” NEAR/6 home)
# 15 11 Topic=(“home infusion”)
# 16 146 #15 OR #14 OR #13 OR #12 OR #11
# 17 91 #16 AND #1
# 18 135 #17 OR #10
Key:
TS= topic tag; searches terms in Title, Abstract, Author Keywords and Keywords Plus fields
*= truncation
“ ”= phrase search
NEAR/6= terms within six words of each other (any order).
Current Controlled Trials
URL: http://controlled-trials.com/mrct/search.html
Date searched: 27 March 2013.
Relevant records found: 0.
Search strategy
chemotherapy AND home 254 - none relevant
‘ambulatory chemotherapy’ 0
‘chemotherapy in the community’ 1 - none relevant
‘domiciliary chemotherapy’ 0
‘home intravenous therapy’ 0
‘self-infusion at home’ 0
‘home infusion’ 6 - none relevant
‘outreach chemotherapy’ 0
‘out-reach chemotherapy’ 0
chemotherapy AND ‘general practice’ 6 - none relevant
chemotherapy AND ‘primary care’ 66 - none relevant
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Key:
‘ ’= phrase search
Dissertation Abstracts
URL: www.dialog.com
Date range: 1861 to March 2013.
Date searched: 27 March 2013.
Records found: 24.
Search strategy
S1 47073 (CANCER? OR NEOPLAS? OR TUMOR OR TUMORS OR TUMOUR OR TUMOURS OR
MALIGNANT OR MALIGNANCY OR ONCOLOGY OR CARCINOMA?)
S2 3395 CHEMOTHERAPY
S3 54 SYSTEMIC(W)THERAPY
S4 2 INTRAVENOUS(W)DRUG(W)THERAPY
S5 119 ADJUVANT(W)THERAPY
S6 3523 S2 OR S3 OR S4 OR S5
S7 9903 (SERVICE? OR THERAPY OR TREATMENT?)(6N)(HOME OR COMMUNITY - OR OUTREACH OR
OUT(W)REACH OR AMBULATORY OR DOMICIL?)
S8 1689 HOSPITAL(W)AT(W)HOME OR HOSPITAL(W)IN(W)THE(W)HOME OR OWN(- W)HOME? OR HOME
(W)CARE OR HOMECARE OR CLOSER(W)TO(W)HOME
S9 11189 S7 OR S8
S10 11 S1 AND S6 AND S9
S11 18 CHEMOTHERAPY(6N)(HOME OR COMMUNITY OR OUTREACH OR OUT(W)REACH OR
AMBULATORY OR DOMICIL?)
S12 3 CHEMOTHERAPY(6N)SERVICE?
S13 0 CHEMOTHERAPY(6N)(GENERAL(W)PRACTITIONER? OR FAMILY(W)PRACTITIONER? OR FAMILY(W)
DOCTOR? OR PRIMARY(W)CARE(W)PHYSICIAN?)
S14 0 SELF(W)INFUSION(6N)HOME
S15 6 HOME(W)INFUSION
S16 27 S11 OR S12 OR S13 OR S14 OR S15
S17 16 S1 AND S16
S18 24 S10 OR S17
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Key:
?= truncation
(W)= terms adjacent to each other (same order)
(6N)= terms within 6 words of each other (any order).
EconLit
URL: http://ovidsp.ovid.com
Date range: 1961 to February 2013.
Date searched: 25 March 2013.
Records found: 1.
Search strategy
1. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,ab. (1014)
2. chemotherapy.ti,ab. (50)
3. systemic therapy.ti,ab. (3)
4. intravenous drug therapy.ti,ab. (0)
5. adjuvant therapy.ti,ab. (2)
6. or/2-5 (54)
7. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory
or domicil$)).ti,ab. (893)
8. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to
home).ti,ab. (345)
9. 7 or 8 (1175)
10. 1 and 6 and 9 (1)
11. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,ab. (1)
12. (chemotherapy adj6 service$).ti,ab. (0)
13. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician$
or primary care physician$)).ti,ab. (0)
14. (self-infusion adj6 home).ti,ab. (0)
15. home infusion.ti,ab. (1)
16. or/11-15 (2)
17. 1 and 16 (1)
18. 10 or 17 (1)
Key:
$= truncation
.ti,ab.= terms in either title or abstract fields
adj6= terms within six words of each other (any order).
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EMBASE
URL: http://ovidsp.ovid.com
Date range: 1974 to 22 March 2013.
Date searched: 25 March 2013.
Records found: 2719.
Update
Date range: 1974 to 28 October 2013.
Date searched: 29 October 2013.
Records found: 2940.
Search strategy
1. exp neoplasm/ (3,205,629)
2. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,
ab. (2,642,872)
3. exp oncology nursing/ (5654)
4. or/1-3 (3,707,658)
5. chemotherapy/ or adjuvant chemotherapy/ or cancer chemotherapy/ or combination chemotherapy/ or
consolidation chemotherapy/ or induction chemotherapy/ or maintenance chemotherapy/ or
multimodal chemotherapy/ (252,289)
6. antineoplastic agent/ (211,787)
7. chemotherapy.ti,ab. (314,754)
8. systemic therapy.ti,ab. (8828)
9. intravenous drug therapy.ti,ab. (53)
10. adjuvant therapy.ti,ab. (20,039)
11. or/5-10 (580,292)
12. home care/ (45,243)
13. *outpatient/ (6050)
14. *ambulatory care/ or *ambulatory care nursing/ (11,954)
15. *outpatient department/ (11,572)
16. community care/ or community health nursing/ (68,672)
17. general practitioner/ or general practice/ (115,882)
18. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory
or domicil$)).ti,ab. (54,756)
19. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to
home).ti,ab. (18,147)
20. or/12-19 (289,243)
21. 4 and 11 and 20 (2138)
22. home intravenous therapy/ (17)
23. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,
ab. (1000)
24. (chemotherapy adj6 service$).ti,ab. (254)
25. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician$
or primary care physician$)).ti,ab. (28)
26. (self-infusion adj6 home).ti,ab. (27)
27. home infusion.ti,ab. (350)
28. or/22-27 (1624)
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29. 4 and 28 (954)
30. 21 or 29 (2733)
31. animals/ or nonhumans/ (1,821,160)
32. humans/ (14178823)
33. 31 not (31 and 32) (1,363,257)
34. 30 not 33 (2719)
Key:
/= indexing term (EMTREE heading)
*= focussed EMTREE heading
exp= exploded EMTREE heading
$= truncation
.ti,ab.= terms in either title or abstract fields
adj6= terms within six words of each other (any order).
Google
URL: www.google.com
Date searched: 10 September 2013.
Additional records found: 16.
Checked first 100 hits for all search strings for relevancy.
Search strategy
(“home infusion therapy” AND chemotherapy AND (cancer OR neoplasms)) filetype:pdf= 21,000 hits
(“home chemotherapy” AND (cancer OR neoplasms)) filetype:pdf= 1160 hits
(“chemotherapy at home” AND (cancer OR neoplasms)) filetype:pdf= 4360 hits
(“outreach chemotherapy” AND (cancer OR neoplasms)) filetype:pdf= 177 hits
(“ambulatory chemotherapy” AND (cancer OR neoplasms)) filetype:pdf= 1190 hits
(“hospital at home” AND chemotherapy AND (cancer OR neoplasms)) filetype:pdf= 27,000 hits
(“closer to home” AND chemotherapy AND (cancer OR neoplasms)) filetype:pdf= 22,800 hits
Health Management Information Consortium
URL: http://ovidsp.ovid.com
Date range: 1979 to January 2013.
Date searched: 25 March 2013.
Records found: 44.
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Search strategy
1. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,ab. (12,171)
2. chemotherapy.ti,ab. (542)
3. systemic therapy.ti,ab. (9)
4. intravenous drug therapy.ti,ab. (1)
5. adjuvant therapy.ti,ab. (35)
6. or/2-5 (579)
7. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory
or domicil$)).ti,ab. (9283)
8. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to
home).ti,ab. (2469)
9. 7 or 8 (10,981)
10. 1 and 6 and 9 (24)
11. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,
ab. (30)
12. (chemotherapy adj6 service$).ti,ab. (37)
13. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician
$ or primary care physician$)).ti,ab. (0)
14. (self-infusion adj6 home).ti,ab. (0)
15. home infusion.ti,ab. (0)
16. or/11-15 (55)
17. 1 and 16 (35)
18. 10 or 17 (44)
Key:
$= truncation
.ti,ab.= terms in either title or abstract fields
adj6= terms within six words of each other (any order).
Inside Conferences
URL: www.dialog.com
Date range: 1993 to March 2013.
Date searched: 27 March 2013.
Records found: 25.
Search strategy
S1 113738 (CANCER? OR NEOPLAS? OR TUMOR OR TUMORS OR TUMOUR OR TUMOURS OR
MALIGNANT OR MALIGNANCY OR ONCOLOGY OR CARCINOMA?)
S2 10350 CHEMOTHERAPY
S3 97 SYSTEMIC(W)THERAPY
S4 0 INTRAVENOUS(W)DRUG(W)THERAPY
S5 408 ADJUVANT(W)THERAPY
S6 10815 S2 OR S3 OR S4 OR S5
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S7 2387 (SERVICE? OR THERAPY OR TREATMENT?)(6N)(HOME OR COMMUNITY - OR OUTREACH OR
OUT(W)REACH OR AMBULATORY OR DOMICIL?)
S8 656 HOSPITAL(W)AT(W)HOME OR HOSPITAL(W)IN(W)THE(W)HOME OR OWN(- W)HOME? OR HOME
(W)CARE OR HOMECARE OR CLOSER(W)TO(W)HOME
S9 2938 S7 OR S8
S10 12 S1 AND S6 AND S9
S11 24 CHEMOTHERAPY(6N)(HOME OR COMMUNITY OR OUTREACH OR OUT(W)REACH OR
AMBULATORY OR DOMICIL?)
S12 3 CHEMOTHERAPY(6N)SERVICE?
S13 0 CHEMOTHERAPY(6N)(GENERAL(W)PRACTITIONER? OR FAMILY(W)PRACTITIONER? OR FAMILY(W)
DOCTOR? OR PRIMARY(W)CARE(W)PHYSICIAN?)
S14 2 SELF(W)INFUSION(6N)HOME
S15 12 HOME(W)INFUSION
S16 40 S11 OR S12 OR S13 OR S14 OR S15
S17 18 S1 AND S16
S18 25 S10 OR S17
Key:
?= truncation
(W)= terms adjacent to each other (same order)
(6N)= terms within 6 words of each other (any order).
Inspec
URL: http://ovidsp.ovid.com
Date range: 1969 to week 10 2013.
Date searched: 25 March 2013.
Records found: 4.
Search strategy
1. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,ab. (63,025)
2. chemotherapy.ti,ab. (2100)
3. systemic therapy.ti,ab. (40)
4. intravenous drug therapy.ti,ab. (0)
5. adjuvant therapy.ti,ab. (54)
6. or/2-5 (2176)
7. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory
or domicil$)).ti,ab. (5829)
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8. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to
home).ti,ab. (1339)
9. 7 or 8 (6986)
10. 1 and 6 and 9 (3)
11. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,ab. (4)
12. (chemotherapy adj6 service$).ti,ab. (2)
13. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician$
or primary care physician$)).ti,ab. (0)
14. (self-infusion adj6 home).ti,ab. (0)
15. home infusion.ti,ab. (4)
16. or/11-15 (9)
17. 1 and 16 (3)
18. 10 or 17 (4)
Key:
$= truncation
.ti,ab.= terms in either title or abstract fields
adj6= terms within six words of each other (any order).
OHE HEED
URL: http://onlinelibrary.wiley.com/book/10.1002/9780470510933
Date searched: 14 May 2013.
Relevant records found: 29.
Search strategy
chemotherapy AND home 52 - 19 relevant
‘ambulatory chemotherapy’ 2
‘chemotherapy in the community’ 0
‘domiciliary chemotherapy’ 1
‘home intravenous therapy’ 3 - 2 relevant
‘self-infusion at home’ 0
‘home infusion’ 13 - 5 relevant
‘outreach chemotherapy’ 0
‘out-reach chemotherapy’ 0
chemotherapy AND ‘general practice’ 3 - 2 relevant
chemotherapy AND ‘primary care’ 12 - 1 relevant
Key:
‘ ’= phrase search.
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PsycINFO
URL: http://ovidsp.ovid.com
Date range: 1806 to week 3 2013.
Date searched: 25 March 2013.
Records found: 72.
Search strategy
1. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,ab. (46,619)
2. chemotherapy.ti,ab. (3347)
3. systemic therapy.ti,ab. (369)
4. intravenous drug therapy.ti,ab. (0)
5. adjuvant therapy.ti,ab. (246)
6. or/2-5 (3906)
7. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory
or domicil$)).ti,ab. (24,037)
8. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to
home).ti,ab. (4691)
9. 7 or 8 (27,793)
10. 1 and 6 and 9 (46)
11. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,
ab. (42)
12. (chemotherapy adj6 service$).ti,ab. (17)
13. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician$
or primary care physician$)).ti,ab. (2)
14. (self-infusion adj6 home).ti,ab. (1)
15. home infusion.ti,ab. (6)
16. or/11-15 (61)
17. 1 and 16 (44)
18. 10 or 17 (72)
Key:
$= truncation
.ti,ab.= terms in either title or abstract fields
adj6= terms within six words of each other (any order).
PubMed
URL: www.ncbi.nlm.nih.gov/pubmed
Date range: all dates to 27 March 2012.
Date searched: 27 March 2013.
Records found: 975.
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Update
Date range: all dates to 29 October 2012.
Date searched: 29 October 2013.
Records found: 1007.
Search strategy
#1 Search neoplasms[MeSH Terms] 2,415,714
#2 Search ((((((cancer*[Title/Abstract]) OR neoplas*[Title/Abstract]) OR tumor*[Title/Abstract]) OR tumour*
[Title/Abstract]) OR malignan*[Title/Abstract]) OR oncolog*[Title/Abstract]) OR carcinoma*[Title/
Abstract] 2,032,899
#3 Search oncologic nursing[mh:noexp] 6072
#4 Search ((#1) OR #2) OR #3 2,923,865
#5 Search drug therapy[mh:noexp] 33,188
#6 Search antineoplastic combined chemotherapy protocols[mh:noexp] 96,554
#7 Search ((chemotherapy, adjuvant[mh:noexp]) OR consolidation chemotherapy[mh:noexp]) OR
maintenance chemotherapy[mh:noexp] 27,399
#8 Search infusion, intravenous[mh:noexp] 45,706
#9 Search chemotherapy[Title/Abstract] 225,942
#10 Search “systemic therapy”[Title/Abstract] 5969
#11 Search “intravenous drug therapy”[Title/Abstract] 40
#12 Search “adjuvant therapy”[Title/Abstract] 14,837
#13 Search (((((((#5) OR #6) OR #7) OR #8) OR #9) OR #10) OR #11) OR #12 359,727
#14 Search (home care services[mh:noexp]) OR home care services, hospital based[mh:noexp] 27,991
#15 Search outpatients[majr:noexp] 2120
#16 Search ambulatory care[majr:noexp] 14,543
#17 Search (ambulatory care facilities[majr:noexp]) OR outpatient clinics, hospital[majr:noexp] 13,413
#18 Search ((community health services[mh:noexp]) OR community health nursing[mh:noexp]) OR
community health centers[mh:noexp] 47,623
#19 Search ((general practitioners[mh:noexp]) OR physicians, family[mh:noexp]) OR physicians, primary care
[mh:noexp] 16,302
#20 Search (general practice[mh:noexp]) OR family practice[mh:noexp] 60,996
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#21 Search (((((((((((((((((“home service*”[Title/Abstract]) OR “home therapy”[Title/Abstract]) OR “home
treatment*”[Title/Abstract]) OR “community service”[Title/Abstract]) OR “community therapy”[Title/
Abstract]) OR “community treatment”[Title/Abstract]) OR “outreach service*”[Title/Abstract]) OR “outreach
therapy”[Title/Abstract]) OR “outreach treatment*”[Title/Abstract]) OR “out-reach service*”[Title/Abstract])
OR “out-reach therapy”[Title/Abstract]) OR “out-reach treatment*”[Title/Abstract]) OR “ambulatory
service*”[Title/Abstract]) OR “ambulatory therapy”[Title/Abstract]) OR “ambulatory treatment*”[Title/
Abstract]) OR “domicil* service*”[Title/Abstract]) OR “domicil* therapy”[Title/Abstract]) OR “domicil*
treatment*”[Title/Abstract] 5808
#22 Search (((((“hospital at home”[Title/Abstract]) OR “hospital in the home”[Title/Abstract]) OR “own
home*”[Title/Abstract]) OR “home care”[Title/Abstract]) OR homecare[Title/Abstract]) OR “closer to
home”[Title/Abstract] 14,748
#23 Search ((((((((#14) OR #15) OR #16) OR #17) OR #18) OR #19) OR #20) OR #21) OR #22 180,529
#24 Search ((#4) AND #13) AND #23 845
#25 Search home infusion therapy[mh:noexp] 580
#26 Search (((((“home chemotherapy”[Title/Abstract]) OR “community chemotherapy”[Title/Abstract]) OR
“outreach chemotherapy”[Title/Abstract]) OR “out-reach chemotherapy”[Title/Abstract]) OR “ambulatory
chemotherapy”[Title/Abstract]) OR “domicil* chemotherapy”[Title/Abstract] 171
#27 Search “chemotherapy service*”[Title/Abstract] 11
#28 Search ((((“general practitioner chemotherapy”[Title/Abstract]) OR “family practitioner
chemotherapy”[Title/Abstract]) OR “family doctor chemotherapy”[Title/Abstract]) OR “family physician
chemotherapy”[Title/Abstract]) OR “primary care physician chemotherapy”[Title/Abstract] 0
#29 Search “self-infusion at home”[Title/Abstract] 0
#30 Search “home infusion”[Title/Abstract] 259
#31 Search (((((#25) OR #26) OR #27) OR #28) OR #29) OR #30 890
#32 Search (#4) AND #31 238
#33 Search (#24) OR #32 975
Key:
[MeSH Terms]= indexing term (MeSH heading)
[mh:noexp]= non-exploded MeSH heading
[Title/Abstract]= terms in either title or abstract fields
“ ”= phrase search
*= truncation.
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Social Policy and Practice
URL: http://ovidsp.ovid.com
Date range: all dates to January 2013.
Date searched: 25 March 2013.
Records found: 3.
Search strategy
1. (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or oncolog$ or carcinoma$).ti,ab. (1854)
2. chemotherapy.ti,ab. (42)
3. systemic therapy.ti,ab. (58)
4. intravenous drug therapy.ti,ab. (0)
5. adjuvant therapy.ti,ab. (0)
6. or/2-5 (100)
7. ((service$ or therapy or treatment$) adj6 (home or community or outreach or out-reach or ambulatory
or domicil$)).ti,ab. (10,540)
8. (hospital at home or hospital in the home or own home$ or home care or homecare or closer to
home).ti,ab. (4276)
9. 7 or 8 (13,575)
10. 1 and 6 and 9 (0)
11. (chemotherapy adj6 (home or community or outreach or out-reach or ambulatory or domicil$)).ti,ab. (2)
12. (chemotherapy adj6 service$).ti,ab. (3)
13. (chemotherapy adj6 (general practitioner$ or family practitioner$ or family doctor$ or family physician$
or primary care physician$)).ti,ab. (0)
14. (self-infusion adj6 home).ti,ab. (0)
15. home infusion.ti,ab. (0)
16. or/11-15 (4)
17. 1 and 16 (3)
18. 10 or 17 (3)
Key:
$= truncation
.ti,ab.= terms in either title or abstract fields
adj6= terms within six words of each other (any order).
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Appendix 2 Studies which investigated only
one setting
Home studies (single setting)
Alfieri P, Bertocchi M, Petocchi B, Torelli G, Favale E. Intravenous chemotherapy at home in hematology
patients: a report from the A.I.L. hematology home care service in Modena. Haematologica 2009;94:179.
Anderson H, Addington-Hall JM, Peake MD, McKendrick J, Keane K, Thatcher N. Domiciliary chemotherapy
with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a
feasibility study. Br J Cancer 2003;89:2190–6.
Bassot V, Brasnu D, Lacau-St-Guily J, Fabre A, Menard M, Jacquillat C, et al. [Chemotherapy at home.
A new methodology.] Ann Otolaryngol Chir Cervicofac 1986;103:77–81.
Brown DF, Muirhead MJ, Travis PM, Vire SR, Weller J, Hauer-Jensen M. Mode of chemotherapy does not
affect complications with an implantable venous access device. Cancer 1997;80:966–72.
Butler MC. Families’ responses to chemotherapy by an ambulatory infusion pump . . . at home. Nurs Clin
North Am 1984;19:139–44.
Chen JT, Ida K, Hasumi K, Masubuchi K. [Maintenance of housewife activity and the quality of familiar
interactions by home continuous infusion chemotherapy in patients with recurrent gynecological cancer.]
Gan To Kagaku Ryoho 1991;18:2517–22.
Close P, Burkey E, Kazak A, Danz P, Lange B. A prospective, controlled evaluation of home chemotherapy
for children with cancer. Pediatrics 1995;95:896–900.
Crisp N. Chemotherapy at home: keeping patients in their ‘natural habitat’. Ph.D. thesis. Edmonton, AB:
University of Alberta; 2010.
D’Andrea B, Belliveau D, Birmingham J, Cooper D. High-dose chemotherapy followed by stem cell
transplant: the clinic/home care experience. J Care Manag 1997;3:46–52.
Dahan M, Paule B, Vordos D, Larre S, Salomon L, Yiou R, et al. [Home hospitalisation in urological cancer:
assessment of the first 5 years and a satisfaction survey.] Prog Urol 2007;17:855–9.
DeMoss CJ. Giving intravenous chemotherapy at home. Am J Nurs 1980;80:2188–9.
Frohmüller S, Schlag P, Leucht R, Ophof J, Ruoff G. [Oncologic therapy at home: a trial model.] Deutsche
Medizinische Wochenschrift 1989;114:1055–8.
Guillevic S, Comont T, Khalifa J, Recher C, Adoue D, Ollier S, et al. Home azacitidine administration in high
risk myelodysplastic syndromes: favorable results of a pilot study in 48 patients. Blood 2011;118:749.
Hansson H, Kjaergaard H, Johansen C, Hallström I, Christensen J, Madsen M, et al. Hospital-based home
care for children with cancer: feasibility and psychosocial impact on children and their families. Pediatr
Blood Cancer 2013;60:865–72.
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Harrison DE, Fitch MI. Toronto-Sunnybrook Regional Cancer Centre Home Oncology Model Evaluation
(H.O.M.E.) pilot program. Can Oncol Nurs J 1995;5:85–92.
Hooker L, Kohler J. Safety, efficacy, and acceptability of home intravenous therapy administered by parents
of pediatric oncology patients. Med Pediatr Oncol 1999;32:421–6.
Jayabose S, Escobedo V, Tugal O, Nahaczewski A, Donohue P, Fuentes V, et al. Home chemotherapy for
children with cancer. Cancer 1992;69:574–9.
Joo EH, Rha SY, Ahn JB, Kang HY. Economic and patient-reported outcomes of outpatient home-based
versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Support Care Cancer
2011;19:971–8.
Lange BJ, Burroughs B, Meadows AT, Burkey E. Home care involving methotrexate infusions for children
with acute lymphoblastic leukemia. J Pediatr 1988;112:492–5.
Lashlee M, O’Hanlon Curry J. Pediatric home chemotherapy: infusing ‘quality of life’. J Pediatr Oncol
Nurs 2007;24:294–8.
Lewden-Bernadac B, Courant-Menanteau M, Perrocheau G, Barbarot V, Thomare P. [Outpatient
chemotherapy and oncology network: Onco Pays-de-la-Loire experiment.] Bull Cancer 2008;95:543–9.
Liston B, Meenaghan T, Wilson H. Home chemotherapy service from University College Hospital Galway.
EJHP Pract 2009;15:45.
Lüthi F, Fucina N, Divorne N, Santos-Eggimann B, Currat-Zweifel C, Rollier P, et al. Home care – a safe
and attractive alternative to inpatient administration of intensive chemotherapies. Support Care Cancer
2012;20:575–81.
Midorikawa Y, Suzuki K, Kasuga T, Takemura A. [Our outpatient cases for home anti-cancer
chemotherapy.] Gan To Kagaku Ryoho 2005;32(Suppl. 1):1–3.
Oakley C, Wright E, Ream E. The experiences of patients and nurses with a nurse-led peripherally inserted
central venous catheter line service. Eur J Oncol Nurs 2000;4:207–18.
Ranuzzi M. Home-care in advanced breast cancer: results in 144 patients. Ann Oncol 2009;20:ii69.
Ranuzzi M, Taddei A, Brunetti S, Gentile S, Vercelloni R, Scarpati S. 10 years experience in home-care with
cancer patients. Support Care Cancer 2009;17:973.
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Appendix 4 Randomised controlled trial risk
of bias
Type of bias
Judgement (high,
low or unclear risk) Support for judgement
Borras et al. 200135
Random sequence
generation
Low Random numbers were selected in blocks of eight, stratified according
to type of tumour
Allocation
concealment
Unclear Does not report who performed the randomisation or any details of
concealment process
Similarity at baseline Low Groups very similar for gender, age, tumour site, toxicity, treatment
type or radiotherapy use
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High Patient-reported outcomes subjective (patients not blinded)
Low Adverse events/toxicity unlikely to be affected
Low Use of health-care resources (unplanned hospitalisation, or primary
care or emergency department visits) unlikely to be affected
Incomplete outcome
data
Unclear 6/42 (14%) outpatients and 1/45 (2%) home patient withdrew
voluntarily. This difference was statistically significant. However, no
details were provided
Selective reporting Low Could not locate trial protocol, although it appears from the paper that
all collected outcomes were reported (and in sufficient detail)
Other bias (crossover trials only): N/A
Chen and Hasuimi 199927
Random sequence
generation
Unclear ‘Random’
Allocation
concealment
Unclear Study reported as a brief conference abstract
Similarity at baseline Unclear Study reported as a brief conference abstract
Blinding of
participants and
researchers
Unclear Study reported as a brief conference abstract
Blinding of outcome
assessment
Unclear Study reported as a brief conference abstract
Incomplete outcome
data
Unclear Study reported as a brief conference abstract
Selective reporting High No actual data reported for quality-of-life (and related) outcomes
Other bias (crossover trials only):
Crossover a suitable design? N/A
Appropriate statistical analysis used (to allow for pairing)? N/A
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Type of bias
Judgement (high,
low or unclear risk) Support for judgement
Christiansen et al. 201128
Random sequence
generation
Unclear ‘Randomised’ only details given
Allocation
concealment
Unclear Not reported
Similarity at baseline Low Crossover trial: within participant comparisons
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High Patient-reported outcomes subjective (patients not blinded)
Incomplete outcome
data
Unclear 14 patients did not complete treatment, no further details reported
Selective reporting Unclear Protocol not available, and unclear from abstract whether or not other
outcomes were assessed
Other bias (crossover trials only):
Crossover a suitable design? Unclear – abstract only available
Appropriate statistical analysis used (to allow for pairing)? Unclear – abstract only available
Corrie et al. 20134
Random sequence
generation
Low Randomised by independent centre using minimisation
Allocation
concealment
Low Central allocation – participants were allocated a unique trial number
and the treatment setting defined. The randomisation outcome
information was provided to the investigator within 24 hours
Similarity at baseline Low Well balanced in terms of key characteristics due to use of
minimisation
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High
Low
Low
Patient-reported outcomes and service use data, for example family
care and travel time (patients not blinded)
Adverse events unlikely to be affected
Incomplete outcome
data
Low Data for 57 patients could be analysed at end of trial. Six patients
failed to start treatment, 17 patients did not complete 12 weeks of
treatment
Home: 33 allocated, 33 started, five stopped, five incomplete data sets
GP: 32 allocated, 29 started, eight stopped, four incomplete data sets
Hospital: 32 allocated, 29 started, four stopped, eight incomplete data
sets
Selective reporting Low Protocol available and checked
Other bias (crossover trials only): not relevant
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Type of bias
Judgement (high,
low or unclear risk) Support for judgement
Hall and Lloyd 200830
Random sequence
generation
Unclear ‘Randomly allocating’ patients
Allocation
concealment
Unclear No details reported
Similarity at baseline Unclear No details reported
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High Patient-reported outcomes subjective (patients not blinded)
Incomplete outcome
data
Unclear Appear to have full follow-up data (although not explicitly stated)
Selective reporting Unclear Could not locate trial protocol, appears from the paper that all
collected outcomes were reported
Other bias (crossover trials only): N/A
King et al. 200031
Random sequence
generation
Low Random number table, stratified by cancer type
Allocation
concealment
Unclear Mentions use of sealed envelopes but not whether they were opaque
or sequentially numbered
Similarity at baseline Low Crossover trial: within-participant comparisons
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High Patient-reported outcomes subjective (patients not blinded)
Incomplete outcome
data
Low Eight participants withdrew from receiving home treatment after
experiencing outpatient treatment. However, additional analyses were
conducted which assumed such patients preferred outpatient
treatment
Selective reporting Unclear Protocol not available
Other bias (crossover trials only):
Crossover a suitable design? Overall, yes, although seven patients dropped out because of disease progression (using only
the early breast cancer population may have been preferable)
Appropriate statistical analysis used (to allow for pairing)? Yes, used paired analyses and checked for period effects
(data from both periods were used), interactions and carryover effects
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Type of bias
Judgement (high,
low or unclear risk) Support for judgement
Pace et al. 200929
Random sequence
generation
Unclear ‘Telephone randomisation, in blocks of 10, to local Research Support
Unit’, but unclear exactly how sequence was generated
Allocation
concealment
Low Although this is assuming the blocks of 10 were used only by the local
research support unit and not by the investigators
Similarity at baseline Low Crossover trial: within-participant comparisons
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High Patient-reported outcomes subjective (patients not blinded)
Incomplete outcome
data
Unclear 43% attrition throughout the study due to disease progression and
cessation of chemotherapy, all outcomes reported for completing
patients. Attrition not reported by treatment location so difficult to
assess if differential loss of data
Selective reporting Low Could not locate trial protocol, but appears from the paper that all
collected outcomes were reported
Other bias (crossover trials only):
Crossover a suitable design? Probably not – too many patients withdrew due to disease progression and cessation
of chemotherapy
Appropriate statistical analysis used (to allow for pairing)? Unclear, although data from both time periods were used
Remonnay et al. 200234
Random sequence
generation
Unclear ‘Order of passage was selected at random’ only reported in English
paper
Allocation
concealment
Unclear Not reported
Similarity at baseline Low Crossover trial: within-participant comparisons
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
Unclear Not reported
Incomplete outcome
data
Unclear No numerical data (only a percentage) reported for preference data
Selective reporting High No protocol available; only economic data reported although quality of
life also measured
Other bias (crossover trials only):
Crossover a suitable design? No – six patients died and four reported deterioration requiring change of treatment
(total n= 52)
Appropriate statistical analysis used (to allow for pairing)? Details not reported
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Type of bias
Judgement (high,
low or unclear risk) Support for judgement
Rischin et al. 200032
Random sequence
generation
Low Computer-generated randomisation chart using an allocation scheme
based on a biased coin design
Allocation
concealment
Unclear Not described, mention of a chart suggests may not have been
concealed
Similarity at baseline Low Crossover trial: within-participant comparisons
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High
Low
Patient-reported outcomes subjective (patients not blinded)
Serious adverse events unlikely to be affected
Incomplete outcome
data
Low Three withdrawals in hospital first arm, and two in home first arm with
reasons given
Selective reporting Unclear Protocol not available, and unclear from paper whether or not other
outcomes were assessed
Other bias (crossover trials only):
Crossover a suitable design? Yes, no withdrawals due to disease progression
Appropriate statistical analysis used (to allow for pairing)? Yes, used paired analyses using data from both time periods,
and checked for period and carryover effects
Stevens et al. 200633
Random sequence
generation
Low Table of random numbers
Allocation
concealment
Unclear Allocation performed by study site manager but unclear if group
identity was concealed
Similarity at baseline Low Crossover trial: within-participant comparisons
Blinding of
participants and
researchers
High Neither participants nor researchers were blinded
Blinding of outcome
assessment
High
Low
Patient-reported outcomes subjective (patients not blinded)
Adverse events unlikely to be affected
Incomplete outcome
data
Low 23/29 children completed both phases and appear to have recorded all
outcome data; relapse similar in both arms but reasons for withdrawal
(n= 2) not reported
Selective reporting Low Could not locate trial protocol; appears from the paper that all
collected outcomes were reported
Other bias (crossover trials only):
Crossover a suitable design? Appears reasonable, disease course relatively stable
Appropriate statistical analysis used (to allow for pairing)? Paired analyses (data from both periods) were used and checked
for period and programme effects or interactions
N/A, not applicable.
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Appendix 5 Results
Results for quality-of-life outcomes
Study Outcomes
Randomised trials
Corrie et al. 20134 EORTC QLQ-C30 self-rated QoL
Community (n= 39) vs. outpatient (n= 17): –0.01 (95% CI –0.87 to 0.86; p= 0.99)
Home (n= 23) vs. GP (n= 16): –0.06 (95% CI –0.99 to 0.88; p= 0.90)
Home (n= 23) vs. outpatient (n= 17): –0.03 (95% CI –0.99 to 0.93; p= 0.95)
GP (n= 16) vs. outpatient (n= 17): 0.03 (95% CI –0.99 to 1.05; p= 0.96)
EORTC QLQ-C30 Emotional Function domain
Community (home and GP, n= 38) vs. outpatient (n= 17): –7.2 (95% CI –19.5 to 5.2; p= 0.25)
Home (n= 23) vs. GP (n= 15): 15.2 (95% CI 1.3 to 29.1; p= 0.033)
Home (n= 23) vs. outpatient (n= 17): –1.5 (95% CI –14.5 to 11.5; p= 0.82)
GP (n= 15) vs. outpatient (n= 17): –16.6 (95% CI –31.4 to –1.9; p= 0.028)
EQ-5D
Utility scores: not reported
QALYs
Home: 0.174 (SD 0.034)
Community (GP): 0.191 (SD 0.040)
Hospital: 0.165 (SD 0.053)
Borras et al. 200135 EORTC QLQ-C30 self-rated QoL
Home (n= 33): 71 (SD 17); outpatient (n= 23): 68 (SD 20); ‘no difference’, nor in changes
from baseline
EORTC QLQ-C30 Emotional Function domain
Home (n= 33): 76 (SD 24); outpatient (n= 23): 79 (SD 19); ‘no difference’, nor in changes
from baseline
EORTC QLQ-C30
Results were also presented for the individual items of the functional and symptom domains of
EORTC QOL-C30
King et al. 200031 FLIC (self-administered questionnaire)
Overall total FLIC score: 76 (SD 14, interaction p= 0.23). Setting-specific scores were not reported.
The ‘location effect’ was –0.49 (p= 0.79), i.e. treatment location (home or hospital) did not have a
significant impact on quality of life
Note: ‘period effects’ also reported
FLIC Emotional Function subscore: overall average score of 72 (SD= 19, interaction p= 0.30).
The location effect was –0.09 (p= 0.98)
Note: other FLIC subscores were also recorded (role function, pain, hardship, current health,
sociability and nausea)
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Study Outcomes
Christiansen et al.
201128
EORTC QLQ-C30 self-rated QoL
There was no significant difference between hospital-treated and home-treated patients’ QoL
scores. No raw results were reported
Stevens et al.
200633
POQOLS; Child Behaviour Checklist
POQOLS
Factor 1 (sensitivity to restrictions in physical functioning and the ability to maintain a normal
physical routine):
Crossover to outpatient led to a 5.2 increase (n= 13 before switch, n= 13 after, lower is
better). Crossover to home led to a 10.5 decrease (n= 14 before switch, n= 10 after). The
difference between the two groups was significant (p= 0.023). There were 13 patients with
baseline measurements in the home group, with a maximum of 14 observations at any
follow-up period, and 12 at the final follow-up. For the hospital group, there were 14 patients
at baseline, and 10 at final follow-up
Factor 2 (emotional distress):
No significant difference due to crossover. Patients starting at home had statistically significantly
higher scores (lower QoL) at 6 months than those starting in outpatient setting (6.8 difference,
p= 0.043)
Factor 3 (reaction/response to current medical treatment)
Non-statistically significantly higher scores in home group (8.3 difference, p= 0.61)
Long-term trends appeared to indicate little difference between treatment locations in any
POQOLS factor
Remonnay et al.
200234
FLIC (self-administered questionnaire)
Results not reported
Chen and Hasuimi
199927
Unclear QoL measures
The authors stated that, by day 5 of the first course, quality-of-life items (such as mood, smell,
appetite and satisfaction) were ‘significantly decelerated’ in the home-first group compared with
the hospital-first group, but no data were reported
Intergroup analysis in the hospital first group indicated that the second infusion at home
significantly improved QoL status in appetite, taste, mood and satisfaction
Non-randomised studies
Hansson et al.
201338
PedsQL Scale Generic Core Child self-reported and parent proxy (0–100 scale); PedsQL Cancer
Module child self-reported and parent proxy (seven dimensions, 0–100 scale); PedsQL Family Impact
Module (eight dimensions)
PedsQL Generic Core: child self-reported
Home care n= 13; hospital n= 26 at T1 (recruitment), n= 25 at T2 (3 months). At T1 and T2 all
home-care group results were higher than standard care. At T2 self-reported mean scores were
statistically significantly higher in the home-care group vs. outpatient in the dimensions of total
score (75.3 vs. 61.1; p= 0.02), psychosocial health (74.6 vs. 62.4; p= 0.03) and emotional
functioning (78.1 vs. 62.2; p= 0.04). The crude mean difference between settings in global total
score between T1 and T2 was 14.2 (95% CI 2.0 to 26.3; p= 0.02). The adjusted mean difference
was 14.8 (95% CI –0.4 to 30.1; p= 0.06). Subscores across time points were reported (see paper).
The only dimension statistically significant for the adjusted mean difference value was social
functioning: mean difference= 15.5 (95% CI 0.0 to 31.1; p= 0.05)
(Variables adjusted for age, diagnosis, gender and time since diagnosis)
Several children did not attend school, which affects the mean score in the school dimension
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Study Outcomes
PedsQL Generic Core: parent proxy
Home care T1 n= 40, T2= 41; outpatient T1 n= 62, T2 n= 66. All home scores were higher than
outpatient care scores at both time points. The crude mean difference for total score between
settings was 7.7 (95% CI 0.4 to 14.9; p= 0.04). The adjusted mean difference was 7.7 (95% CI 0.6
to 16.1; p= 0.07). For the adjusted scores, only the physical health score was significant: mean
difference= 14.2 (95% CI 3.3 to 25.2; p= 0.01) (full domain scores reported in paper)
Cancer Module: child self-reported
There were no statistically significant differences between the home-care group and outpatient
group across any of the items
Cancer Module: parent proxy
For the adjusted results there were two statistically significant domains: nausea
(mean difference= 9.9 (95% CI –0.2 to 19.5; p= 0.04) and worry (mean difference= 10.5
(95% CI –0.4 to 20.6; p= 0.04) (higher scores are better, scores favoured home setting).
Full domain scores in paper
Family Impact Module
The mean scores were similar overall between groups (no result detail reported)
Payne 199246 Domains of a bespoke quality of life implement developed for the study (not detailed elsewhere)
All results reported as (mean; SD). HADS Anxiety and Depression form the Psychological Stress
domain (see psychological results table). The number of patients for each component was
not reported
Only gastrointestinal complaints (p< 0.01) and housework (p= 0.01) had statistically significant
differences
Physical complaints:
l Home – tiredness (4; 2.5), gastrointestinal (2.6; 3.0), pain (1.8; 1.5)
l Outpatient – tiredness (5.1; 2.4), gastrointestinal (11.3; 4.2), pain (1.3; 1.6)
Marital:
l Home – satisfaction (5.3; 2.1) vs. outpatient – satisfaction (6.2; 2.1)
Activity:
l Home – housework (7.0; 2.0), Karnofsky Performance Scale (45.7; 5.3), plans for the future
(6.7; 1.7), self-esteem (72.0; 8.4)
l Outpatient – housework (5.8; 1.2), Karnofsky Performance Scale (41.9; 9.4), plans for the
future (6.2; 1.8), self-esteem (69.6; 8.4)
Regression analyses were conducted to find influential variables. Anxiety accounted for 82% of
variance and depression accounted for 10%
Souadjian et al.
199248
Activities of Daily Life
Home patients reported an improvement in quality of life after compared with outpatient
chemotherapy. Data were not reported, nor was the method of measurement
QoL, quality of life; T1, time point 1; T2, time point 2.
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Results for clinical outcomes
Study Outcomes
Randomised trials
Corrie et al.
20134
EORTC QLQ-C30 self-rated health
Community (n= 39) vs. outpatient:
0.30 (95% CI –0.51 to 1.12; p= 0.46)
Home (n= 23) vs. GP (n= 16):
–0.07 (95% CI –0.97 to 0.83; p= 0.88)
Home (n= 23) vs. outpatient (n= 17):
0.28 (95% CI –0.62 to 1.17; p= 0.54)
GP (n= 16) vs. outpatient: (n= 17)
0.34 (95% CI –0.64 to 1.33; p= 0.49)
Borras et al.
200135
EORTC QLQ-C30 self-rated health
Home (n= 33) 71 (SD 17) vs. outpatient (n= 23) 68 (SD 20). Difference not significant
Karnofsky Index
Home (n= 33) 85 (SD 11) vs. outpatient (n= 23) 85 (SD 11)
Stevens et al.
200633
Caregiving Burden Scale
No evidence of effect from location
Non-randomised studies
Payne 199246 Karnofsky Performance Scale
Home: 45.7 (SD 5.3) vs. outpatient: 41.9 (SD 9.4) (p= 0.19)
Pong et al.
200037
Self-rated health status, seven-category Likert sale – survey posted questionnaire
Categories 2 and 3, and 5 and 6 were combined
Community (COCN) patients (n= 153):
l 1 (bad): 1.3%
l 2/3: 9.2%
l 4 (average): 24.2%
l 5/6: 43.8%
l 7 (good): 20.9%
Hospital patients (NEORCC) (n= 225):
l 1: 0%
l 2/3: 15.8%
l 4: 22.8%
l 5/6: 46.5%
l 7: 15.8%
The differences were not statistically significant
NB: the hospital sample included both patients who could have taken part in the community (n= 55)
programme and those who could not
COCN, Community Oncology Clinic Network; NEORCC, Northeastern Ontario Regional Cancer Centre.
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Results for psychological outcomes
Study Outcomes
Randomised trials
Corrie et al. 20134 HADS Anxiety community (n= 40) vs. outpatient (n= 17)
0.97 (95% CI –0.97 to 2.9; p= 0.32)
Home (n= 23) vs. GP (n= 17): –1.97 (95% CI –4.10 to 0.17; p= 0.07)
Home (n= 23) vs. outpatient (n= 23): 0.13 (95% CI –1.97 to 2.23; p= 0.90)
GP (n= 23) vs. outpatient (n= 17): 2.10 (95% CI –0.16 to 4.35; p= 0.07)
HADS Depression community (n= 40) vs. outpatient (n= 17):
2.10 (95% CI –0.02 to 4.22; p= 0.05)
Home (n= 23) vs. GP (n= 17): –2.01 (95% CI –4.31 to 0.27; p= 0.08)
Home (n= 23) vs. outpatient (n= 23): 1.28 (95% CI –1.00 to 3.55; p= 0.27)
GP (n= 23) vs. outpatient (n= 17): 3.29 (95% CI 0.81 to 5.77; p= 0.01)
Pace et al. 200929 HADS Anxiety
No raw data reported; text states no significant difference between arms although tendency for
anxiety to decrease over time in both groups
HADS Depression
No raw data reported; text states no significant difference between arms although both groups
reported rise in depression mid-way in trial; final depression scores lower than mean baseline scores
Stevens et al.
200633
Child Behaviour Checklist
No significant differences between treatment groups at any follow-up point
Remonnay et al.
200234
Hamilton Anxiety Scale
Results not reported
Montgomery–Åsberg Depression Rating Scale (MADRS)
Results not reported
Payne 199246 HADS Anxiety
Home 35.6 (SD= 22) vs. outpatient 44.2 (SD= 32.2) (p= 0.42)
HADS Depression
Home 28.7 (SD= 20) vs. outpatient 33.5 (SD= 18.3) (p= 0.51)
Non-randomised studies
Herth 198943 Herth Hope Scale (score range 0–32)
Jalowiec Coping Scale (score range 90–200)
Outpatients had significantly higher levels of coping response and hope
Hope: home (n= 20) 24.1 vs. outpatient (n= 20) 27.0 (p< 0.01)
Coping: home (n= 20) 121.9 vs. outpatient (n= 20) 140.2 (p< 0.01)
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Results for satisfaction outcomes
Study Outcomes
Randomised trials
Corrie et al. 20134 Questionnaire
78% of patients expressed satisfaction with their treatment setting, whatever their location
Borras et al. 200135 Questionnaire (score range 1–100, larger scores equate to greater satisfaction)
There were significant differences between groups in:
l Perceptions of nursing availability [home 87 (SD 7) vs. outpatient 54 (SD 16)]
l Communication with nurse [home 100 (SD 0) vs. outpatient 82 (SD 25)]
l Personal qualities of nursing [home 98 (SD 6) vs. outpatient 84 (SD 15)]
Health care in general was borderline significant [home 86 (SD 13) vs. outpatient 78 (SD 19)];
difference in means –8 (95% CI –17 to 0)
There were no significant differences reported for the remaining three types of care (availability of
doctor, continuity of care and communication with doctor). Home n= 33 and outpatient n= 23
(for all)
Hall and Lloyd
200830
Individual semistructured interviews
See qualitative data extraction
King et al. 200031 Questionnaire (interview) on patient satisfaction
The only statistically significant (setting-related) difference in satisfaction with home vs. outpatient
care related to the depressing nature of the place of treatment: 15/40 patients found hospital, but
not home, a depressing treatment option; one patient found home, but not hospital, depressing;
24 patients found both depressing. The location effect on this item was –1.23; p= 0.00
A significant period effect was found: patients felt significantly less secure during period 2,
regardless of setting (p= 0.04)
Questionnaire (interview) on patient perception of unmet need
There were no statistically significant location effects on the five patient needs dimensions for the
34 patients who completed the questionnaire
Self-administered questionnaire (carers)
There were no statistically significant location effects on the carer satisfaction scores
Pace et al. 200929 Chemotherapy Patient Satisfaction Questionnaire (CPSQ)
Seven dimensions, each item scored from 1–5, low scores= greater satisfaction
Patients were significantly more satisfied with the outreach location for ease of access and
environment (p< 0.001), and there was greater satisfaction with the outreach centre for
interpersonal and technical aspects of nursing care (p< 0.01)
There were no significant differences in anxiety and global satisfaction
More complete data in full paper for each dimension
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Study Outcomes
Rischin et al. 200032 Questionnaire (patients)
None of the patients reported concerns with chemotherapy being given in their home; 4/20 (20%)
reported concerns with treatment in hospital, relating to transport difficulties and waiting times
(no raw data given)
18/20 (90%) of patients felt there were advantages with treatment in the home. The reasons given
included convenience; avoidance of travel and parking problems (particularly not having to travel
while feeling unwell); reduction in treatment-associated anxiety; not burdening their carers and
family; and being able to continue their duties such as caring for their dependents. One (5%)
patient thought that there were specific advantages to chemotherapy in the hospital: being able to
see other people who were worse off
Stevens et al. 200655 Qualitative patient satisfaction interviews
See qualitative data extraction
Non-randomised studies
Grusenmeyer et al.
199642
0–100-mm visual analogue scale (VAS)
Outpatient satisfaction was 98mm on the VAS; home satisfaction was not reported
Lowenthal et al.
199645
Number of patients choosing to discontinue home treatment
2 of 424 patients
Barker 200640 Participant comments to the author
See qualitative results
Pong et al. 200037 Questionnaire: posted survey (7-point sale: 7= strongly agree, 4= neutral, 1= strongly disagree)
Patient satisfaction:
Community patients (n= 153) were asked a series of questions about patient satisfaction and
acceptance of the community programme. Hospital patients (n= 114) were asked similar questions
in order to provide a basis for comparison
Generally satisfaction was high
About half of those who had received their first chemotherapy treatment at hospital said that the
treatment skills and knowledge of those at hospital were superior to those at the community clinics.
Hospital patients tended to have more access to sources of information, but did not necessarily use
these sources more frequently than community patients. About 85% of the hospital patients
68% of community patients felt that there were sufficient supportive care services
Concerning the overall quality of care received, 12.5% of community patients felt that their care
had been extremely bad or less than average, compared with 0% of hospital patients; 4.6% of
community patients thought that the care had been average, compared with 0% for hospital; and
83% of community patients felt that their care had been good or extremely good, compared with
100% of hospital patients
Detailed results reported in paper
Community respondents who were dissatisfied tended to be patients in smaller and low-volume
clinics
Also reported satisfaction with physician and chemotherapy nurses, satisfaction with amount of
information provided before first hospital visit, availability of information, suggestions for improving
the community programme
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Study Outcomes
NHS Bristol 201036 Questionnaire
When patients were asked if felt they were given sufficient privacy, 62% of outpatients said
always, compared with 76% at the community health centre and 97% at home
When asked if they received caring and sensitive nurse care 85% of outpatients said always,
compared with 100% at the community health centre and 97% at home
When asked about having sufficient opportunity to ask the chemotherapy nurse a question,
78% of outpatients said always, compared with 100% at the community health centre and 82%
at home; 78% of outpatients said they always received an understandable reply, compared with
86% at the community health centre and 78% at home
87% of outpatients said they always had a clear explanation of impending medical procedures,
compared with 95% at the community health centre and 87% at home
Top five reasons for choosing treatment location:
Outpatient:
1. Being with others receiving chemotherapy
2. Keeping to a routine
3. Access to support/added services
4. Getting to treatment
5. Access to doctor and medical staff
Community:
1. Concern about hospital-acquired infections
2. Concern about waiting time
3. Travel costs
4. Getting to treatment
5. Car parking
Home:
1. Concern about hospital-acquired infections
2. Getting to treatment
3. Car parking
4. Concern about waiting time
5. Being in familiar surroundings
Total sample size= 118, but unclear how many in each setting
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Results for preference outcomes
Study Outcomes
Randomised trials
Corrie et al. 20134 Questionnaire
82% of patients expressed a preference for future treatment in the community: the proportions that
would prefer any future treatment in the same location were as follows: outpatient 57%, GP surgery
81% and home 90%
King et al. 200031 Questionnaire (interview) on patient preference
Including only patients who completed both home and outpatient treatments: 29/40 (73%) of
patients preferred treatment at home compared with treatment at hospital (95% CI 59% to 86%;
p= 0.01). 11/40 (27.5%) of patients preferred hospital treatment
10/29 (34%) patients who preferred home treatment changed their preference to outpatient
treatment if home treatment meant waiting another hour. 3/11 patients who preferred outpatient
treatment changed their choice to home treatment if they had to wait an hour longer at hospital
Including the 13 patients who chose not to be randomised because they preferred the outpatient
setting, and the eight patients who dropped out after receiving outpatient chemotherapy during
run-in (because they felt more secure at hospital): 29/61 (48%) of patients preferred home care
(95% CI 35 to 60; p= 0.61)
For trial recruits only (i.e. including the eight who dropped out during run-in): 29/48 (60%) of
patients preferred home care (95% CI 47% to 74%; p= 0.19)
Self-administered questionnaire (carers)
Of 25 carers who completed the questionnaires, 17/25 (68%) preferred treatment at home (95% CI
50% to 86%; p= 0.11)
Pace et al. 200929 Two preference questions:
1. Preferred location for remaining treatment: 30/31 (97%) patients chose outreach location when
asked after first crossover period. One patient chose cancer centre as moving house and would
be closer
2. Preferred location for all treatment: 30/31 (97%) patients said they would have preferred to
receive all their treatment at the outreach centre. One patient preferred the cancer centre
because of decor and gloomy atmosphere in outreach location
Christiansen et al.
201128
Questionnaire (patients)
Not reported
Rischin et al. 200032 Questionnaire (patients)
All 20 patients (100%; 95% CI 83% to 100%) preferred to have their remaining therapy given at
home
When asked where they would have preferred to receive their first two treatments if they had had
their time again, 14/20 (70%) patients said they would have preferred both treatments at home
[7/9 (78%) in the hospital-first group, 7/11 (64%) in the home-first group]; 2/20 (10%) said they
would prefer the first treatment at home and the second in hospital [0 in the hospital-first group;
2/11(18%) in the home-first group]; 2 (10%) said they had no preference [1/9 (11%) in the
hospital-first group, 1/11 (9%) in the home-first group]; and 0 patients said they would prefer both
treatments at hospital
Stevens et al.
200655
Qualitative patient preference interviews
See qualitative data extraction
Remonnay et al.
200234
Questionnaire
95% of all patients asked preferred chemotherapy treatment at home. Number of patients asked is
not clear owing to dropouts
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Study Outcomes
Non-randomised studies
Souadjian et al.
199248
Questionnaire
Authors reported that home was the preferred option for patients
Pong et al. 200037 Questionnaire: posted survey
n= 153
For the first treatment community patients chose whether to receive their first chemotherapy
treatment at the hospital or community clinic. Almost half said that they had received their
first treatment at the hospital
Reasons for choosing community care:
Community respondents (n= 153). Top three reasons from a given list were weighted on basis of
choice. Top five reasons (in order) were:
1. Able to go home immediately after chemo treatment (weighted score 227)
2. Time required for travel to and from the cancer centre, i.e. main hospital (score 115)
3. Cost of travelling to and from the cancer centre (score= 93)
4. Support of family and friends in my community while receiving chemo treatment in local hospital
(score= 74)
5. Receiving treatment close to home where my family physician is (score= 73)
Perceived disadvantages of the community program
Similarly, community patients were asked to pick the top three disadvantages of community care.
37% did not answer, many of whom said that they believed there were no disadvantages in
participating in the programme. Top five responses:
1. There are no cancer specialists in my community (137)
2. The health professionals in my community may not be as up to date about cancer treatment as
those at the hospital cancer centre (84)
3. The cancer centre in Sudbury (main hospital) is a new and more cheerful building than my local
hospital (37)
4. There are more supportive care services at the cancer centre in Sudbury (31)
5. Not having enough contact with other cancer patients (31)
See paper for full list of ranked answers
Hospital patients’ (n= 114) reasons for not participating in community programme:
l 50% stated they were not eligible (< 50 km from hospital)
l 23% said they had never heard of the programme (all but two of whom came from
communities that had a community clinic and, thus, were eligible)
l 27% said that they were eligible but chose not to take part. Of those, 75% felt that they would
receive better-quality care at the hospital cancer centre. Some mentioned that they had
switched back to the hospital after having ‘bad experiences’ with COCN programme (no
numbers given)
Also reported: information issues surrounding COCN programme (pp. 4–18)
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Results for compliance outcomes
Study Outcomes
Randomised studies
Corrie et al. 20134 Proportions of patients receiving compliant dosing schedules
Unclear (17 did not complete 12 weeks of treatment mainly due to disease progression)
Borras et al. 200135 Proportions of patients receiving compliant dosing schedules
Unclear
Non-randomised studies
Satram-Hoang and
Reyes 201147
Proportions of patients receiving compliant dosing schedules
Rituximab+ chemotherapy compliance with dosing schedule (once every 3 weeks for up to eight
cycles): 34% in outpatient setting (n= 541) vs. 54% in community clinics (n= 3149); p< 0.001
Number of cycles of chemotherapy delivered
l Community: 61% received < 6 cycles, 21% received 6–8 cycles and 18% received > 8 cycles
l Outpatient: 77% received < 6 cycles, 12% received 6–8 cycles and 11% received > 8 cycles
Frølund 201141 Number of scheduled chemotherapy treatments completed (completed/scheduled):
l Patient 1: 10/24
l Patient 2: 20/24
l Patient 3: 16/16
l Patient 4: 14/24
l Patient 5: 14/16
l Patient 6: 13/24
Number of chemotherapy treatments delivered at home:
l Patient 1: four
l Patient 2: 11
l Patient 3: nine
l Patient 4: six
l Patient 5: seven
l Patient 6: three
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Results for safety outcomes
Study Outcomes
Randomised studies
Corrie et al. 20134 Adverse events
Four of 39 SAEs recorded during this study were assessed as being related to treatment setting
Borras et al. 200135 Adverse events
No data other than withdrawal details (see study characteristics)
Chemotherapy toxicity
No differences between groups for withdrawals due to toxicity (16 cases in total)
Pace et al. 200929 Adverse events
There were no adverse reactions during chemotherapy at any location. On one occasion a nurse
was unable to cannulate a patient in the outreach centre; patient returned to cancer centre and
was treated there
Chemotherapy toxicity
Measured with C-SAS
The most common side effects were nausea, vomiting, fatigue, feeling weak and difficulty sleeping.
These showed no significant differences between the locations (Fisher’s exact test)
No further data reported
Christiansen et al.
201128
Chemotherapy toxicity
There was no significant difference in treatment toxicity between the two groups (p= 0.10).
14.8% of patients treated at home had to be seen at the outpatient clinic for toxicity evaluation
and prescription of chemotherapy, in particular due to difficulties in precise evaluation of hand-foot
skin reactions by telephone interviews
Mode of measurement not reported
Hospitalisation
14.8% of patients treated at home had to be seen at the outpatient clinic (see toxicity)
Rischin et al. 200032 Complications
There were no major complications with the chemotherapy administration
Stevens et al.
200633
Adverse events
No statistically significant differences in overall adverse events. Regardless of treatment allocation,
change of location resulted in significantly more adverse effects in patients who had no previous
adverse events
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Study Outcomes
Non-randomised studies
Lowenthal et al.
199645
Adverse events
‘Infrequent difficulties with venous access’
‘One serious complication’ – patient had dystonic reaction to drug (metaclopramide, an antiemetic),
transferred to hospital for treatment but not admitted. The authors assumed equal effectiveness
due to insignificant numbers of adverse events
Souadjian et al.
199248
Adverse events
4/83 home chemotherapy patients had chemotherapy related adverse events requiring
hospitalisation: two thrombosed catheters; one accidental catheter removal by patient;
and one sepsis
Data were not presented for the outpatient setting
Barker 200640 Chemotherapy toxicity
NB: seven outreach patients received 86 cycles of chemotherapy; seven patients received 112 cycles
of home chemotherapy
WHO toxicity grading scale:
l Nausea: 15% of cycles in the home; 21% in the outreach clinic
l Skin changes: 19% of cycles in the home; 49% in the outreach clinic
l Diarrhoea: 25% of cycles in the home; 51% in the outreach clinic
l Lethargy: 16% of cycles in the home; 62% in the outreach clinic
The author stated that the results reported were ‘examples of the results for the audit’
Pong et al. 200037 Postal questionnaire (hospital n= 114, community n= 153):
40% of hospital respondents and 45% of community respondents reported that they had called for
medical help concerning their chemotherapy. 29% of hospital patients who had called for help
said they had encountered difficulty vs. 46% of community patients who said they also had
encountered problems (p< 0.01)
Vergnenègre et al.
200649
Adverse events
Home: two adverse events in 24 cycles
Hospital: seven adverse events in 30 cycles
No statistically significant difference (p= 0.27)
C-SAS, Chemotherapy Symptom Assessment Scale; SAE, serious adverse event; WHO, World Health Organization.
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Appendix 6 Costs data
Randomised studies
Corrie et al. 20134 Home: £2139 (SD £1590)
GP: £2497 (SD £1759)
Hospital: £2221 (SD £1831)
ICER: GP vs. hospital= £16,235/QALY
King 200031 (CEA study: cost consequences)
Costs
The net additional cost of home chemotherapy (per treatment) was AUS$68.81
This figure was the sum of:
l additional nursing cost: $39.79 for time spent in organisation, preparation and clean-up
l travel time: $19.90
l use of motor vehicles: $9.09
l special equipment required for home administration: $0.03
The total cost of establishing a new chemotherapy ward was estimated to be $70,581 ($5187
annual cost)
A range of different estimates (reported in table) for the additional cost of a new ward
per treatment were calculated, based on a range of treatments per annum, projected increase in
workload (assuming full capacity of new ward is 1560 treatments per annum, based on current
ward capacity), annual capital costs per treatment, and additional overhead and joint cost
per treatment (assuming incremental cost is 20% of existing overhead allocation)
On this basis it was estimated that home chemotherapy would be a less expensive means of
expanding the service by up to 50% of the ward capacity (additional cost= $65.54 per treatment
for establishing a new ward at 50% capacity is less than the cost of $68.81 per treatment for
home care). So, if capacity could be expected to increase by 50% or more it would be less costly to
set up a new ward
The interest rate in this calculation was varied from 3% to 10%, which made no difference to the
break-even point because the opportunity cost of capital accounted for only 7% of the costs of
capital and overhead
Pace et al. 200929 Service costs:
Mileage cost per session= £12.83
Mileage costs per six-session cycle= £76.98 (assumes £0.53 per mile)
Opportunity cost of travelling time for each nurse was £32.08 per clinic (using average pay for a
specialist oncology nurse outside London= £29,538 per annum. Plus on-costs, this amounts to
£15.11 per hour)
Marginal cost per clinic session= £64.16
Marginal cost per cycle of six clinic sessions= £384.96
There was no charge for running the clinics in the community hospitals during the study
Patient costs:
Mean cost of travel to outreach centre= £4.85
Mean cost of travel to cancer centre= £8.77
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Based on travel costs per mile (£0.40 per mile, inland revenue rate) plus parking charges
Patient-borne costs of travelling (including public transport costs) to:
l outreach centre= £8.70
l cancer centre= £14.99
Additional/marginal cost to patient of £6.29 per session or £37.74 per cycle of six sessions to
attend the hospital cancer centre
Stevens et al. 200633 Costs were reported as median (n, range) in CAN$
Home (time 3, 6 months, before crossover): 1318 (n= 14, 298 to 6302)
Home (time 5, 12 months, after crossover): 851 (n= 13, 147 to 8726)
Hospital (time 3, 6 months, before crossover): 1409 (n= 11, 419 to 7342)
Hospital (time 5, 12 months, after crossover): 1050 (n= 9, 29 to 10,278)
No differences were statistically significant but there was a trend towards lower costs in the home
group. The home group also had higher baseline costs (1795, n= 15, 327 to 7227) than the
hospital group (1374, n= 14, 98 to 4381)
Rischin et al. 200032 (CEA study: cost consequences)
Costs
Perspective: treating hospital
Home chemotherapy was associated with an estimated average increased cost of $83 (95% CI $46
to $120; p= 0.0002) for each chemotherapy treatment, relative to the cost of chemotherapy in the
hospital
The average cost of the first course of treatment was estimated to be $57 more than the cost of
the second (95% CI $20 to $94; p= 0.004) (non-setting specific). There was no carry-over effect
(p= 0.16)
Remonnay et al.
200234
Costs were reported in 1998 US$. Statistical significance was measured using Wilcoxon tests
Costs of personnel for one chemotherapy administration
Health-care personnel: home= 69.10 (SD 19.20) vs. outpatient= 51.70 (SD 10.60) (p< 0.0001)
Co-ordination: home= 20.20 (based on assumption) vs. outpatient= 0 (assumption of no hospital
costs)
Other: home= 6.60 vs. outpatient= 3.30
Total: home= 95.80 (SD 19.20) vs. outpatient= 55.00 (SD 10.60) (p< 0.0001)
Additional costs for health-care personnel at home were driven by the costs of physician home
consultations ($19.8 for home vs. $7.8 for consultation)
Medication costs
All chemotherapy drugs: home= 136.70 (SD 81.90) vs. outpatient= 74.00 (SD 52.80) (p< 0.0001)
Three most common regimens:
AC: home= 169.10 vs. outpatient= 76.50
CMF: home= 76.20 vs. outpatient= 22.10
Navelbine: home= 140.5 vs. outpatient= 111.90
Other marginal costs for outpatient chemotherapy (per administration)
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Randomised studies
Transportation 21.80
Laundering 6.10
Overhead costs
Home= 20.10 vs. outpatient= 120.30
Total costs (marginal costs do not include overhead costs)
Marginal: home= 232.50 (SD 81.80) vs. outpatient= 157.0 (SD 62.00) (p< 0.001)
Average: home= 252.60 (SD 81.80) vs. outpatient= 277.30 (SD 62.00) (p= 0.0002)
Sensitivity analysis of total costs assuming equal medication costs (home-care access to hospital
pharmacy)
Marginal: home= 170.00 (SD 58.20) vs. outpatient= 157.00 (SD 62.00) (p< 0.001)
Average: home= 190.00 (SD 58.20) vs. outpatient= 277.30 (SD 62.00) (p< 0.001)
Costs per hour or per tariff activity were provided in the paper
Non-randomised studies
Grusenmeyer et al.
199642
Home care:
l 5-FU+ leucovorin (5 days) $799
l Cyclophasphamide+ doxorubicin $797
l Cisplatin+ etoposide $2196
l Cisplatin, mitomycin+ vinblastine $2063
l Hydration $308
l Transfusion $435
l Amphotericin $277
Hospital:
l 5-FU+ leucovorin (5 days) $151
l Cyclophasphamide+ doxorubicin $249
l Cisplatin+ etoposide $1096
l Cisplatin, mitomycin+ vinblastine $1107
l Hydration $151
l Transfusion $359
l Amphotericin $181
Lowenthal et al.
199645
Home treatment costs:
Total cost per treatment: $49.93
Salary $36.39 (including 15% overhead, and travel time, at $24.38 per hour salary)
Special equipment $9.11 (106 computer-activated drug-delivery devices at $29.66 each)
Car expenses $4.43 (petrol, maintenance, insurance, registration and depreciation)
Hospital treatment costs:
$116.00 ($165.71 multiplied by the percentage of time spent administering chemotherapy)
Marginal cost of delivering treatments at home
The estimated costs of adding hospital capacity equivalent to the number of patients receiving
home treatment was compared with the cost of delivering treatment at home. Chemotherapy was
not evaluated independently for this analysis. Expanding capacity for the hospital assumed
extending hours to 20.30 from 17.00 and paying a higher night wage for nurses ($29 per hour)
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Hospital $38,207
Home $45,767
Further details for the marginal analysis were provided
Souadjian et al.
199248
All costs are in US$/treatment-day
Home:
l 5-FU (continuous infusion) $89
l CDDP (continuous infusion) $1113
l CDDP+ ETOP+ BLEO (rapid infusion) $1839
l CDDP+ ETOP+ FUDR (continuous infusion) $1730
l CARBO+ ETOP+ IFOS/mesna (continuous infusion) $3283
Hospital:
l 5-FU (continuous infusion) $294
l CDDP (continuous infusion) $1348
l CDDP+ ETOP+ BLEO (rapid infusion) $2958
l CDDP+ ETOP+ FUDR (continuous infusion) $2414
l CARBO+ ETOP+ IFOS/mesna (continuous infusion) $4876
Hansson et al.
201338
Feasibility study (home setting only):
The daily hospital charge for a home visit was US$597 vs. $600 for an outpatient visit
(The home-care operational costs, payroll costs and overheads were compared with the costs billed
for an outpatient visit)
The home-care cost included the following items: wages, fuel, uniforms, nursing-bags, parking, car,
mobile telephone, various expenses, leasing of car, and medication. Costs (no resource use) were
given for each of these items for 2 years
Pong et al. 200037 Survey posted questionnaire:
COCN, n= 153; NEORCC, n= 55
Costs reported in CA$
Transport costs
Respondents were asked to estimate the total amount they spent on transportation for a typical
trip to and from the hospital. Transport costs included costs of gasoline, car rental, bus fare, etc.
Community patients: $44 (range $0–160)
Hospital patients: $33 ($0–140)
When removing individuals who did not incur any travel costs (e.g. driven by volunteers):
Community: $49 (range $15–160)
Hospital: $39 ($12–140)
Total travel expenses (less any subsidies received from government travel grants), including cost of
gas/car rental/bus fare, transportation and accommodation, food, lost wages and other expenses,
vehicle operating and ownership expenses:
Community patients: $294 (range $58–1010)
Hospital patients: $188 (range $40–495)
(All costs items reported disaggregated; see paper for more detailed costs)
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Travel time to community clinics was not considered as community patients lived within a relatively
short distance from a clinic and so it was assumed the travel costs would be minimal
NB: A budget impact model was also conducted. This has not been extracted as it was a
non-comparative assessment (only looked at the cost impact at the hospital site and
included non-unique costs)
Ingleby et al. 199944 Costs in GBP (£)
Mean weekly costs:
Hospital: £230 (DeGramont), £92 (Lokich), £35.39 (Tomudex)
Home: £135.27 (DeGramont), £41.77 (Lokich), £33.01 (Tomudex)
Home setting additional costs:
DeGramont: £689
Lokich: £311
Tomudex: £143
Vergnenègre et al.
200649
Average cost per cycle was €2829.51 (95% CI €2560.74 to €3147.02) for hospital infusion,
€2372.50 (95% CI €1962.75 to €2792.88) for home-based care (–16.15%). Difference was
€–457.01 by cycle (95% CI –€919.74 to €26.82). Real costs by infusion for home was €484.42
(95% CI €424.18 to €540.32) vs. a fee of €699.89 (95% CI 643.64; 750.23) (–30.79%)
5-FU, 5-fluorouracil; AC, adriablastin (doxorubicin), endoxan (cyclophosphamide); BLEO, bleomycin; CARBO, carboplatin;
CDDP, cisplatin; CEA, cost-effectiveness analysis; CMF, cyclophosphamide, methotrexate and 5-flourouracil;
ETOP; etoposide; FUDR, floxuridine; IFOS, ifosfamide.
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Appendix 7 Non-randomised study characteristics
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